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vAbstract
The interest in the development of anticancer metal complexes for cancer
therapy is growing spurred by the encouraging successful stories of platinum
drugs. Osmium arene chlorido complexes had been found to show anticancer
activity in vitro. In this thesis, the osmium arene iodido complexes were mainly
explored and investigated.
It is found that iodido OsII arene complexes with a general structure: [Os(η6-
arene)(XY)I]PF6 (XY = p-hydroxy or p-dimethylamino phenylazopyridine, arene
= p-cymene or biphenyl) are potently cytotoxic at nanomolar concentrations
toward a panel of human cancer cell lines. In contrast to the chlorido osmium
arene anticancer complexes, the iodido complexes are stable and inert toward
aquation.
More than thirty half sandwich azopyridine OsII arene complexes [Os(η6-
arene)(azopyridine)X]+ (where X is chloride or iodide, the arene is p-cymene or
biphenyl and the pyridine ring of azopyridine ligand bearing a variety of
substituents) were synthesized and characterized. A preliminary structure activity
relationships (SARs) were built up based on the anticancer activity towards
A2780 human ovarian cancer cell line. In general, the introduction of an electron-
withdrawing group (e.g. F, Cl, Br or I) at specific positions on the pyridine ring
significantly increases cytotoxic activity and aqueous solubility. Changing the
arene from p-cymene to biphenyl or the monodentate ligand (X) from chloride to
iodide resulted in a significant increase in the anticancer activity. Studies in
A2780 human ovarian cancer cells suggested that cellular uptake and targeting to
cellular organelles play important roles in determining the anticancer activity.
According to the 60 cancer cell lines screening results from National Cancer
Institute (NCI), the anticancer activity achieved by the most potent OsII arene
azopyridine complex is 100 times more than cisplatin; 1000 times activity was
vi
found in some cell lines. The mechanism of action may involve the inhibition of
tubulin polymerization.
One iodido osmium complex was selected for anticancer efficiency evaluation
in vivo: [Os(η6-p-cym)(Azpy-NMe2)I]PF6 (FY026). This complex delayed the
growth of HCT116 human colon cancer xenografts in mice, with negligible
toxicity. It is the first example of in vivo antitumour activity for an organometallic
osmium arene complex. Its activity appears to involve redox mechanisms. Its
potency towards A2780 ovarian and A549 lung cancer cells is increased
significantly when used in combination with L-buthionine-sulfoximine (L-BSO)
indicating that L-BSO can be a good candidate for combination therapy treatment
with iodido osmium complexes.
Further study on the bioisosteres of FY026 was carried out by changing the
azo bond (N=N) to imine bond (CH=N). Sixteen osmium arene iminopyridine
complexes were synthesized, well characterized and showed good anticancer
activity. Different structure-activity relationships comparing iminopyridine
complexes with azopyridine complexes were identified which suggested a
different anticancer mechanism. In contrast to FY026, [Os(η6-p-cym)(Impy-
NMe2)I]PF6 (6) and [Os(η6-p-cym)(Impy-NMe2)Cl]PF6 (14) were found to
undergo hydrolysis and the binding was observed between their hydrolyzed
product (14A) and 9-ethylguanine.
Moreover, a hydride transfer from NADH to form an osmium hydride
intermediate which is involved in a catalytic process resulting in the formation of
NAD+ was discovered. This process might be involved in the anticancer
mechanism of action. A dual mechanism of action was proposed based in the
interaction of these compounds with DNA nucleobase and catalytic oxidation of
NADH.
vii
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This thesis is concerned with the synthesis and elucidation of the mechanism
of action of osmium(II) arene complexes and their potential application as
anticancer drugs. A strong focus of this work involves looking at the structure-
activity relationships with a view to improve the design and optimize the
anticancer activity and increase our understanding of the mechanisms of action.
This chapter introduces metallodrugs, pays special attention to cancer therapy
development, novel anticancer targets for metallodrugs and the chemistry and
design of osmium anticancer agents.
1.1 Cancer Therapy
It is well-known that a “war on cancer” was declared after the signing of the
National Cancer Act in 1971 by Richard Nixon (the US president serving from
1969 to 1974). The progress of cancer therapy is evident and there are more
anticancer drug candidates than any other disease nowadays in clinical trials.
However, the success rate for anticancer drugs entering clinical development is
much lower than for cardiovascular disease.1 At a very crucial time for the war
against cancer, in 2009, Barack Obama (the US president serving from 2008 to
present) announced that the US would devote more than three percent of its GDP
to research and development; within this budget, the US government would spend
$6 billion to support cancer research. This encouraging news from the US will
also attract more researchers and more public attention to the war against cancer
globally.
Cancer cells are abnormal cells which grow uncontrollably at a rapid pace;
they often metastasize and invade normal tissue. Cancer caused about 13% of all
human deaths worldwide in 2007 (7.9 million). In the UK, about one in three will
develop some form of cancer during their life time according to Cancer Research
UK (CRUK 2008). The great danger and high occurrence rate make improved
cancer therapy essential and in high demand.
Among all the cancer therapies, chemotherapy is the most powerful therapy. It
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1955 1965
Surgery Radiotherapy Chemotherapy
Immunotherapy and Gene therapy
Targeted therapy
makes use of the ability of antineoplastic drug(s) to kill cancer cells. It also has
some ability to kill cancer cells which are just starting to metastasize due to the
lack of target selectivity. This method is always accompanied by serious side
effects through affecting the fast-growing normal cells in humans, such as cells in
the hair follicles, bone marrow and lining of the mouth and intestines. However,
because the normal cells are able to recover, these side effects can be alleviated by
combination treatment to lower the toxic response; they can also gradually
disappear after chemotherapy, because the normal cells are capable to recover.
In the 1960s, the discovery of certain cytotoxic chemical agents facilitated the
use of chemotherapy considerably. Administrations of certain combinations of
cytotoxic chemical agents were able to cure some kinds of cancers, including
childhood acute lymphoblastic leukemia (ALL), testicular cancer and Hodgkins
disease, which were all previously considered universally fatal. In that, this
discovery of cytotoxic anticancer drugs was a breakthrough in the development of
anticancer medicine. Conventional cytotoxic chemotherapy has not only shown
the capability to cure some types of cancer, but also proven effective in an
adjuvant setting, and in reducing the risk of recurrence after surgery for high-risk
breast cancer, colon and lung cancer which are still very difficult cases to treat
nowadays.
Figure 1.1. Brief timeline of the development of cancer therapy.
To avoid the drawbacks of chemotherapy, the newly developed targeted
therapy seems to have a very bright future (Fig. 1.1). It moves the design and
development of anticancer drugs from observation-driven to target-driven.
Targeted therapy works by inhibiting the function of certain proteins that are
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essential for the growth and/or proliferation of cancer cells. For example,
bevacizumab (Avastin) prevents the formation of new blood vessels, which stops
the tumour from growing by limiting the provision of nutrients; the mechanism of
action involves blocking vascular endothelial growth factor. Another good
example is erlotinib (Tarceva) which can block the epidermal growth factor
receptor (EGFR), a protein that is found on the surface of cells that signals the
cells to grow and divide.2 For the cancer cells which overexpress EGFR, erlotinib
can prevent their proliferation selectively.3 Unlike anticancer drugs for
conventional chemotherapy which are mostly derived from natural products or
discovered by chance, development of targeted therapy drugs is mainly based on
rational designs and massive screenings in order to achieve high selectivity to the
target(s). However, targeted therapy does not mean no side effects, Avastin4 (a
well-known drug that blocks angiogenesis), can cause serious bleeding. Tarceva5
(a tyrosine kinase inhibitor which acts on EGFR) can cause tiredness, diarrhea,
and acne-like rash. Another bottle neck is that targeted therapies are not able to
work for all patients.
Other than chemotherapy and targeted therapy, Current topics of researches on
cancer therapy also include boosting the immune system, cancer vaccines, gene
therapy, photodynamic therapy, radiation therapy and reoviridae6 (Reolysin drug
therapy), which also contribute for today’s anticancer treatment.
1.2 Anticancer Drugs for Chemotherapy
The development of anticancer drugs plays a key role in the optimisation of
cancer therapy. For several decades, the discovery of anticancer drugs was
concentrating on conventional cytotoxic agents which can block essential
functions of cells and target dividing cells. These drugs normally have pleiotropic
effects: such as modifying DNA (CDDP7, Fig 1.2), interfering with microtubule
(Taxol8), influencing metabolite synthesis (Methotrexate9) or having an effect on
chromosome topology (Rinotecan10). There are also some exceptions such as
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Ti
Cl
Cl
Pt
NH3Cl
NH3Cl
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FerroceneCisplatin Titanocene dichloride
oestrogen receptor modulators in the anti-hormonal therapy (e.g. Tamoxifen11)
and epidermal growth factor receptor tyrosine kinase inhibitors (e.g. Gefitinib12).
Among all of these, one of the most successful and commercially profitable
anticancer drugs is cisplatin (CDDP7), a metal complex, which has been widely
used for the treatment of solid malignancies for more than 30 years.
Figure 1.2. Metal complexes which can be considered to be milestones in the
development of anticancer drugs.
In the early days, metals were not obvious candidates as pharmaceuticals
because their compounds were generally known as toxic, not stable or have
properties not suitable for drugs. In 1964, Barnett Rosenberg made a serendipitous
discovery that platinum compounds can inhibit cell division when investigating
the effect of electric fields on the growth of bacteria. The discovery led to the
FDA approved drug cisplatin in 1978. Even though cisplatin was known for more
than 100 years, the first report of its medical use was also a stimulus for
researches on various metal-based anticancer compounds for clinical use. The
success of cisplatin in clinical therapy of cancer has paved a way for the study of
organometallic compounds which are compounds containing bonds between
carbon and metal for the treatment of cancer.
From coenzyme B12 which is a natural organometallic compound13 discovered
in 1961 to titanocence dichloride (Fig. 1.2) which was the first anticancer non-
platinum organometallic compound to achieve clinical trial in 1998,14
bioorganometallic chemistry has developed at a very fast speed. Historically,
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ferrocene (bis-cyclopentadienyl iron, Cp2Fe, first synthesized in 1952) was the
first reported anti-proliferative organometallic compound (Fig 1.2),15 following
which ruthenium and osmium organonometallic complexes all joined this field
and played very active roles. Recent developments in this field have been
reviewed by Metzler-Nolte et al.16 Remarkable advances in promising areas of
organometallic chemistry including catalysis, theoretical studies, mechanistic
studies, “unconventional” reaction media, materials, supramolecular assemblies
and bioorganometallic chemistry17 will assist original improvements to the design
of organometallic anticancer drugs.18
It was noticed that cisplatin was used in ca. 70% of all treatments for solid
tumours. Despite the success of cisplatin in the clinic, it is also notable that it can
cause general toxicity, is inactive against certain types of cancer, and leads to drug
resistance and undesirable side-effects.19-21 Even after the improvements made by
second and third generations of platinum anticancer drugs (carboplatin and
oxaliplatin), targeting DNA by different generations of platinum drugs22, 23 offers
an inherently limited possibility for rational improvements to increase its
selectivity on cancerous cells with the aim to minimize undesired side effects.
With the purpose of overcoming the drawbacks of platinum drug, it is necessary
to develop a new generation of anticancer complexes of platinum and other
precious metals. To avoid the similar side effects of cisplatin, it is necessary to
convert the mechanism of action from the classical non-selective DNA binding to
other mechanisms.24, 25 Compared to purely organic compounds, organometallics
complexes are able to obtain a greater structural variety which offers a potential to
provide more possibilities to tune binding to drug targets. By the rational design
of the ligand, organometallic complexes were already found to show effects
through different mechanisms mainly by targeting different biomolecules. For
instance, different half-sandwich ruthenium(II) complexes can act as bio-catalysts
(Fig 1.3, Complex B),26 protein kinase inhibitors27 or DNA modifiers28 by varying
their chelating N,N-ligand.
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1.3 Targets for Organometallic Anticancer Agents
DNA, proteins and redox systems are three major achievable targets for
organometallic anticancer complexes; the details of successful examples of
organometallic complexes are going to be discussed in this section.
1.3.1 DNA
To avoid the similar undesirable toxicity and side effects induced by cisplatin
(anticancer drug targeted to DNA), organometallic complexes had shown a
promising future through targeting DNA in a different way of cisplatin. For
instance, other than the classical nonselective binding to DNA, organometallic
ruthenium compounds had shown a potential to target topoisomerase (e.g. Fig 1.3,
complex A),29 special DNA sequence30 or G-quadruplex31(e.g. Fig 1.3, complex
D); Control of the DNA targeting with sequence specificity was achieved by
osmium compounds by targeting C5-methylated pyrimidines in DNA, this method
was realized through osmium oxidation, though in the very early stage, it had shed
light on the use for gene therapy in the future.32
1.3.2 Essential Proteins for Proliferation
In recent years, various protein targeting agents have shown promising
progress on anticancer treatment: aurora-kinase inhibitors, epidermal growth
factor receptor (EGFR) inhibitors and cyclin-dependent-kinase (CDK) inhibitors.
EGFR has become one very important research topic in recent years. It is also
note-worthy that Tarceva (erlotinib, an EGFR inhibitor), an oral anti-cancer drug
developed by OSI Pharmaceuticals, Genentech and Roche, had been approved by
the U S Food and Drug Administration (FDA). Tarceva is showing remarkable
results for the treatment of Non-Small Cell Lung Cancer (NSCLC), however, the
cost for extending life by an average of 3.3 months is so high (US$92,233) that
not every patient can afford this expense.5 An inorganic compound, ferrocene
carboxaldehyde, has been found to be an EGFR inhibitor; it has the inhibition
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effect on the kinase VEGFR-2 and exhibits an anticancer activity in vitro.
Although there is still a long way to go to clinical application, ferrocene
carboxaldehyde does bring a new hope to lower the price of treatment by using
EGFR inhibitors by introducing a good competitor in the anticancer drug
market.33
Other than kinase inhibitors, anti-tubulin anticancer drugs are also important
for anticancer therapy in medical use. Tubulin belongs to globular proteins, the
two most common types of tubulins (α-tubulin and β-tubulin) can polymerize and 
form microtubules which are important for spindle formation during the mitosis
stage of cells. There are two classes of tubulin-polymerization-targeted drugs in
clinical use, one stabilizes microtubules (eg. taxol), another destabilises like vinca
alkaloids (eg. vincristine, vinblastine, and vinorelbine) which were discovered
after taxol. Both of the two types of drugs work by interfering with the cell’s
ability of forming mitotic spindles appropriately, they work by inducing or
preventing the normal polymerization of tubulin during the G2/M phase of the cell
cycle respectively.34 The discovery of tubulin-targeting anticancer drugs was
mainly based on natural products,35 a lot of progress on designing inhibitors of
tubulin polymerization had also been made based on organic structures,36-40
however, there is still no report linking organometallic compounds to the
inhibition of tubulin polymerization though an osmium carbonyl cluster (Fig 1.3,
complex C) was reported to hyperstabilize microtubules in 2009.35
The mechanism of action for ruthenium(II) arene anticancer complexes was
generally believed to target DNA: labile-ligand substitution can generate an active
site on the ruthenium centre, it can bind to the DNA base to cause DNA damage
and kill cancer cells. But recent studies of a series of ruthenium(II) arene
anticancer compounds revealed that DNA was not necessarily the primary target
and these compounds might prefer to bind to proteins:41 ruthenium(II) arene
RAPTA derivatives containing two chloride ligands were found to be susceptible
to hydrolysis and were firstly anticipated that DNA was a primary target.41 To
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gain more insight, Messori et al. studied and found the inhibition activity of a
series of RAPTA compounds towards two enzymes, i.e., cathepsin B (Cat B) and
thioredoxin reductase (TrxR), which are possible targets for anticancer
ruthenium(II) RAPTA complexes. However, the in vitro anticancer activities for
these RAPTA complexes are far from reaching the activity of cisplatin; it makes
them less promising for potential clinical use independently.42
Figure 1.3. Examples of organometallic anticancer complexes.
The design and development of cytotoxic organometallic anticancer drugs are
primarily observation-driven: the anticancer effect was usually found before the
disclosure of the mechanism of action. However, one strategy for designing
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anticancer organometallic complexes by making use of known organic anticancer
drugs was newly developed. Using this strategy, Meggers’ group had shown
promising results for designing organometallic complexes for inhibitions of
kinases.43 The strategic procedure of making an extension from organic anticancer
drugs can be summarized as follows:
1. Selection of a target and analysis of existing co-crystal structure of organic
compound with the target active site. (Example: a number of the class of
indolocarbazole alkaloids, which are potent ATP-competitive protein kinase
inhibitors).
2. Identification of the main pharmacophore and incorporation into a ligand
(for metal-binding).
3. Targeting metal complex to the active site by the incorporation of
pharmacophore ligand (Additional ligand in the metal coordination sphere can
form bonds to other parts of the active site to improve the biological effect and/or
selectivity; and the metal can contribute coordinative binding to the active site).
The achievable advantages are summarized below:
1. The diversity of coordination numbers and geometries of metals might be
used to exploit original design of pharmacophores that are not easily reached with
organic elements.
2. The synthetic routes for metal complexes are generally easy. It makes the
synthesis of complexes with desired features by combinatorial library design for
high throughput screening (HTS) and evaluation more applicable.
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3. Distinctive and tunable properties of metals can be exploited for the
generation of a tailored function.
4. Crucial coordinate bonds can be achieved between metal and active binding
site which are totally different from hydrogen bonds or covalent bonds which are
common binding modes for organic drugs.44
In general, it is possible to tune the biological activity and drug properties
through changing the metal`s coordination numbers, geometries, oxidation states
and charges. It is also noted that the catalytic ability and other unique chemical
properties of metal complexes have the potential to be developed as favorable
physicochemical properties of drugs for different diseases.
1.3.3. Redox Status
The thiol/disulfide levels are closely related to the redox status in cells. Other
than DNA and proteins which were mentioned above, the manipulation of
thiol/disulfide levels in cells is also gaining attention as a method to kill cancer
cells. There is one anticancer agent that can down-regulate thiol levels in clinical
trial: L-buthionine sulfoximine (L-BSO). L-BSO is a glutathione-lowering drug
which can sensitize CDDP-resistant ovarian cancer cells; it can also increase the
sensitivity of antihormone-resistant human breast cancer cells to estrogen-induced
apoptosis45 and enhance apoptosis with the treatment of transforming growth
factor-alpha of pancreatic cancer cells46 (pancreatic cancer is the 5th most common
cause of death from cancer in the world). Moreover, phase I study of L-BSO had
proven it to be safe and well-tolerated in patients. In summary, L-BSO is a potent
anticancer drug candidate with low toxicity for the combination treatment with
other anticancer drugs.
To elucidate the redox status of cells, with the help of redox western analysis
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and redox-sensitive green fluorescent protein assays, the following order from
most reducing to most oxidizing was found:
mitochondria > nuclei > cytoplasm > endoplasmic reticulum > extracellular
space.47
This sequence indicates that the mitochondria to be a sensitive target of
oxidant-induced damage, the damage of mitochondria can lead to apoptosis and
necrosis of cells. At the same time, the alkaline pH maintained by mitochondria
will possibly amplify the damage.47 The thiols
,
levels are important for the
protection of cells against reactive oxygen species and free radicals. In that,
anticancer drugs which can change the cellular thiols levels may have a potential
to kill cancer cells through mitochondria-mediated cell death.
There are three major thiol/disulfide couples, namely glutathione
(GSH)/glutathione disulfide (GSSG), reduced thioredoxin [Trx-(SH)2]/oxidized
thioredoxin (Trx-SS) and cysteine (Cys)/cystine (CySS).48 Within these redox
couples, glutathione (GSH) content is believed to play the most important role for
maintaining the cellular redox status, because its concentration can range from 2
to 10 mM depending on the cell type which is much higher than other
thiol/disulfide couples.49 GSH (γ-glutamylcysteinylglycine) is an ubiquitous tri-
peptide that acts as an important radical scavenger;50, 51 it can protect the cells
against reactive oxygen species (ROS). Moreover, relatively high GSH levels than
normal tissues were observed in a range of human cancer tissues such as ovary,52
breast,53 colon,54 lung,55 bone marrow,56 and larynx;57 it was also discovered that
GSH levels in tumour tissues were associated with their resistance to
chemotherapy.58
Although ROS are generally believed to be toxic to cells, they act as a
‘double-edged sword’ for the proliferation of cell. In cells, when the ROS level is
up-regulated on a small scale, the ROS may contribute to the proliferation; if the
ROS level is raised further, it can cause DNA damage which will induce cell
cycle arrest and apoptosis.59 Therefore the selectivity to cancer cells rather than
normal cells can be achieved by increasing the ROS levels, because the basal ROS
levels in cancer cells are higher than normal cells (Fig. 1.4).
Another importan
production is the cellular O
HIF (hypoxia-inducible factor) signal pathway. Generally due to the consequence
of a poor and disorganized blood supply, solid tumours contain regions of low
oxygen tension (hypoxia), which will affect neovascularization, glucose
metabolism, survival and
HIF, a master transcriptional factor in nutrient stress signal pathway.
Overexpression of HIF is associated with increased tumo
vascularization and metastasis,
with another anticancer drug which is targeting
applicable for increasing the anticancer activity.
Figure 1.4. ROS level as ‘double
which can be achieved by increasing ROS.
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2 content. The content of oxygen in cells
tumour spread. This pleiotropic action is orchestrated by
in that, a combination therapy of HIF inhibitor
the redox system can be
61
-edged sword’ and the anticancer selectivity
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60
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Chapter 1: Introduction
14
There are two important families in cells contributing to the redox balance,
one is thiol/disulfide couples, the other one is nicotinamide adenine dinucleotide
(NADH) and its oxidised form (NAD+) together with their phosphorylated forms
NADPH/NADP+. NADH is not only a reducing part of the redox system balance
but also an important intermediate of mitochondrial respiration and glycolysis
which are crucial processes to provide energy for cells.62
Early work by Steckhan63 and Fish64 had shown an economical process for
the regeneration of NADH from NAD+ by rhodium catalysts. Following that,
ruthenium arene complexes were found to be able to regioselectivly reduce NAD+
to NADH through transfering hydride under physiological conditions in the
presence of formate.65 However, the involvement of the reactions between
NADH/NAD+ and metal complexes in the biological environment still need
further investigations.
1.4 Background of Osmium
1.4.1 Discovery of Osmium
In 1803, Smithson Tennant
in London (UK). Currently, osmium is principally acquired from the processing of
platinum and nickel
"osme" which means "smell". Unlike its closest relatives in the platinum group
(Fig 1.5, they have similar physical and chemical properties and occur together in
the same mineral deposits in most cases), o
such as ruthenium (in honour of Russia), palladium (namesake of the goddess
Pallas Athene), iridium ("rainbow" in Greek) and rhodium ("rose").
Figure 1.5. Periodic table: platinum group metals are labelled in blue.
1.4.2 Physical and Chemical Characteristics of Osmium
Osmium is an extremely
metal in the platinum group
element, 22610 kg⁄m³
densest element iridium
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and William Hyde Wollaston discovered osmium
ores.66 The origin of the name 'osmium' is the Greek word
smium was not given a beautiful name
dense, hard, brittle, blue-gray or blue
and its atomic number is 76. It is the densest natural
(22.61 g⁄cm³), slightly larger than the density of the second
: 22560 kg⁄m³ (22.56 g⁄cm³).
15
67
-black transition
Chapter 1: Introduction
16
The usual oxidation states of osmium are +4 and +3, but oxidation states from
-2 to +8 are all available. There are merely two osmium compounds which have
major applications: osmium tetroxide (OsO4) which is used for staining tissue for
electron microscopy and the non-volatile osmates which can act as catalysts in
organic oxidation reactions.68, 69
1.4.3 Isotopes of Osmium
There are at least 34 isotopes of osmium, but only seven exist in nature (Table
1.2). Although it is possible to observe the NMR signal of 187Os, it is one of the
most insensitive nuclei, so 187Os NMR is usually observed in complexes by
indirect detection via proton coupling.70
Table 1.2. Stable isotopes of osmium.71
Isotopes Natural Abundance Nuclear Spin
184Os 0.02% 0
186Os 1.59% 0
187Os 1.96% 1/2
188Os 13.24% 0
189Os 16.15% 3/2
190Os 26.26% 0
192Os 40.78% 0
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1.5 Design of Osmium Anticancer Complexes
1.5.1 Making Extension from Ru to Os
Since osmium and ruthenium belong to the same family, making extension
from one to the other can be achieved by a similar synthetic method; it may lead
to novel ruthenium/osmium complexes with similar physical and biological
properties. For example, the extension from OsO4 to RuO4 resulted in the
discovery of novel ruthenium electron microscopy fixing agent (RuO4) for
cytoplasmic membranes.72 Ruthenium and osmium complexes with similar
structures may share similar anticancer mechanism of action; in that, a lot of work
has been done to compare them on anticancer activity and mechanism of action
(Fig. 1.6). There are also some intriguing differences have been found on the
chemical properties between organometallic RuII and OsII arene complexes even
though their three-dimensional structures can be almost identical.73 For instance,
the two types of metal complexes have shown differences in redox potentials and
photoreacitons;74 osmium complexes are often considered to be more inert (a
common characteristic of low-spin d6 metal ions and especially 3rd row transition
metals).75, 76
Ruthenium complexes have shown a good potential as anticancer agents. The
design of osmium anticancer complexes, which are their heavier congeners,
should build on knowing the role that the coordination metal played in
maintaining its biological activity. When the ruthenium centre in the scaffold has
a solely structural role, only the shape of the organometallic complex is
responsible for its bioactivity, its osmium analogue is able to maintain the activity
because the atomic radii of the two elements (Ru and Os) are almost identical due
to the lanthanide contraction.27, 77 For example, the isostructural ruthenium(II) and
osmium(II) complexes were found to be good protein kinase inhibitors showing a
similar potency.78 Similarly, osmium(II) complexes with paullone derivatives
(known to be potent inhibitors of cyclin-dependent kinases) as chelating ligand
Chapter 1: Introduction
18
have been designed to increase the solubility and bioavailability of paullone
ligands; there is also no significant differences of antiproliferative activities
between the osmium and ruthenium analogues.79 In general, this method cannot
improve dramatically on anticancer activity with the metal serving as a structural
centre.
Other than making extension from ruthenium(II) to osmium(II), the extension
from ruthenium(III) to osmium(III) showed similar/better anticancer activity as
well. Although investigations are still needed to establish the mechanism of action
of ruthenium anticancer complexes, two Ru(III) complexes are already
undergoing clinical trials: NAMI-A and KP1091. Their anticancer mechanism of
action involves the reduced Ru(II) species, however, the reason for the
antimetastatic activity for NAMI-A is still unclear. This encouraging result has led
to the pursuit for more novel osmium complexes with similar structures. For
instance, NAMI-A type complexes of osmium have been synthesized and fully
characterized in Prof. Keppler`s group.80 In contrast to the ruthenium complexes,
the osmium analogues are more inert to hydrolysis similar to the rhodium and
iridium analogues which results in reduced binding to the DNA nucleobase
analogue, 9-methyladenine; Osmium complexes are able to show comparable
antiproliferative activity to the ruthenium congeners, and in some cases, the
osmium complex is 10 times more potent than the ruthenium congeners.80 The
osmium analogue of indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)]
(KP1019) also showed promising anticancer activity.81
Ruthenium and osmium polypyridyl complexes have shown interesting
photophysical properties82, 83 which can be employed for anticancer treatment.
There are two types of photochemistry expected which can be used for anticancer
treament: (1) photo-redox processes with important biomolecules such as DNA;
complexes with this type of photochemistry have the potential to become
candidates for photodynamic therapy (PDT)84 which makes use of
photosensitizers to produce reactive oxygen species (ROS) to kill cancer cells;85, 86
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(2) photo-substitution of a ligand by a biomolecule such as nucleobase; this
property can be developed for photoactivated chemotherapy (PACT)87-90 which
have been highlighted recently.74, 90 Considering the comparisons between
ruthenium and osmium for PDT, there is one advantage of using osmium instead
of ruthenium: osmium complexes have lower oxidizing power and undergo
exclusive photoreactions from the 3MLCT state, which results in a red shift in the
UV–Vis spectra and indicates the possibility of using longer wavelengths91 for
PDT.92 Other than osmium centred PDT, it is also noted that osmium-porphyrin
complexes have been investigated and reviewed recently relating to the
supramolecular chemistry of metalloporphyrins.93
Figure 1.6. Examples of osmium anticancer complexes developed by different
research groups which also have their ruthenium analogues.
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1.5.2 Design of Osmium Anticancer Complexes
Osmium has a similar potential to ruthenium in binding to a variety of
biomolecules such as DNA.94-96 There are two major reasons to study osmium
analogues of ruthenium: (1) to broaden the knowledge through the comparisons of
the structures, spectroscopic properties, electrochemical behaviours, DNA binding
properties, aqueous stabilities and reduction potentials; (2) to achieve better drug
properties and anticancer activities by exploiting the differences between the two
metals.
As to the clinical use of osmium, in history, the first clinical used osmium
compound was osmium tetroxide (OsO4). It was used on a limited basis for the
treatment of arthritis in human about 35 years ago, principally in Europe. In 1976,
a group of researchers in Switzerland reported that over 70 patients were helped
by this treatment. Regarding the mechanism of action, the treatment used OsO4 as
one synovectomy agent.97 This clinical use of osmium tetraoxide without any
serious toxicity reports suggests the bio-compatibility even for osmium (VIII); the
+8 oxidation state is the highest for osmium and any other chemical element.
Lower than oxidation state of osmium tetraoxide, a family of nitridoosmium(VI)
schiff-base complexes were reported to show anticancer activity in vitro and one
of the complexes showed anticancer activity in vivo without apparent induced
toxic side-effect.98
In order to avoid the potential of oxidizing toxicity introduced by osmium in
high oxidation state, the osmium work in this thesis will concentrate on osmium
complexes with lower oxidation state of osmium than OsO4 and
nitridoosmium(VI) schiff-base complexes: osmium(II). The design of the half-
sandwich structure is based on the work on ruthenium complexes previously
reported in Sadler`s group. Organometallic half-sandwich complexes [M(η6-
arene)(YZ)(X)], where YZ is typically a chelating diamine ligand (e.g.
ethylenediamine) and X is a halide (e.g. Cl), M = RuII, were found to exhibit
anticancer activity in vitro and in vivo.99, 100 Similar to cis-platin, the target is
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believed to be DNA, the labile Ru-Cl bond is able to undergo hydrolysis to form
Ru-OH2 intracellularly, whereas the hydrolysis is suppressed extracellularly.101
The hydrolysis generates one reactive site on ruthenium which can bind to a DNA
base (e.g. guanine) and lead to cell death.102 The activity can also be tuned by
changing the arene and the leaving group. Because the arene can contribute an
intercalation effect to DNA binding and the leaving group modulate the
hydrolysis: high activity: halide---easy hydrolysis, low activity, e.g. pyridine, inert
to hydrolysis.103, 104 Their osmium analogues were also studied and the
mechanism of action which is similar to that of the ruthenium complexes was
summarized below in Figure 1.7.
Figure 1.7. General structure of osmium anticancer complexes with piano-
stool structure containing an arene, a chelating ligand YZ and a monodentate
ligand X which can be labile to provide an active reactive site for the binding of
biomolecules or is inert to hydrolysis to maintain its structure with anticancer
activity through novel mechanisms. In water, the Os-X bond (when X is labile) is
able to hydrolyse to generate the corresponding aqua product which can be
deprotonated to from the hydroxo-Os adduct.
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Figure 1.8. The mechanism of activity of iodido ruthenium azopyridine
complexes involving catalytic oxidation of GSH.26
Another work on ruthenium from Sadler`s group had shown when M = Ru,
XY = azopyridine chelating ligand and Z = iodide, the half-sandwich complexes
were inert toward hydrolysis but could still show anticancer activities. A possible
mechanism involves the iodido RuII azopyridine complexes acting as catalysts for
oxidation of the tripeptide glutathione which is the major reducing agent in cells,
in that, the oxidative stress will kill the cancer cells (Fig. 1.8).26 The azopyridine
ligands are well known for their strong π-acidity,105 stabilizing the lower oxidation
states of a metal. Azo compounds as ligands are very important for redox
reactions of iodido RuII complexes; interestingly, the azo ligands themselves also
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have a potential to oxidize GSH to GSSG which is facilitated by O2.106-108
Inspired by the ruthenium work previously carried out in our group, the
analogous osmium(II) complexes109 are studied in this thesis (Fig. 1.9). The goal
of anticancer research programs is to identify novel, synthetically-feasible
molecules that can exhibit good anticancer activity with minimal side-effects. One
efficient approach is the study of bioisosterism, a term coined to describe the
modification of biological activity by isosterism.110-112 Following this design, the
general structures of osmium complexes are shown below in Figure 1.9.
Figure 1.9. Osmium complexes designed in this thesis.
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1.6 Aims
The general aim of this project is to synthesize, characterize and undertake
tests on cancer cell toxicity and establish structure-activity relationships to help
with the rational design and understanding of the mechanism of action on three
new families of osmium(II) arene complexes which are generated by
modifications on the chelating ligands. The individual aims are summarized
below:
1. To gain an understanding of the aqueous solution chemistry and anticancer
activity in vitro and in vivo of osmium(II) arene azopyridine complexes in relation
to their chemical structures.
2. To discover the mechanism of action of osmium arene azopyridine
complexes by using the structure activity relationship (SAR) of anticancer activity
and combination treatments.
3. To explore the possibility of transferring hydride from NADH and
investigate the mechanism of action of osmium(II) arene iminopyridine anticancer
complexes.
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In this chapter, the general techniques and instrumentation used in this thesis
are described. More details of individual experiments are described in each
appropriate chapter. The synthesis and characterization of osmium iodido dimers
used as starting materials are also included.
2.1 Materials and Synthesis
2.1.1 Materials
OsCl3.3H2O and osmium Specpure Plasma Standard were purchased from
Alfa-Aesar. Ethanol and methanol were dried over Mg/I2 or anhydrous quality
was used (Aldrich). All other reagents used were obtained from commercial
suppliers and used as received. The preparations of the starting materials [Os(η6-
bip)Cl2]2 and [Os(η6-p-cym)Cl2]2 have been previously reported.1 The synthesis
method of the azopyridine ligands has been previously described.2 The A2780
human ovarian carcinoma cell line and A549 human lung adenocarcinoma
epithelial cell line were purchased from the European Collection of Animal Cell
Cultures (Salisbury, UK), RPMI-1640 media and trypsin were purchased from
Invitrogen, bovine serum from Biosera, penicillin, streptomycin, trichloroacetic
acid (TCA) and sulforhodamine B (SRB) from Sigma-Aldrich, and
tris[hydroxymethyl]aminomethane (Tris) from Formedium.
[Os(η6-bip)I2]2. The dimer [Os(η6-bip)Cl2]2 (100.4 mg, 0.12 mmol) was stirred at
353 K for 1 h suspended in water (200 mL). The solution then hot-filtered and KI
(1039.8 mg, 6.26 mmol) was added to the solution. A deep orange precipitate was
formed immediately. The solution was left in the fridge (277K) for 2 h. The
precipitate was collected by filtration and washed with cold ethanol and diethyl
ether, then dried in a desiccator overnight. Yield: 95.4 mg (66.0%). Anal. 1H
NMR(DMSO-d6) δ 7.74 (d, 4H), 7.45 (m, 6H), 6.84 (d, 4H), 6.56 (d, 2H), 6.34 (d, 
4H). CHN analysis: Found C, 24.33 %; H, 1.64 %, Calcd for C24H20I4Os2: C,
24.09 %; H, 1.68 %.
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[Os(η6-p-cym)I2]2. The dimer [Os(η6-p-cym)Cl2]2 (103.8 mg, 0.135 mmol) was
stirred at 353 K for 1 h to allow it dissolved in water (50 mL). Then KI (2683.9
mg, 16.18 mmol) was added to the solution and heated under reflux for 1 h. A
deep orange precipitate was formed immediately. The solution was left in a fridge
(277K) for 2 h. The precipitate was collected by filtration and washed with cold
ethanol and diethyl ether, then dried in a desiccator overnight. Yield: 112.6 mg
(67.9%). Anal. 1H NMR (DMSO-d6) δ 6.10 (dd, 8H), 3.04 (m, 2H), 2.43 (s, 6H), 
1.25 (d, 12H). CHN analysis: Found: C, 20.78 %; H, 2.35 %, Calcd for
C20H28I4Os: C, 20.77 %; H, 2.44 %.
2.1.2 Synthesis
Osmium complexes studied in this thesis were synthesized through one
general method: stirring osmium dimer with chelating ligand in methanol or
methanol/water mixture at ambient temperature or 353K for a period of time, then
an excess of NH4PF6 was added to the solution, the precipitate (product) was
collected by filtration and washed with cold ethanol and diethyl ether, finally
dried under vacuum. The general synthesis route was summarized below in Chart
2.1.
Chart 2.1. Synthesis route for osmium complexes studied in this thesis.
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2.2 Instrumentation and Methods
2.2.1 NMR Spectroscopy3
1H NMR spectra were acquired in 5 mm NMR tubes at 298K or 310K on
either Bruker DPX-400, Bruker DRX-500, Bruker AV III 600 or Bruker AV II
700 spectrometers. 1H NMR chemical shifts were internally referenced to acetone
(2.09 ppm), 1, 4-dioxane (3.71 ppm), CHCl3 (7.27 ppm) or DMSO (2.50 ppm). A
lot of NMR were performed in aqueous solutions so as to be biological relevant.
The use of aqueous solutions results in a huge HOD signal which can obscure
other proton peaks in the 1H spectrum. To minimize this effect, the HOD signal
can be suppressed by presaturation.4 This technique involves the saturation of the
HOD peak by irradiation of the frequency of water between pulse sequences. The
disadvantage of this technique is that the signals close to HOD peak are also
reduced in terms of intensity. All data processing was carried out using MestReC
or TOPSPIN version 2.0 (Bruker U.K. Ltd.).
2.2.2 Electrospray Ionisation Mass Spectrometry (ESI-MS)
Spectra were obtained by preparing the samples in 50% CH3CN and 50% H2O
(v/v) and infusing into the mass spectrometer (Varian 4000). The mass spectra
were recorded with a scan range of m/z 500-1000 for positive ions. Data were
processed using Data Analysis version 3.3 (Bruker Daltonics).
2.2.3 Elemental Analysis
Elemental analysis (carbon, hydrogen, and nitrogen) was carried out through
Warwick Analytical Service using an Exeter analytical elemental analyzer
(CE440).
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2.2.4 UV-Vis Spectroscopy
UV-Vis spectra were recorded on a Cary 50-Bio spectrophotometer using 1-
cm path-length quartz cuvettes (0.5 mL) and a PTP1 Peltier temperature controller.
Spectra were recorded at 310 K from 800 to 200 nm. All data processing was
carried out using Excel 2007 (Microsoft, USA) or Origin 7.5 (Origin, USA).
2.2.5 pH* Measurements
pH* (pH meter reading from D2O solution without correction for effects of
deuterium on glass electrode) values were measured at ambient temperature
before the NMR spectra were recorded, using a Corning 240 pH meter equipped
with a microcombination electrode calibrated with Aldrich buffer solutions at pH
4, 7 and 10. The pH* values were adjusted with dilute NaOH or HNO3 solutions in
D2O.
2.2.6 Calculations of pKa* Values
1H NMR spectra were recorded when the pH* values of aqua complexes in
D2O were varied from ca. 1 to 12 in pH* by adjusting with diluted NaOH or
HNO3 solutions in D2O. The chemical shifts of the ligands were plotted against
pH* values. The curve from the pH* titration was fitted to the Henderson-
Hasselbalch equation5 using ORIGIN 7.5, with the assumption that the observed
chemical shifts are weighted averages according to the populations of the
protonated and deprotonated species. These pKa* values can be coverted to pKa
values by using the equation pKa=0.929pKa*+0.42 as suggested by Krezel and
Bal.6
The Henderson-Hasselbalch Equation: pH = pKa + log10([A-]/[HA])
When half is dissocated: [HA] = [A-] and pH = pKa
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When δobs is the chemical shift of observation at a given pH and δHA and δA
-
are the chemical shifts at low and high pH respectively, the Henderson-
Hasselbalch equation can be modified as below7:
δobs = [δHA + δA
- × 10 (pKa*- pH*)]/[1 + 10 (pKa*- pH*)]
2.2.7 X-ray Crystallography
X-ray diffraction data were generally obtained on an Oxford Diffraction
Gemini four-circle system with a Ruby CCD area detector using Mo Kα 
radiation.8 Absorption corrections were applied using ABSPACK. The crystals
were mounted in oil and held at 100(2) K with the Oxford Cryosystem
Cryostream Cobra. The structures were solved by direct methods using SHELXS
(TREF) with additional light atoms found by Fourier methods.9 Refinement used
SHELXL 97.10 H atoms were placed at geometrically calculated positions and
refined riding on their parent atoms. All the data collection and solution of crystal
structures were carried out by Dr. Guy Clarkson from Department of Chemistry,
University of Warwick. Details of the acquisition and solving the individual
crystal structures are explained in the corresponding chapters.
2.2.8 Electrochemistry
The electrochemical study was carried out using the similar conditions as for
the ruthenium analogues reported previously.2 It was performed with a CHI730A
bipotentiostat (CH Instrument, USA) system. All of the electrochemical
techniques used a three-electrode configuration with all the electrodes in solution,
one 2 mm diameter platinum disc electrode was used as the working electrode
with a chloridized silver wire as the quasi-reference electrode and a Pt counter
electrode (CH Instrument, USA). The reference electrode was Ag/AgCl in a
solution of 0.1 M [TBA][BF4] in DMF against which E1/2 for the
ferrocenium/ferrocene couple was measured to be +0.55 V.
2.2.9 Cell Cultures
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A549 non-small cell lung and A2780 ovarian human cell lines (ECACC,
Salisbury, UK) were cultured in RPMI 1640 cell culture medium supplemented
with 1 mM sodium pyruvate, 2 mM L-glutamine and 10% fetal bovine serum.
2.2.10 Determination of IC50 Values
The concentrations of the osmium complexes that inhibit 50% of the
proliferation of human ovarian A2780 cancer cells were determined using the
sulforhodamine B assay (Fig. 2.1).11 A2780 cells were seeded in 96-well plates
(Falcon) at 5000 cells/well, after incubation for 48 h. The complexes were
solubilised in DMSO (Sigma) to provide 10 mM stock solutions. These were
serially diluted with cell culture media to give concentrations four-fold greater
than the final concentrations for the assay. The complexes diluted in cell culture
media were added to the 96-well plates with cells in triplicate. The final DMSO
concentration in each well was no more than 1% (v/v). The media containing the
complexes were removed after 24 h. The cells were washed with phosphate
buffered saline once and cell culture medium was added (150 µL/well). The cells
were then allowed to grow for a further 72 h. The surviving cells were fixed by
adding 150 µL/well of 50% (w/v) trichloroacetic acid and incubated for 1 h in a
refrigerator (277 K). The plates were washed with tap water three times and dried
under a flow of warm air, 0.4% sulforhodamine B (Sigma) solution (100 µL/well)
was added, followed by washing with 1% acetic acid five times and drying under
a flow of warm air. The dye was dissolved in 10 mM Tris buffer (200 µL/well).
The absorbance of each well was determined using a Multiskan Ascent plate
reader (Labsystems) at 540 nm. The absorbance of SRB in each well is directly
proportional to the cell number. Then the absorbance was plotted against
concentration and the IC50 determined by using Origin software (version 7.5).
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Figure 2.1 Chemical structure of SRB
2.2.11 NAC and L-BSO Combination Treatments
A2780 cells or A549 cells were treated with 50 μM NAC or L-BSO and 
various concentrations of osmium complexes for 24 h. Then NAC/L-BSO and
osmium complexes were removed at the same time and the cells were washed
with PBS once, then incubated for a further 72 h for recovery. Cell viability was
determined by using the SRB assay as described above.
2.2.12 Inductively Coupled Plasma Mass Spectroscopy (ICP-MS)
ICP-MS analyses were carried out on an Agilent Technologies 7500 series
ICP-MS instrument. The water used for ICP-MS analysis was double deionized
using a USF Elga UHQ PS water deionizer. To make the stock solution of
osmium standard, the osmium Specpure plasma standard was diluted in double
deionized water to 20 ppm; the osmium standards for calibration were freshly
prepared by diluting this stock solution with 3.6 % HNO3 in double deionized
water. The concentrations used were 400, 200, 100, 50, 25, 10, 5, 1, 0.5 and 0.1
ppb of 189Os. In this thesis, ICP-MS was employed to analyze the osmium
concentration in water solution, cell samples and tissue samples after digestions.
All the water used for ICP-MS was double deionised by using USF Elgar UHQ
water system.
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2.2.13 Determination of Partition Coefficient (log P)
Octanol-saturated water and water-saturated octanol were prepared by stirring
the mixtures of octanol and water for 24 h. Aliquots of stock solutions of osmium
complexes in octanol-saturated water (2 mL) were added to the same volumes of
water-saturated octanol (2 mL), and the solutions were shaken in an IKA Vibrax
VXC basic shaker for 4 h at the speed of 500 g/min after partition. The aqueous
layer was transferred into test tubes for osmium analysis. Aqueous samples before
and after partitioning were diluted with 3.6 % HNO3 to the appropriate range for
the analysis by ICP-MS calibrated with aqueous standards (osmium, 0.1-400 ppb).
These procedures were carried out at ambient temperature (ca. 298 K). Log P
values for osmium complexes were calculated using the equation log Poct =
log([Os]oct/[Os]aq).12
2.2.14 Cellular Uptake
A2780 cells were seeded at the concentration of 106 cells/well in 6-well plates.
After 24 h incubation, cells were exposed to osmium complex. After drug
exposure, the drug-containing medium was removed. Then samples were washed
with PBS twice, trypsinized, collected and stored at 253 K until ICP-MS analysis
for osmium content. The numbers of cells were counted using a cytometer. The
whole cell pellets were digested as described above. Firstly, 0.5 mL of freshly
distilled 72% HNO3 was added to each 1 mL cells pellets, and the samples were
transferred into Wheaton V-Vials. The vials were heated in an oven at 373 K for
16 h to digest the samples fully, allowed to cool, and then transferred to Falcon
tubes. The vials were washed with double deionized water three times and diluted
10 times with double deionized water to obtain 6% HNO3 sample solutions. A
blank and the standards were loaded into the sample tray and were run from the
lowest to the highest concentration in a ‘no gas’ mode, followed by the samples.
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2.2.15 Separation of Cell Fractions
The A2780 cells were seeded into Petri dishes at a concentration of 5×106
cells/dish. After 24 h incubation, osmium compounds were added. The cells were
harvested after a further incubation with osmium compound for 24 h. Then the
four cell fractions (cytosol, membrane plus particulate fraction, nucleus and
cytoskeleton) were separated following the protocol described for the kit
(Biovision, Inc, USA). The concentrations of osmium in different fractions were
measured by ICP-MS after digestion following the same method as for the cellular
uptake study.
2.2.16 Detection of ROS
To detect changes in general oxidative stress,13 the level of ROS (including
O2-, OH∙, H2O2) in A2780 cells was determined using the probe 2 ′ ,7 ′ -
dichlorodihydrofluorescein-diacetate (DCFH-DA, Figure 2.2). When taken up by
live cells, DCFH-DA hydrolyzes to 2′,7′-dichlorodihydrofluorescein (DCFH), 
which in turn is oxidized to 2′,7′-dichlorofluorescein (DCF) in the presence of 
ROS and detected by its intense fluorescence.14, 15
Figure 2.2 Mechanism of de-esterification from DCFH-DA to DCFH, which
is oxidized to fluorescent DCF.
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Propidium iodide (PI)
The vial of DCFH-DA was opened under N2 protection, and contents were
dissolved in DMSO to give a 10 mM stock solution. A2780 cells were seeded
(5000 cells/well) into black 96-well plates and incubated for 24 h at 310 K, 5%
CO2, high humidity. Cells were loaded with DCFH-DA (10 µM) and incubated
for 30 min. The probe was removed and PBS was used to wash the cells twice.
The cells were then kept in PBS solution and osmium compound was added.
Hydrogen peroxide was also added as the positive control. The fluorescence was
recorded over a period of 4 h at 310 K by excitation at 480 nm and emission at
530 nm on a TECAN plate reader.
2.2.17 Cell Cycle Analysis16
To analyze the cell cycle distributions, propidium iodide (Fig. 2.3) is used as
one fluorescent probe for cell cycle and apoptosis analysis.17 It can be excited
with 488 nm wavelength light then show red fluorescence. It binds to DNA by
intercalating between the nucleobases with little sequence preference, it can also
bind to RNA, so it is necessary to use RNAse to treat the cell samples to avoid
this effect before analyzing cell cycle. Once the PI dye is bound to nucleic acids,
its fluorescence is enhanced 20~30 fold which makes it more sensitive for
detection. PI is membrane impermeant, in that, for the cell cycle analysis, all the
cells should be fixed or treated by permeabilizing agent (eg. Triton X-100) to
make sure PI can get through cellular membrane.
Figure 2.3 Chemical structure of PI.
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A2780 cells were incubated with osmium complex of various concentrations
for 24 h and then harvested. Then the collected cells were washed with PBS and
fixed in 70% ethanol (253 K). The fixed cells were centrifuged and washed once
with PBS, followed by resuspension in PBS containing 7.5 µM propidium iodide
(PI) and 100 µg/ml RNase A. They were analyzed by flow cytometry (FACS-
Calibur, Beckton Dickenson). The cell cycle distribution was evaluated using the
Flow Jo 7.0 (Tree Star, USA).
2.2.18 Tubulin Polymerization Assay
A cytoskeleton tubulin polymerization assay kit (Cytoskeleton, USA catalogue
no BK004) was used in the tubulin polymerization study. Briefly, 10 μL of 
general tubulin buffer (80 mM PIPES, pH 6.9, 2 mM MgCl2 and 0.5 mM EGTA)
containing osmium compound, colchicine or taxol was pipetted into the
prewarmed 96 well microplate. Tubulin (defrosted to room temperature from -
80 °C and then placed on ice before use) was diluted with tubulin polymerization
buffer with 1 mM GTP to a final concentration of 4 mg mL-1. Diluted tubulin (100
μL) was added into the wells containing osmium compound, colchicine or taxol. 
Diluted tubulin (100 μL) mixed with general tubulin buffer (10 μL) served as 
control. The absorbance at 340 nm was read immediately with a Tecan microplate
reader (TECAN, Switzerland).
2.2.19 Immunofluorescence by Confocal Microscopy18
A2780 Cells were seeded on Lab-TekTM Chamber Slides (Thermo Scientific
Nunc, UK) 10,000 cells/chamber, after 24 h incubation, osmium compound at
different concentrations were added and incubated for another 24 h. Cells were
fixed with 4% formaldehyde in PBS (20 min, 310 K), then rinsed with PBS (3 × 2
mL×2 min), and permeabilized with 0.1% Triton X-100 solution (PBS solution)
for 15 min at ambient temperature. The cells were blocked with blocking buffer (2
mg/ mL BSA, overnight at 269 K), and then, the cell monolayers were incubated
(1 h, 310 K) with monoclonal anti
Molecular Probles, Catalog No. 32
488 was shown in Figure 2.4.
PBS and the immunofluorescence was detected using a Leica SP5 fluorescence
confocal microscope, with 100× objective.
Figure 2.4
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-α-tubulin-Alexa 488 (4 µg/mL) (Invitrogen
-2588) and PI (7.5 µM). The structure of Alexa
After the incubation, the cells were washed with
Chemical structure of Alexa 488.
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3.1 Introduction
The success of platinum complexes (e.g. cisplatin and carboplatin) as
anticancer drugs is well known, however, these drugs have a limited spectrum of
activity, can have severe toxic side-effects, and tumours often develop resistance.1,
2 A number of ruthenium-based compounds have been reported to display
promising anticancer activity3-6 and two octahedral ruthenium(III) complexes
have reached clinical trials.7, 8 The RuIII complexes are thought to be reduced to
active RuII species in vivo. Ruthenium(II) can be stabilized by π-bonded arene 
ligands and a range of RuII arene complexes of the type [Ru(η6-arene)(XY)Z)]
where XY = diamine chelate and Z = Cl, show in vitro and in vivo anticancer
activity.9, 10 These complexes can undergo activation via hydrolysis and bind
strongly to DNA, a potential target.11
Arene complexes of the heavier congener osmium(II) display similar
structures in the solid state to those of RuII but are subtly different with regard to
their chemical reactivity. For example, OsII arene ethylenediamine chlorido
complexes hydrolyze ca. 40x more slowly and the related aqua adducts have pKa
values for OsOH2/OH which are ca. 1.5 pKa units lower (more acidic) than those
of the analogous RuII complexes.9, 12 Faster ligand exchange in OsII complexes can
be achieved by incorporating oxygen-containing chelating ligands, e.g.
picolinates.13, 14 Several examples of OsII arene complexes which exhibit cancer
cell cytotoxicity have now been reported.15-19
The introduction of strong π-acceptor chelating (XY) ligands such as 
bipyridine or azopyridine (Azpy), dramatically changes the properties of the Os
and Ru complexes.11, 16, 20 For example, Ru complexes of the type [Ru(η6-
biphenyl)(Azpy)I]+ are relatively inert towards ligand substitution and appear to
kill tumour cells by ligand-centered redox-mediated mechanisms.21 Here we
report the synthesis of a range of osmium complexes of formula [Os(η6-
arene)(azopyridine-R)Z]+ where arene = p-cymene (p-cym) or biphenyl (bip), R =
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hydrogen (H), hydroxyl (OH) or dimethylamino (NMe2), and Z = chloride or
iodide (Chart 3.1). The X-ray crystal structures of five complexes are reported and
their chemical reactivity is investigated. Surprisingly, several of these OsII
azopyridine complexes are an order of magnitude more potent than the clinically-
used drug cisplatin towards a range of human cancer cell lines. An evaluation of
their toxicity in mice bearing xenografted colon tumours is also reported.
3.2 Experimental Section
3.2.1 Synthesis of Azo Ligands. Syntheses of azpy ligands were based on
literature reports.11
3.2.2 Synthesis of Complexes
Complexes 1 – 12 were prepared by the same general method: reaction of the
appropriate azopyridine derivative with the dimers; [Os(η6-bip)Cl2]2, [Os(η6-
bip)I2]2, [Os(η6-p-cym)Cl2]2 or [Os(η6-p-cym)I2]2. The purities of all compounds
prepared were determined to be ≥95% by elemental analysis.
[Os(η6-bip)(Azpy)I]PF6 (1)
[Os(η6-bip)I2]2 (30 mg, 0.025 mmol) in methanol (30 mL) and water (10 mL ) was
heated under reflux at 353 K under nitrogen for 2 h. Azpy (9.15 mg, 0.05 mmol)
in methanol (10 mL) was added drop-wise. The solution-colour changed from
orange to red immediately. After heating under reflux for another 2 h; the solution
was hot-filtered and the volume was reduced to about 10 mL on a rotary
evaporator. Ammonium hexafluorophosphate (40.0 mg. 0.25 mmol) was added.
The solution was left in the fridge for 2 h. A brown powder precipitated out. The
powder was collected by filtration and washed with little cold ethanol and diethyl
ether, then dried in a dessicator overnight. Yield: 20 mg (61.1%). Anal. ESI-MS
Calcd for C23H19IN3Os: m/z 656.0, found 655.9. 1H NMR((CD3)2CO)  δ 9.44 (d, 
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1H, J = 8 Hz), 9.01 (d, 1H, J = 8 Hz), 8.38 (t, 1H, J = 8 Hz), 7.98 (d, 2H, J = 8 Hz),
7.76 (m, 3H), 7.47 (m, 6H), 7.12 (d, 1H, J = 6 Hz), 6.98 (t, 1H, J = 6 Hz), 6.83 (m,
2H), 6.72 (t, 1H, J = 5 Hz). CHN analysis Found: C, 35.41%; H, 2.40%; N, 5.55%,
Calcd for C23H19F6IN3OsP: C, 34.55 %; H, 2.40 %; N, 5.26 %.
[Os(η6-p-cym)(Azpy)I]PF6 (2)
[Os(η6-p-cym)I2]2 (30.5 mg, 0.0264 mmol) was dissolved in methanol (20 mL)
and Azpy (9.6mg, 0.053 mmol) in methanol (10 mL) was added drop-wise. The
solution-colour changed from yellow to brown gradually and was stirred at
ambient temperature for 3 h. The volume was reduced to about 10 mL by removal
of methanol on a rotary evaporator. Ammonium hexafluorophosphate (17.7 mg.
0.11 mmol) was added. Then the solution was left in the freezer for 24 h; a dark
coloured powder precipitated, which was collected by filtration and washed with
cold ethanol and diethyl ether, then finally dried in vacuum. Yield: 14.5 mg
(35.3%). Anal. Calcd for C21H23IN3Os: m/z 636.1, found 636.0. 1H
NMR((CD3)2CO) δ 9.66 (d, 1H, J = 6 Hz), 9.04 (d, 1H, J = 8 Hz), 8.41 (t, 1H, J = 
8 Hz), 8.20-8.19 (m, 2H), 7.87-7.75 (m, 4H), 6.77 (d, 1H, J = 6 Hz), 6,43 (d, 1H, J
= 6 Hz), 6.38 (d, 1H, J = 5 Hz), 6.32 (d, 1H, J = 5 Hz), 2.67 (s, 3H), 2.62 (m, 1H),
1.04 (d, 3H, J = 7 Hz), 1.02 (d, 3H, J = 7 Hz). CHN analysis Found: C, 32.19%; H,
2.85%; N, 5.34%, Calcd for C21H23F6IN3OsP: C, 32.36%; H, 2.97%; N, 5.39%.
Single crystals suitable for X-ray diffraction were obtained by slow evaporation of
a methanol solution of complex 2 at ambient temperature.
[Os(η6-bip)(Azpy-OH)I]PF6 (3)
[Os(η6-bip)I2]2 (86.1 mg, 0.072 mmol) in methanol (30 mL) and water (10 mL )
mixture was heated under reflux at 353 K under nitrogen for 2 h. Azpy-OH (19.0
mg, 0.096 mmol) in methanol (10 mL) was added drop-wise, the solution colour
changed from orange to red immediately, the solution was heated to reflux for
further 2 h, hot-filtered, and the volume was reduced to about 10 mL by removal
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of methanol on a rotary evaporator. Ammonium hexafluorophosphate (118.5 mg,
0.73 mmol) was added and the solution was left in the fridge for 2 h. A deep
brown powder precipitated which was filtered off and washed with cold ethanol
and diethyl ether, then dried in a dessicator overnight. Yield: 63.1 mg (53.7%).
Anal. ESI-MS Calcd for C23H19IN4OOs: m/z 672.02, found 671.9. 1H
NMR((CD3)2CO) δ 9.30 (d, 1H, J = 9 Hz), 8.80 (d, 1H, J = 8 Hz), 8.31-9.27 (m, 
1H), 8.02 (d, 2H, J = 9 Hz), 7.66-7.63 (m, 1H), 7.46 (m, 5H), 7.01 (d, 1H, J = 6
Hz), 6.93 (d, 2H, J = 6 Hz), 6.82 (m, 2H), 6.72 (t, 1H, J = 6 Hz), 6.66 (d, 1H, J = 6
Hz). CHN analysis Found: C, 34.07%; H, 2.34%; N, 5.03%, Calcd for
C23H19F6IN4OOsP: C, 33.87%; H, 2.34%; N, 5.03%. Single crystals of [(η6-
bip)Os(azpy-O)I]·0.5H2O suitable for X-ray diffraction were obtained by slow
evaporation of a methanol solution of complex 3* at ambient temperature.
[Os(η6-p-cym)(Azpy-OH)I]PF6 (4)
[Os(η6-p-cym)I2]2 (50.5 mg, 0.0437 mmol) was dissolved in methanol (50 mL);
Azpy-OH (17.4 mg, 0.087 mmol) in methanol (10 mL) was added drop-wise; The
solution was stirred at ambient temperature for 24 h with 10 drops of 1 M HCl
solution; The volume was reduced to about 2 mL by removal of methanol on a
rotary evaporator. The complex was purified by chromatography on a Sephadex
LH20 column. Ammonium hexafluorophosphate (28.6 mg. 0.18 mmol) was added.
Then the solution was left in the fridge for 0.5 h. A dark coloured powder
precipitated out, which was collected by filtration and washed with cold ethanol
and diethyl ether, then finally dried in vacuum. Yield: 30.6 mg (43.2%). Anal.
ESI-MS Calcd for C21H23IN3Os: m/z 652.1, found 652.0. 1H NMR((CD3)2CO) δ 
9.75 (bs, 1H), 9.58 (d, 1H, J = 6 Hz), 9.93 (d, 1H, J = 8 Hz), 8.40-8.38 (m, 1H),
8.19 (d, 2H, J = 9 Hz), 7.83-7.82 (m, 1H), 7.15 (d, 2H, J = 9 Hz), 6.72 (d, 1H, J =
6 Hz), 6.43 (m, 2H), 6.34 (d, 1H, J = 6 Hz), 3.35 (s, 3H), 2.63 (m, 1H), 1.04 (d,
3H, J = 7 Hz), 1.02 (d, 3H, J = 7 Hz). CHN analysis Found: C, 31.04%; H, 3.05%;
N, 5.28%, Calcd for C21H23F6IN3OOsP: C, 31.71%; H, 2.91%; N, 5.28%.
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[Os(η6-bip)(azpy-NMe2)I]PF6 (5)
[Os(η6-bip)I2]2 (100 mg, 0.037 mmol) in methanol (30 mL ) and water (10 mL)
was heated under reflux at 348 K under nitrogen for 2 h. Azpy-NMe2 (37.9 mg,
0.074 mmol) in methanol (10 mL) was then added drop-wise, the solution-colour
changed from orange to dark red immediately, then gradually turned to deep blue.
It was further heated to reflux for 1 h, hot-filtered and the volume was reduced to
about 10 mL by removal of methanol on a rotary evaporator, and ammonium
hexafluorophosphate (135.1 mg. 0.37 mmol) was added. Then the solution was
left in the fridge for 1 h. A dark colored powder precipitated and was collected by
filtration, washed with cold ethanol and diethyl ether, then dried under vacuum.
Yield: 22 mg (42.6%). Anal. ESI-MS Calcd for C25H24IN4Os: m/z 699.07, found
699.0, 1H NMR((CD3)2CO) δ  9.12 (d, 1H, J = 6 Hz), 8.54 (d, 2H, J = 8 Hz), 8.14 
(m, 3H), 7.49-7.40 (m, 6H), 7.02 (d, 1H, J = 6 Hz), 6.82 (d, 2H), 6.77 (d, 1H),
6.75-6.67 (m, 2H), 3.40 (s, 6H). CHN analysis Found: C, 36.22%; H, 2.93%; N,
6.81%, Calcd for C25H24F6IN4OsP : C, 35.65%; H, 2.87%; N, 6.65%. Single
crystals of suitable for X-ray diffraction were obtained by slow evaporation of a
methanol solution of complex 5 at ambient temperature.
[Os(η6-p-cym)(Azpy-NMe2)I]PF6 (6)
[Os(η6-p-cym)I2]2 (100.0 mg, 0.086 mmol) was dissolved in methanol (50 mL) at
313 K; Azpy-NMe2 (39.5mg, 0.175 mmol) in methanol (10 mL) was added drop-
wise, the solution-colour changed from orange to blue immediately. The solution
was stirred at ambient temperature for 3 h; The volume was reduced to about 10
mL by removal of methanol on a rotary evaporator, and ammonium
hexafluorophosphate (141.8 mg. 0.87 mmol) was added. Then the solution was
left in the freezer for 24 h; Dark colour powder was precipitated which was
collected by filtration, washed with cold ethanol and diethyl ether, then finally
dried in vacuum. Yield: 122.7 mg (86.7%). Anal. ESI-MS Calcd for C23H28IN4Os:
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m/z 679.1, found 679.0. 1H NMR((CD3)2CO) δ 9.43 (d, 1H, J = 6 Hz), 8.65 (d, 1H, 
J = 8 Hz), 8.29-8.22 (m, 3H), 7.64 (m, 1H), 6.97 (d, 2H, J = 9 Hz), 6.59 (d, 1H, J
= 6 Hz), 6.30 (m, 3H), 3.41 (s, 3H), 2.80 (s, 6H), 2.63-2.56 (m, 1H), 1.02 (d, 3H, J
= 7 Hz), 0.98 (d, 3H, J = 7 Hz).. CHN analysis Found: C, 33.42%; H, 3.28%; N,
6.72%, Calcd for C23H28F6IN4OsP: C, 33.58% H, 3.43% N, 6.81%.
[Os(η6-bip)(Azpy)Cl]PF6 (7)
[Os(η6-bip)Cl2]2 (100.7 mg, 0.121 mmol) in methanol (40 mL) and water (10 mL)
was heated under reflux under nitrogen for 2 h. The solution was hot-filtered to
remove black residue, then azpy (55 mg, 0.3 mmol) in methanol (5 mL) was
added drop-wise, the solution colour changed from orange to black immediately.
The solution was stirred and left to cool down to room temperature for 1 h. The
volume was reduced to about 10 mL by removal of methanol on a rotary
evaporator and ammonium hexafluorophosphate (215.0 mg. 1.32 mmol) was
added. The solution was left in the fridge overnight. A brown powder precipitated,
which was filtered off, washed with diethyl ether, then dried in a dessicator
overnight. Yield: 109.4 mg (77.9%). Anal. ESI-MS Calcd for C23H19ClN3Os: m/z
564.09, found 564.0. 1H NMR((CD3)2CO) δ 9.47 (d, 1H, J = 6 Hz), 8.98 (d, 1H, J 
= 8 Hz), 8.46 (t, 1H, J = 6 Hz), 7.97 (d, 2H, J = 8 Hz), 7.97 (t, 1H, J = 8 Hz), 7.74
(t, 1H, J = 8 Hz), 7.61 (m, 4H), 7.51 (m, 3H), 6.96 (d, 1H, J = 6 Hz), 6.89 (d, 1H, J
= 6 Hz), 6.77 (t, 1H, J = 6 Hz), 6.70 (t, 1H, J = 6 Hz), 6.45 (t, 1H, J = 6 Hz). CHN
analysis Found: C, 39.56%; H, 2.90%; N, 6.48%, Calcd for C23H19F6ClN3OsP: C,
39.80%; H, 3.07%; N, 5.81%.
[Os(η6-p-cym)(Azpy)Cl]PF6 (8)
[Os(η6-p-cym)Cl2]2 (40.7 mg, 0.0515 mmol) was dissolved in methanol (20 mL).
Azpy (21.1mg, 0.116 mmol) in 5 mL of methanol was added drop-wise. The
solution colour changed from yellow to brown gradually, it was stirred at ambient
temperature for 1 h; The volume was reduced to about 10 ml by removal of
Chapter 3: OsII Arene Azopyridine-R Complexes
54
methanol on a rotary evaporator. Ammonium hexafluorophosphate (52.2 mg. 0.32
mmol) was added. Then the solution was left in the freezer for 24 h; Dark colour
powder precipitated out, which was filtered off, washed with cold ethanol and
diethyl ether, then finally dried in vacuum. Yield: 60.5 mg (85.4%). Anal. ESI-
MS Calcd for C21H23ClN3Os : m/z 544.1, found 544.1. 1H NMR((CD3)2CO) δ 
9.65 (d, 1H, J = 6 Hz), 9.01 (d, 1H, J = 9 Hz), 8.50-8.48 (m, 1H), 8.16 (d, 2H, J =
8 Hz), 8.02-7.99 (m, 1H), 7.78 (m, 3H), 6.79 (d, 1H, J = 6 Hz), 6,39 (d, 1H, J = 6
Hz), 6.32 (m, 2H), 2.54 (m, 1H), 2.43 (s, 3H), 1.00 (d, 3H, J = 7 Hz), 0.96 (d, 3H,
J = 7 Hz).. CHN analysis Found: C, 36.61%; H, 3.21%; N 6.10%, Calcd for
C21H23F6ClN3OsP: C, 36.66%; H, 3.37%; N, 6.61%. Single crystals suitable for
X-ray diffraction were obtained by slow evaporation of a methanol solution of
complex 8 at ambient temperature.
[Os(η6-bip)(azpy-OH)Cl]PF6 (9)
[Os(η6-bip)Cl2]2 (51 mg, 0.061 mmol) in methanol (40 mL) and water (10 mL)
was heated under reflux under nitrogen for 2 h. Azpy-OH (30.1 mg, 0.15 mmol)
in methanol (2 mL) was added, the solution turned from orange to deep brown-red.
Then the solution was hot-filtered and left to cool down to ambient temperature
while stirring for 1 h. The volume was reduced to about 10 ml by removal of
methanol on a rotary evaporator. Ammonium hexafluorophosphate (100.6 mg.
1.11 mmol) was added. The solution was left in the fridge for 0.5 h. A brown solid
precipitated which was collected by filtration, washed with diethyl ether and dried
overnight in a dessicator. Yield: 42.0 mg (47.9%). Anal. ESI-MS Calcd for
C23H19ClN3Os: m/z 580.08, found 580.0. 1H NMR((CD3)2CO) δ 9.37 (d, 1H, J = 
9 Hz), 8.83 (d, 1H, J = 8 Hz), 8.39-8.34 (m, 1H), 8.01 (d, 2H, J = 9 Hz), 7.80-7.50
(m, 1H), 7.61-7.59 (m, 2H), 7.50 (m, 3H), 7.02 (d, 2H, J = 6 Hz), 6.86 (d, 1H, J =
6 Hz), 6.76 (d, 1H, J = 6 Hz), 6.72 (m, 2H), 6.45 (t, 1H). CHN analysis Found: C,
38.15%; H, 3.04%; N, 5.19%, Calcd for C23H19F6ClN3OOsP: C, 38.15%; H,
2.64%; N, 5.80%.
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[Os(η6-p-cym)(Azpy-OH)Cl]PF6 (10)
[Os(η6-p-cym)Cl2]2 (50.1 mg, 0.063 mmol) was dissolved in methanol (50 mL).
Azpy-OH (32.8mg, 0.16 mmol) in methanol (10 mL) was added drop-wise. The
solution was stirred at ambient temperature for 24h with 4 drops of 1M HCl. The
complex was purified by chromatography on a Sephadex LH20 column.
Ammonium hexafluorophosphate (54.3 mg. 0.33 mmol) was added. The solvent
was removed on a rotary evaporator. A brown solid was collected by filtration and
washed with cold ethanol and diethyl ether, then finally dried under vacuum.
Yield: 16.5 mg (18.6%). Anal. ESI-MS Calcd for C21H23ClN3OOs: m/z 560.1,
found 560.1. 1H NMR((CD3)2CO) δ 9.58 (d, 1H, J = 6 Hz), 9.93 (d, 1H, J = 8 Hz), 
8.39 (t, 1H, J = 8 Hz), 8.19 (d, 2H, J = 9 Hz), 7.82 (t, 1H, J = 6 Hz), 7.15 (d, 2H, J
= 9 Hz), 6.72 (d, 1H, J = 6 Hz), 6.43 (m, 2H), 6.34 (d, 1H, J=6 Hz), 3.35 (s, 3H),
2.63 (m, 1H), 1.02 (d, 3H, J = 7 Hz), 0.98 (d, 3H, J = 7 Hz). CHN analysis Found:
C, 35.13%; H, 3.40%; N, 4.84%, Calcd for C21H23F6ClN3OsP: C, 35.82%; H,
3.29%; N, 5.97%.
[Os(η6-bip)(azpy-NMe2)Cl]PF6 (11)
[Os(η6-bip)Cl2]2 (104 mg,0.12 mmol) was dissolved in methanol (40 mL) and
water (10 mL), the solution was heated to refluxed under nitrogen for 2 h at 248 K.
Then azpy-NMe2 (70.626 mg, 0.3121 mmol) in 5mL of methanol was added drop-
wise. The solution turned from orange to purple, it was hot-filtered and left to cool
to ambient temperature while stirring for 1 h. Then the solvent was evaporated on
a rotary evaporator and ammonium hexafluorophosphate (182.23 mg. 1.11 mmol)
was added. The solution was left in the fridge overnight. A purple solid
precipitated and filtered off, washed with diethyl ether and dried overnight in a
dessicator. Yield:135.5 mg (89%). Anal. ESI-MS Calcd for C25H24ClN4Os: m/z
607.13, found 607.0. 1H NMR((CD3)2CO) δ 9.16 (d, 1H, J = 6 Hz), 8.51 (d, 1H, J 
= 8 Hz), 8.23-8.20 (m, 1H), 8.14 (d, 2H, J = 6 Hz), 7.69-7.47 (m, 6H), 6.94 (d, 1H,
Chapter 3: OsII Arene Azopyridine-R Complexes
56
J = 6 Hz), 6.87 (d, 2H, J = 6 Hz), 6.77 (d, 1H, J = 6 Hz), 6.68-6.63 (m, 2H), 6.44
(t, 1H, J = 6 Hz), 3.40 (s, 6H). CHN analysis Found: C, 39.99%; H, 3.16%; N,
7.45%, Calcd for C25H24F6ClN4OsP: C, 39.98%; H, 3.22%; N, 7.46%. Single
crystals suitable for X-ray diffraction were obtained diffusion of diethyl ether into
a solution of complex 11 in methanol at 277 K.
[Os(η6-p-cym)(Azpy-NMe2)Cl]PF6 (12)
[Os(η6-p-cym)Cl2]2 (100.0 mg, 0.126 mmol) is dissolved in methanol (40 mL).
Azpy-NMe2 (57.4 mg, 0.254 mmol) in methanol (5mL) was added drop-wise. The
solution-colour changed from yellow to blue immediately, it was stirred at
ambient temperature for 1 h. The volume was reduced to about 10 mL by removal
of methanol on a rotary evaporator. Ammonium hexafluorophosphate (205.8 mg.
1.26 mmol) was added. Then the solution was left in the freezer for 24h; A dark
colour powder precipitated, which was colleted by filtration and washed with cold
ethanol and diethyl ether, then finally dried in vacuum. Yield: 148.5 mg (80.6%).
Anal. ESI-MS Calcd for C23H28ClN4Os: m/z 587.2, found 587.4. 1H
NMR((CD3)2CO) δ 9.04 (d, 1H, J = 6 Hz), 8.58 (d, 1H, J = 8 Hz), 8.31-8.23 (m, 
3H), 7.70 (m, 3H), 6.58 (d, 1H, J = 6 Hz), 6.32-6.26 (m, 3H), 2.80 (s, 6H), 2.48-
2.45 (m, 1H), 2.47 (s, 3H), 0.98 (d, 3H, J = 7 Hz), 0.94 (d, 3H, J = 7 Hz). CHN
analysis Found: C, 37.72%; H, 3.72%; N, 7.69%, Calcd for C23H28F6ClN4OsP: C,
37.78 %; H, 3.86%; N, 7.66 %.
3.2.3 Stability and Hydrolysis. Aqueous solutions of osmium complexes 6, 8 and
12 (50 µM) in 5% MeOD-d4/ 95% deuterated phosphate buffer (10 mM, pH*=7.0)
were monitored for 24 h at 310 K by 1H NMR spectroscopy. The stability of 6
was further investigated by monitoring the UV-vis spectrum of a ca. 30 µM
solution in 5% methanol/95% water at various time intervals over 24 h at 310 K.
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3.2.4 Study of Complex 6 with N-Acetyl-L-Cysteine (NAC). The 1H NMR
spectrum of a solution containing 1.0 mM [(η6-p-cym)Os(Azpy-NMe2)I]PF6 (6)
and 7.35 mM NAC in 30% acetone-d6 and 70% phosphate buffer (7.35 mM,
pH*=7.0) was monitored for a period of 24 h at 310 K.
3.2.5 GSH Reaction. A solution containing [Os(η6-p-cym)(Azpy-NMe2)I]PF6 (6)
(100 µM) and GSH (10 mM) was incubated at 310 K in 95% D2O phosphate
buffer (10 mM) and 5% methanol-D4 and was monitored by 1H-NMR
spectroscopy for a period of 24 h.
3.2.6 Reaction with Silver Nitrate. Complex 12 (25 mg, 0.034 mmol) and silver
nitrate (5.8 mg, 0.034 mmol) were heated under reflux overnight at 1:1 mol ratio
in a mixture of methanol (10 mL) and water (10 mL). The mass spectrum was
recorded to monitor the product.
3.2.7 ROS Detection. DCFH-DA was handled under an N2 atmosphere, dissolved
in DMSO to give a 10 mM stock solution. A2780 cells were seeded at 5000
cells/well into black 96-well plate and incubated for 24 h at 310 K, 5% CO2, and
high humidity. Cells were incubated for 20 min with DCFH-DA (10 µM). To
remove extracellular probe, the cells were washed twice with PBS. The cells were
then kept in PBS solution and either the osmium complex, or osmium complex
plus L-BSO (50 µM), or hydrogen peroxide (50 µM, as the positive control) were
added. The fluorescence was recorded over a period of 4 h at 310 K by excitation
at 480 nm and emission at 530 nm using a TECAN plate reader.
3.2.8 X-ray Crystallography. X-ray crystallographic data for compounds 2, 3*, 5,
8, 11 and 14 have been deposited in the Cambridge Crystallographic Data Centre
with CCDC references numbers 776271, 776270, 776273, 776268, 776269 and
776272, respectively. The collection and structure solution were carried out by Dr.
Guy J. Clarkson.
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3.2.9 ICP-MS. ICP-MS analyses were carried out on an Agilent Technologies
7500 Series ICP-MS instrument. The water used for ICP-MS analysis was double
deionised (DDW) using a USF Elga UHQ water deionizer. The osmium Specpure
plasma standard (Alfa Aesar, 1000 ppm in 5% HCl) was diluted with DDW to 20
ppm. The standards for calibration were freshly prepared by diluting this stock
solution with 3% HNO3 in DDW. The concentrations used were 100, 60, 20, 10,
5, 4, 2, 1, 0.4 and 0.1 ppb.
3.2.10 Combination Treatment with 6 and L-BSO. To determine the effect of
decreased GSH levels on the cytotoxicity of 6, A2780 human ovarian and A549
human lung cancer cells were co-incubated with 50 µM L-BSO and various
concentrations of 6 for 24 h. Cell viability was then determined using the
sulforhodamine (SRB) assay.
3.2.11 Animals. Six to ten week old female BALB/cOlaHsd-Foxn1nu mice
(Harlan, Blackthorn, UK), maintained with food (Teklad 2018 diet, Harlan) and
water ad libitum, were used according to UKCCCR guidelines for the welfare of
animals2. Regulated procedures were carried out under a UK Home Office Project
License. This work was carried out by Dr. Steve Shnyder (University of Bradford)
and his team.
3.2.12 Tumour System. HCT-116 (human colon adenocarcinoma line) tumours
were excised from a donor animal, placed in sterile physiological saline
containing antibiotics and cut into small fragments of approximately 2 mm3.
Under brief general inhalation anaesthesia, fragments were implanted in the left
flank of each mouse using a trocar. Once the tumours could accurately be
measured by calipers (mean tumour volume of 32mm3), the mice were allocated
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into groups by restricted randomisation to keep group mean tumour size variation
to a minimum. This work was carried out by Dr. Steve Shnyder (University of
Bradford) and his team.
3.2.13 Plasma and Tissue Distribution Studies. Tumour-bearing mice (n=3 per
time point) were sacrificed at 5 min, 60 min and 240 min following intravenous
administration of a single 10 mg kg-1 dose of FY026 (6). Tumour, liver, lung,
kidneys and plasma were collected, weighed and stored at 193 K until analyzed.
Osmium concentrations in different samples were measured by ICP-MS using the
methodology described above. Tumour and tissue samples were homogenized in
phosphate buffered saline, and digested in HNO3 at 353 K overnight to give clear
solutions. These were then diluted as appropriate for evaluation by ICP-MS.
3.2.14 Chemotherapy Studies. Compounds were administered by single
injection, with the day of therapy designated day 0. The maximum soluble dose of
FY026 when administered as a single intravenous injection was established as 40
mgkg-1. The efficacy of FY026 was compared with the standard anticancer agent
cisplatin which was administered as a single dose intraperitoneally at its
maximum tolerated dose of 8 mg kg-1. The effects of therapy were assessed as
previously described.22 Briefly, daily 2-dimensional caliper measurements of the
tumours were taken, with volumes calculated using the formula (a2 × b) / 2, where
a is the smaller and b the larger diameter of the tumour. Tumour volume was then
normalised to the respective volume on day 0, and semi-log plots of relative
tumour volume (RTV) versus time were made. Mann-Whitney U tests were
performed to determine the statistical significance of any differences in growth
rate (based on tumour volume doubling time) between control and treated groups,
and between the 2 compounds. This work was carried out by Dr. Steve Shnyder
(University of Bradford) and his team.
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3.3 Results and Discussions
Previously Peacock et al. reported the synthesis of the OsII azopyridine
complexes [Os(η6-arene)(Azpy-NMe2)Cl]PF6 with arene = biphenyl (11) and p-
cymene (12).16 Cytotoxicity tests for these complexes were hampered by their low
solubility and the occurrence of precipitation under the test conditions used. No
activity towards human A549 lung cancer cells was detected up to concentrations
of 100 µM. In the present chapter, the similar OsII azopyridine complexes with
iodido replacing chlorido (Z), and with azpy-R (R = H, OH, and NMe2) were
explored. The complexes remained in solution under the cell testing conditions
with no apparent precipitation (vide infra).
3.3.1 Chemistry
Six novel cationic iodido osmium arene complexes containing chelating
azopyridine ligands (azpy, azpy-OH and azpy-NMe2) were synthesized where PF6
acts as the counter ion. In general, they have poor aqueous solubility ( 0.2 mM),
with the biphenyl complexes being less water-soluble than the p-cymene
complexes. The structures of the iodido complexes with azpy (2), azpy-OH (3)
and azpy-NMe2 (5) (Chart 3.1) were determined by X-ray crystallography. For
comparison, six chlorido analogues were synthesized and the structures of the
azpy complex 8 and azpy-NMe2 complex 11 were also determined by X-ray
crystallography. The X-ray structure of 12 has been reported previously.16 The
structure of the dimer [Os(η6-p-cym)I2]2 which is an important synthetic
intermediate in this work was also determined by X-ray crystallography (Fig. 3.1).
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Figure 3.1. The dimer [Os(η6-p-cym)I2]2 lies on an inversion centre between the
two bridging iodides; only the asymmetric unit is labelled. (A) X-ray structure
with thermal ellipsoids drawn at 50% probability, the hydrogen atoms were
omitted for clarity. (B) Crystallographic space-filling view. Salient bond lengths
(Å) and angles (deg):  Os1−(para-cymene centroid): 1.665; Os1−I1: 2.7250(4); 
Os1−I2: 2.7347(4); I2−Os1−I1: 88.319(12); Os1-I2-Os2: 97.484(11). 
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Chart 3.1. Osmium azopyridine arene complexes studied in this chapter.
Complex Arene R X
1 bip H I
2 p-cym H I
3 bip OH I
4 p-cym OH I
5 bip NMe2 I
6 p-cym NMe2 I
7 bip H Cl
8 p-cym H Cl
9 bip OH Cl
10 p-cym OH Cl
11 bip NMe2 Cl
12 p-cym NMe2 Cl
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All the osmium complexes adopt the familiar pseudo-octahedral ‘piano-stool’
structure (Fig. 3.2), with bond lengths and angles within the expected ranges.16
The crystal of the neutral complex [Os(η6-bip)(Azpy-O)I]·0.5H2O (3*) was
obtained by slow evaporation of a methanolic solution of complex 3 [Os(η6-
bip)(Azpy-OH)I]PF6. 3* has a relatively short O15C12 bond length (1.258(4) Å)
indicating deprotonation of the OH group, with the iodido ligand balancing the
charge on OsII to afford a neutral complex. A water molecule in the lattice forms a
short H-bond with the phenoxide group and bridges two phenoxides of
neighboring complexes (Fig. 3.3). The pKa of the azpy-OH ligand in 3 was
determined to be ca 6.9 (comparable with a value of 6.48 for the ruthenium
analogue)11 and so the complex would be expected to be deprotonated under the
conditions of the cytotoxicity assays (pH = 7.4), as shown in the X-ray structure.
Selected bond lengths and angles for these structures are listed in Table 3.1.
Figure 3.2. X-ray crystal structures (A) [Os(
bip)(Azpy-O)I] (3*), (C) [Os(
cym)(Azpy)Cl]+ (8), and (E)
ellipsoids drawn at 50% probability.
solvent water molecules have been omitted for clarity.
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Figure 3.3. Hydrogen bond formation between water and the phenoxide ligand in
the x-ray crystal structure of [Os(η6-bip)(Azpy-O)I]·0.5H2O.
Table 3.1. Selected bond lengths (Å) and angles (deg) for [Os(η6-p-
cym)(Azpy)I]PF6 (2), [Os(η6-bip)(Azpy-O)I]·0.5H2O (3),  [Os(η6-bip)(Azpy-
NMe2)I]PF6 (5), [Os(η6-p-cym)(Azpy)Cl]PF6 (8), [Os(η6-bip)(Azpy-NMe2)Cl]PF6
(11).
(A)
bond length/angle 2 3 5
Os(1)-N(8) 2.010(3) 2.080(2) 2.1017(18)
Os(1)-N(1) 2.052(3) 2.054(2) 2.0804(18)
Os(1)-C(15) 2.186(3) 2.206(3) 2.189(2)
Os(1)-C(19) 2.206(3) 2.211(3) 2.199(2)
Os(1)-C(18) 2.225(3) 2.211(3) 2.205(2)
Os(1)-C(16) 2.244(3) 2.215(3) 2.206(2)
Os(1)-C(20) 2.246(3) 2.217(3) 2.211(2)
Os(1)-C(17) 2.284(3) 2.225(3) 2.222(2)
Os(1)-I(1) 2.6856(3) 2.7185(2) 2.70798(19)
N(7)-N(8) 1.293(4) 1.323(3) 1.314(3)
N(8)-Os(1)-N(1) 74.85(11) 75.12(9) 76.74(7)
N1-Os-I 87.81(8) 87.59(6) 86.00(5)
I-Os-N8 83.07(8) 87.83(6) 86.60(5)
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Table 3.1. Selected bond lengths (Å) and angles (deg) for [Os(η6-p-
cym)(Azpy)I]PF6 (2), [Os(η6-bip)(Azpy-O)I]·0.5H2O (3),  [Os(η6-bip)(Azpy-
NMe2)I]PF6 (5), [Os(η6-p-cym)(Azpy)Cl]PF6 (8), [Os(η6-bip)(Azpy-
NMe2)Cl]PF6, [Os(η6-bip)(Azpy-NMe2)Cl]PF6 (11).
(B)
bond length/angle 8 11
Os(1)-N(8) 2.0225(15) 2.072(2)
Os(1)-N(1) 2.0543(15) 2.049(2)
Os(1)-C(15) 2.1843(18) 2.198(3)
Os(1)-C(19) 2.2196(18) 2.205(3)
Os(1)-C(18) 2.2313(18) 2.205(3)
Os(1)-C(16) 2.2381(18) 2.214(3)
Os(1)-C(20) 2.2474(19) 2.218(3)
Os(1)-C(17) 2.2619(18) 2.218(2)
Os(1)-Cl(1) 2.3817(5) 2.3992(6)
N(7)-N(8) 1.290(2) 1.297(3)
N(8)-Os(1)-N(1) 74.84(6) 75.23(9)
N1-Os-Cl 84.35(5) 85.12(6)
Cl-Os-N8 86.59(5) 83.82(6)
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3.3.2 Cytotoxicity
In contrast to previous studies on complexes 11 and 12,16 the complexes were
soluble in the culture medium at the concentrations tested and no precipitation
was observed after 24 h. None of the azopyridine ligands themselves showed
cytotoxic activity against A2780 human ovarian cancer cells at concentrations up
to 100 µM. The IC50 values of the osmium azopyridine complexes (Table 3.2)
ranged from 0.14 µM for the iodido biphenyl complexes 3 and 5 with azpy-OH
and azpy-NMe2 ligands, to > 50 µM for the chlorido complex 8 containing azpy in
the human ovarian cell line A2780 (Table 3.2A). According to these preliminary
results, three complexes (3, 6 and 12) were selected for further evaluation against
a cisplatin-resistant sub-line of A2780, A2780/cis, and also against a panel of
human cancer cell lines of differing histiotype. Complexes 3 and 6 (Table 3.2B)
showed at least 10-fold greater potency than cisplatin against all cell lines tested
apart from RT-112 (bladder), which demonstrated a 3-fold difference for complex
3. Complex 12 showed similar potency to cisplatin over the cell line panel. The
highest activity in comparison to the reference cisplatin for all three complexes
was seen for the PC-3 (prostate) cell line. Interestingly, complexes bearing
electron-donating hydroxyl or dimethylamino substituents on the phenyl ring of
the azopyridine ligands are an order of magnitude more active compared to
complexes bearing unsubstituted azpy ligands. This may indicate that redox
processes associated with the chelated ligand21 are important for activity. In
contrast octahedral RuII complexes such as [Ru(azpy)2Cl2] containing two
unsubstituted azpy ligands have been reported to be as active as cisplatin against
A2780 cells.23
The high potency of the organometallic iodido osmium complexes reported
here, with IC50 values within the nanomolar range, is notable. This is
unprecedented for cytotoxic organometallic osmium arene complexes, for which
activities generally fall in the micromolar range.16, 18, 19 In addition, their
ruthenium analogues were significantly less cytotoxic (7 to more than 56 times
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less active) in the A2780 ovarian cancer cell line.21 In particular, the Ru analogue
of complex 3 ([Ru(η6-bip)(Azpy-OH)I]PF6) is 35 times less active.
Table 3.2. (A) IC50 values for complexes 112 in human ovarian cell line A2780;
(B) IC50 values for 3, 12, 6 in A2780/cis ovarian, A549 lung, HCT-116 colon,
MCF-7 breast, PC-3 prostate and RT-112 bladder human cancer cell lines.
(A)
Complex IC50(µM)
[Os(η6-bip)(Azpy)I]PF6 1 5.4(±0.8)
[Os(η6-p-cym)(Azpy)I]PF6 2 10.3(±0.1)
[Os(η6-bip)(Azpy-OH)I]PF6 3 0.14(±0.01)
[Os(η6-p-cym)(Azpy-OH)I]PF6 4 0.32(±0.2)
[Os(η6-bip)Os(Azpy-NMe2)I]PF6 5 0.14(±0.01)
[Os(η6-p-cym)(Azpy-NMe2)I]PF6 6 0.18(±0.01)
[Os(η6-bip)(Azpy)Cl]PF6 7 13.9(±3.8)
[Os(η6-p-cym)(Azpy)Cl]PF6 8 >50
[Os(η6-bip)(Azpy-OH)Cl]PF6 9 0.84(±0.1)
[Os(η6-p-cym)(Azpy-OH)Cl]PF6 10 1.3(±0.2)
[Os(η6-bip)(Azpy-NMe2)Cl]PF6 11 3.9(±0.3)
[Os(η6-p-cym)(Azpy-NMe2)Cl]PF6 12 1.8(±0.1)
Cisplatin 1.8(±0.1)
(B)
Complex/
IC50(µM)
A2780/cis A549 HCT-116 MCF-7 PC-3 RT-112
3 <0.3 0.4 <0.3 0.25 <0.3 0.4
6 <0.3 <0.3 <0.3 0.079 0.6 <0.3
12 1.8 5.2 0.9 1.1 6.8 2.2
Cisplatin 4 4.1 2.6 3 21.5 1.4
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3.3.4 Stability and Hydrolysis
The hydrolysis (aquation) of the azopyridine complexes was investigated since
this is a potential mechanism for activation of halido osmium arene complexes in
their interaction with possible biological targets such as DNA.16, 24
The aqueous behavior of the highly active complexes [Os(η6-p-cym)(Azpy-
NMe2)I]PF6 6 (IC50 = 0.2 µM), moderately active complex [Os(η6-p-cym)(Azpy-
NMe2)Cl]PF6 12 (IC50 = 1.8 µM) and inactive complex [Os(η6-p-
cym)(Azpy)Cl]PF6 8 (IC50 > 50 µM) against A2780, was studied at 310 K over 24
h by 1H NMR.
The 1H NMR spectra of a 50 μM solution of inactive complex 8 in 10 mM
phosphate buffer 95% D2O/5% MeOD-d4 over 24 h showed the disappearance of
the peaks corresponding to the bound azopyridine and p-cymene ligands (Fig. 3.3)
suggesting that this complex is not stable under aqueous conditions. Similar
behavior has been observed for the ruthenium analogue [Ru(η6-p-
cym)(azpy)Cl]PF6.11 In contrast, complexes 6 and 12 did not show ligand loss,
neither did they hydrolyze as judged by their 1H NMR spectra, which remained
unchanged (Fig. 3.3). In addition, ESI-MS analyses showed ions corresponding to
the chlorido and iodido complexes only, and UV-vis spectra in 10%
methanol/90% water, showed no change over 24 h (Fig. 3.4). An attempt to
remove the chloride from the aqueous solution of 12 by reacting it with silver
nitrate under reflux overnight, did not result in the expected aqua product. The
chlorido complex was the only species detected by MS (Fig. 3.5), indicating a
strong OsCl bond.
These observations suggest that active complexes 6 and 12 are stable under
the biologically-relevant testing conditions. In addition, the inertness of the OsI
bond suggests that hydrolysis process is not critical for the activation of these
complexes and it is consistent with previous observations of the analogous RuII
azpy complexes,21 implying that the azpy ligand plays an important role in the
activity.
(A)
(B)
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(C)
Figure 3.3. Hydrolysis and stability experiments of osmium complexes
12. 1H-NMR spectra of (A)
cym)(Azpy)Cl]PF6 (
recorded before and after 24 h incubation at 310 K.
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Figure 3.4. UV-Vis spectra of [Os(η
10% methanol and 90% water soon after dissolution (black curve) and after 24 h
incubation at 310 K (red curve).
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3.3.5 Effect of N-acetyl-L-cysteine (NAC) on cytotoxicity
Pre-treatment of cells with NAC can block cisplatin-dependent caspase-3
activation and apoptosis by inhibiting the accumulation of intracellular reactive
oxygen species (ROS) and maintaining intracellular GSH levels.25 In order to
investigate possible involvement of ROS in the cytotoxicity of azopyridine OsII
arene complexes, the effect of pre-treatment of cells with NAC was investigated.
Cisplatin was used as the positive control, whereas cells not treated with osmium
complexes served as the negative control.
A2780 cells were treated with the iodido complexes 3, 5 and 6 and chlorido
complex 12 at concentrations that were 1.21.8x their respective IC50 values and
for cisplatin a concentration 2.5x its IC50 value was used. These doses reduced cell
growth to <30% of the control value (Fig. 3.6). Pre-treatment with 5 mM NAC for
2 h and co-treatment with osmium complexes for 24 h was employed to increase
the intracellular glutathione concentration,21 resulted in the inhibition of the
antiproliferation effects of iodido complexes 3, 5 and 6. This was shown by their
growth levels of >70% when pre-treated with NAC. For chlorido complex 12, the
NAC pre-treatment and co-treatment had only a small effect on restoring growth
(Fig. 3.6). These results suggest that, unlike the azopyridine osmium arene iodido
complexes or cisplatin, the cytotoxicity associated with osmium chlorido complex
12 does not appear to depend on the production of reactive oxygen species (ROS),
but may be explained by a different mechanism of cytotoxic activity.
In order to investigate the possibility that the complexes might react directly
with NAC and that the effects are not merely due to thiol levels in cells, a solution
containing 1.0 mM [(η6-p-cym)Os(Azpy-NMe2)I]PF6 (6) and excess (7.35 mM)
NAC in 30% acetone-d6 and 70% phosphate buffer (10 mM; pH 7.0) was
monitored by 1H NMR spectroscopy for 24 h at 310 K. No new peaks appeared in
the 1H NMR spectrum (Fig. 3.7), suggesting that complex
iodido complexes do not readily react with NAC.
Figure 3.6. Cell viability of A2780 human ovarian cancer cells after 24 h
exposure to osmium complexes or cisplatin followed by 72 h recovery (red bars),
and cell viability for cells that were pre
the addition of the osmium complexes or cisplatin (blue bars). Doses of
complexes: [Os(η6-
NMe2)I]PF6 (5), 0.25 µM; [Os(
[Os(η6-p-cym)(Azpy-
error bars are standard deviations of six replicates.
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Figure 3.7. 1H NMR spectrum of a solution containing 1.0 mM [Os(η6-p-
cym)(Azpy-NMe2)I]PF6 (6) and 7.35 mM NAC in 30% acetone-d6 and 70%
phosphate buffer (10 mM, pH=7.0) after incubation for 24 h at 310 K. Peak
assignments: NAC, orange; complexes, other colours as indicated on the structure.
3.3.6 Reactions with Glutathione (GSH)
Since some azopyridine ruthenium arene complexes
catalytically to form GSSG,
analogues. The 1H NMR spectrum of a solution containing the highly cytotoxic
iodido complex [Os(η
molar excess of GSH (10 mM, to mimic intracellular conditions) showed little
change over a period of 24 h (Fig 3.8). This suggests that complex
catalytically oxidize GSH, unlike the analogous Ru
The mechanism of cytotoxic activity f
therefore appears to be different from that of the Ru
from those bearing hydrolysable Ru/Os
complexes are more potent.
Figure 3.8. Reaction of complex
(bottom) and in the presence of 100 µM
24 h at 310 K (top).
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3.3.7 Evaluation of in vivo toxicity
Complexes 3 and 6 were selected for further in vivo evaluation based on their
promising activity in vitro. On evaluation of their toxicity in a nude mouse tumour
HCT-116 xenograft model, the complexes demonstrated negligible deleterious
effects at doses up to and including their maximum soluble dose of 40 mg·kg-1.
This dose is approximately six times higher than the maximum tolerated dose of
cisplatin in the same tumour model, and suggests that with the comparative lack
of toxicity of the complexes there is likely to be a much broader therapeutic
window (Fig. 3.9). This will be investigated further in extensive in vivo
pharmacokinetic and efficacy studies.
Figure 3.9. Mean relative body weight curves for 3 and 6 administered
intravenously as a single dose on day 0 at their maximum soluble dose of 40
mg·kg-1 to mice bearing HCT-116 human tumour xenografts (n = 2). Fluctuations
in body weight are well within the normal limits suggesting that neither complex
is toxic.
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3.3.8 Evaluation of the in vivo efficacy
First the anticancer efficacy of complex 6 (FY026, Fig. 3.10) in vivo versus
the subcutaneously implanted HCT-116 xenograft model, when administered as a
single intravenous injection at its maximum soluble dose of 40 mg/kg was
studied. The agent had negligible toxicity, with an observed maximum weight loss
well within the normal limits. Complex 6 was seen to induce a statistically
significant tumour growth delay in the HCT-116 model compared to the untreated
control (p<0.01). The positive control compound the standard agent cisplatin was
employed and administered i.p (standard route for this model) at its MTD in this
mouse model (p<0.05, Figure. 3.11 and Table 3.3). The maximum weight loss
observed with complex 6 was 8%, indicating a lack of toxicity. This combined
with the favourable tumour distribution reported below, would suggest that there
is significant scope to administer this compound on a repeat-dose schedule to
enhance its therapeutic activity.
Figure 3.10. The structure of complex 6 (FY026)
Table 3.3. Evaluation of the
adenocarcinoma s.c. xenograft model.
Compound (dose
in mg kg-1)
Untreated controls
Complex 6 (40.0)
Cisplatin (8.0)
Figure 3.11. Evaluation of the
a single intravenous injection at its maximum soluble dose of 40 mg kg
subcutaneously implanted HCT
Complex 6 shows a greater efficacy than the standard agent cisplatin administered
at its maximum tolerated dose in this model. Points represent mean ± S.D. (n=8).
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Mean tumour
doubling time
(days)
Significance
weight loss (day)
3.9
6.5 p<0.01
6.4 p=0.05
in vivo efficacy of complex 6 when administered as
-116 human colon adenocarcinoma model.
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-116 colon
Maximum %
8 (8)
8 (1)
8 (6)
-1 in the
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3.3.9 Distribution of Osmium after Administration of Complex 6
In HCT116 xenograft-bearing mice, the distribution of 6 was analysed in the liver,
kidneys, tumour, lungs and plasma, 5, 60 and 240 min after administration. The
results are shown in Table 3.4 and Figure 3.12. Osmium was detected in the
tumour and all tissues over the time period of analysis. The amount of osmium in
the plasma was surprisingly low after just 5 min, suggesting a large volume of
distribution or high level of tissue distributions (mainly in kidney).
Table 3.4. Tumour, normal tissue and plasma distribution of osmium from 6
following i.v. administration of a single dose of 10 mg kg-1.
Figure 3.12. Percentage of Os distributions in kidney, lungs, liver and tumour.
Points represent the mean concentration for three mice.
Time/min
g Os / g tissue
Kidney Lungs Liver Plasma Tumour
5 1259.7 ( ± 66.6) 5.81 (± 4.18) 88.6 (± 57.9) 19.6 (± 23.3) 11.9 (± 2.22)
60 513.5 ( ± 208.5) 40.3 (± 15.0) 136.4 (± 4.96) 21.8 (± 2.54) 8.80 (± 1.24)
240 418.6 ( ± 103.3) 28.3 ( ± 3.49) 77.2 ( ±10.5) 19.0 (± 10.6) 6.68 (± 2.77)
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3.3.10 Combination treatment with L-BSO
The azopyridine complex 6 is relatively inert. For example, it does not readily
undergo hydrolysis in aqueous solution or bind to DNA bases, unlike chlorido
diamine OsII arene complexes. Our initial studies on iodido azopyridine OsII arene
complexes suggested that their cytotoxic activity might involve redox
mechanisms. Here we have investigated the ability of complex 6 to generate
reactive oxygen species (ROS) in cancer cells. ROS play important roles in
regulating cell proliferation, death, and senescence. The redox system is also a
significant target for anticancer treatment.26 Targeting the redox system can
induce selective cell death in malignant cells and spare normal cells due to the
higher baseline level of ROS in cancer cells.
The level of ROS induced in A2780 human ovarian cancer cells by complex 6
was determined using the probe 2′,7′-dichlorodihydrofluorescein-diacetate 
(DCFH-DA). This is taken up by live cells, hydrolyzed to 2′,7′-
dichlorodihydrofluorescein (DCFH), and in turn oxidized to 2′,7′-
dichlorofluorescein (DCF) in the presence of ROS and exhibits a green
fluorescence.27 Using this probe, we determined the level of general oxidative
stress induced in cells by 6. The effect of combined exposure to 6 and L-
buthionine-sulfoximine (L-BSO) was investigated. L-BSO, a specific inhibitor of
γ-glutamyl-cysteine synthetase, depletes intracellular glutathione (GSH). 
Gutathione plays a central role in a wide range of cellular functions, including
protection, detoxification, transport, and metabolism. A2780 cells were pre-
incubated for 20 min with 10 µM DCFH-DA. The relative increase in DCF
fluorescence was then detected over a period of 4 h after treatment of the cells
with 1 μM 6, or 1 μM 6 plus 50 μM L-BSO, or 50 μM H2O2 (Figure 3.13). On
treatment with 6 alone, the ROS level increased by 21% compared to the control.
This level increased further to 50% in the presence of L-BSO in addition to 6. The
mode of interference by 6 in the redox balance in cells and the production of ROS
is not yet clear. Complex 6 underwent an electrochemical reduction in
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dimethylformamide with an associated half-wave potential of -0.64 V (vs.
Ag/AgCl). This reduction can be associated with addition of an electron into the
π* orbital centred on the azo group of the azopyridine ligand to form an azo anion 
radical, a process previously detected for the RuII analog, although occurring more
readily in the latter case at a potential of -0.40 V. Unlike the Ru complex, 6 does
not react catalytically with GSH.
These data suggested that L-BSO might enhance the cytotoxicity of complex 6
towards cancer cells. As can be seen from Figure 3.14, L-BSO alone at a dose of
50 μM had no significant effect of the growth of either A2780 human ovarian 
cells or A549 human lung cancer cells, but greatly enhanced the cytotoxicity of
complex 6 at doses of 0.1 and 1 μM for A2780 cells, and 1 and 5 μM for A549 
cells. These results imply that combination treatment with 6 and L-BSO may have
potential as a therapeutic strategy. Clinical trials of L-BSO are currently in
progress on combinations with melphalan in patients with persistent or recurrent
stage III malignant melanoma.28
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Figure 3.13. Relative changes in DCF fluorescence detected over time after
exposure to 1 μM complex 6 (FY026), 1 μM 6 with 50 μM L-BSO, and 50 μM
H2O2. For each experiment the fluorescence was averaged over 8 wells.
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Figure 3.14. Percentage cell survival after 24 h exposure to osmium complex 6
(FY026) with or without 50 μM L-BSO. Left: A2780 ovarian cancer cells. Right: 
A549 lung cancer cells. Previously determined IC50 values are 0.2 μM for A2780 
cells (24 h exposure to 6 followed by 72 h recovery period), and 0.4 μM for A549 
cells (24 h exposure, 96 h recovery period).
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3.4 Conclusions
Pseudo-octahedral ‘piano-stool’ organometallic osmium arene complexes
have the potential for exploration as anticancer complexes. They are attractive
since they provide a hydrophobic arene face amenable to a wide variety of
substitutions together with three other variable coordination positions. Both the
arene and the other ligands can have a major effect on determining the electron
distribution within the complex, controlling their rates of ligand substitution and
their redox properties (metal- or ligand-centered). In this chapter, the chelated
azopyridine ligand is both a σ-donor and a strong π-acceptor, i.e. there is a strong 
back-donation of electrons from OsII onto the azopyridine ligand producing a
large effect on overall reactivity. Iodido complexes were more cytotoxic than the
analogous chlorido complexes. In addition, iodido complexes containing p-
hydroxyl or p-dimethylamino substituents on the azopyridine chelating ligand
(e.g. complexes 3 and 6) were cytotoxic at nanomolar concentrations towards
ovarian, lung, breast, colon, prostate, and bladder human cancer cells, an order of
magnitude more potent than cisplatin, and (unexpectedly) than their RuII
analogues. These iodido complexes are also inert towards hydrolysis.
Interestingly, their cytotoxicity was inhibited by pre-treatment of the cells wth N-
acetyl-L-cysteine suggesting that reactive oxygen species (ROS) are involved in
their mechanism of action, although, unlike their RuII arene azopyridine
analogues, the OsII complexes investigated here do not oxidize GSH catalytically.
More encouragingly, these OsII complexes exhibited low toxicity and negligible
deleterious effects in a HCT-116 tumour xenograft model indicating that they may
exhibit a broad therapeutic window.
The organometallic osmium arene azopyridine complex 6, which has
nanomolar activity in vitro in a panel of human cancer cell lines, exhibits acivity
in vivo against HCT116 human colon cancer xenografts in mice, with negligible
toxicity. This appears to be the first demonstration of significant anticancer
activity in vivo for organometallic half-sandwich osmium complexes. Studies on
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the plasma, tumour and normal tissue distribution of 6 suggest that there is scope
to optimize the therapeutic activity using multiple-dose schedules without the risk
of off-target toxicity.
3.5 Summary
Iodido osmium(II) complexes [Os(η6-arene)(XY)I]+, XY = p-hydroxy or p-
dimethylamino azopyridine, arene = p-cymene or biphenyl, are potently cytotoxic
at nanomolar concentrations towards a panel of human cancer cell lines. They
exhibit low toxicity and negligible deleterious effects in a colon cancer xenograft
model, giving rise to the possibility of a broad therapeutic window. The most
active complexes are stable and inert towards aquation. Their cytotoxic activity
appears to involve redox mechanisms. The activity of a potent complex 6 (FY026)
in vivo versus HCT116 human colon cancer xenografts and the distribution of
osmium in plasma and tissues were investigated. Further insight into the
mechanism of action of 6 (FY026) was obtained from studies of its redox
potential, its ability to generate Reactive Oxygen Species (ROS) in cells, and the
effect of L-buthionine-sulfoximine (L-BSO), a specific inhibitor of γ-glutamyl-
cysteine synthetase known to reduce intracellular thiol levels,29 on the cytotoxicity
of the complex.
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4.1 Introduction
The only recognised clinical use of osmium appears to be for synovectomy in
arthritic patients in Scandinavia.1-3 This involves the local administration of
osmium tetroxide (OsO4), usually considered to be a highly toxic compound. The
lack of reports of long term side effects suggests that osmium itself can be
biocompatible, although clearly this might be dependent on the exact nature of the
compound administered. Osmium carbohydrate polymers (osmarins) have been
also investigated as potential antiarthritic agents.4
Recently, non-organometallic osmium(VI) complexes were reported to show
anticancer activity in vivo.5 In previous chapter, certain half-sandwich
organometallic iodido osmium azopyridine arene complex (FY026) was found to
be able to exhibit potent in vitro and in vivo anticancer activity; FY026 showed
much higher activity than the clinical drug cisplatin to a panel of cancer cell lines
in vitro.6, 7 Similar to RuII,8 the introduction of the strong π-acceptor azopyridine 
as a ligand in organometallic OsII complexes has a major effect on their chemical
and biological properties.5
For OsII arene picolinate complexes, log P values correlate with cellular
uptake, which indicates that increased lipophilicity favours uptake by cancer cells,
probably through a passive diffusion pathway, and results in an increase in
anticancer activity.9 However, increasing lipophilicity to improve anticancer
activity can result in difficulties with clinical formulation and lower
bioavailability10. Hence there is a need for rational design aimed at tuning
lipophilicity while maintaining anticancer activity.
The goal of anticancer research programs is to identify novel, synthetically-
feasible molecules that exhibit useful anticancer activity with minimal side-effects.
One efficient approach is the study of bioisosterism, a term coined to describe the
modification of biological activity by isosterism.11-13 In this chapter, a series of
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bioisosteres of OsII arene complexes containing chelated azopyridines with
various substitutents on the pyridine ring were studied. Cellular reactive oxygen
species (ROS) were found to accumulate but do not lead to the death of cancer
cells, suggesting a mechanism different from that for related complexes with an
unsubstituted pyridine ring and a substitutent on the phenyl ring. In addition, it is
found that down-regulation of the cellular GSH level results in lowering of
anticancer activity, a property which has been found only for the anticancer drug
taxol, which kills cancer cells in a GSH-dependent manner.14
4.2 Experimental
4.2.1 X-ray Crystallography
X-ray diffraction data for  [Os(η6-bip)(1-Cl-Azpy)Cl]PF6 (7)  [Os(η6-bip)(2-F-
Azpy)Cl]PF6 (10,  [Os(η6-bip)(2-Cl-Azpy)I]PF6 (13), [Os(η6-p-cym)(2-Cl-
Azpy)I]PF6 (14), [Os(η6-p-cym)(2-Cl-Azpy)Cl]PF6 (16), [Os(η6-p-cym)(2-Br-
Azpy)I]PF6 (18), [Os(η6-bip)(2-Br-Azpy)Cl]PF6 (19), [Os(η6-p-cym)(2-Br-
Azpy)Cl]PF6 (20), [Os(η6-p-cym)(3-Cl-Azpy)I]PF6 (24) and [Os(η6-p-cym)(3-Cl-
Azpy)Cl]PF6 (26) were obtained on an Oxford Diffraction Gemini four-circle
system with a Ruby CCD area detector using Mo Kα radiation.15 Absorption
corrections were applied using ABSPACK. The crystals were mounted in oil and
held at 100(2) K with the Oxford Cryosystem Cryostream Cobra, except
compound 7 for which data was collected at ambient temperature. The structures
were solved by direct methods using SHELXS (TREF) with additional light atoms
found by Fourier methods.16 Refinement used SHELXL 97.17 H atoms were
placed at geometrically calculated positions and refined riding on their parent
atoms. X-ray crystallographic CIF ﬁles for complexes 18, 16, 14, 13, 19, 10, 7, 24,
20, and 26 have been deposited in the CCDC with reference numbers 821519 –
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821528, respectively. The collection and structure solution were carried out by Dr.
Guy J. Clarkson.
4.2.2 Synthesis and Characterization
[Os(η6-bip)(1-CF3-4-Cl-Azpy)I]PF6 (1). [Os(η6-bip)I2]2 (50.0 mg, 0.042 mmol)
was dissolved in methanol (40 mL) at 353 K. 1-CF3-4-Cl-azpy (24.0 mg, 0.084
mmol) in methanol (10 mL) was added drop-wise. The solution was stirred at 353
K for 16 h. The volume was reduced to about 10 mL by removal of methanol on a
rotary evaporator, and ammonium hexafluorophosphate (27.7 mg, 0.17 mmol)
was added. The solution was then left in a freezer at 253 K for 24 h. The dark
coloured precipitate was collected by filtration, washed with cold ethanol and
diethyl ether, then finally dried in vacuo. Yield: 43.1 mg (57.1 %). ESI-MS Calcd
for C24H17ClF3IN3Os: m/z 758.0, found 757.8. 1H NMR((CD3)2CO): δ 9.80 (s, 
1H), 8.71 (d, 1H, J = 2 Hz), 7.96 (d, 2H, J = 8 Hz), 7.72 (t, 1H, J = 8 Hz), 7.56-
7.44 (m, 6H), 7.42-7.38(m, 2H), 7.27 (t, 1H, J = 6 Hz), 7.22 (d, 1H, J = 6 Hz),
6.98 (t, 1H, J = 6 Hz), 6.88 (d, 1H, J = 6 Hz), 6.77 (t, 1H, J = 6 Hz), CHN analysis:
Found: C, 31.98%; H, 2.08%; N, 4.34%. Calcd for C24H17ClF9IN3OsP: C, 31.96%
H, 1.90% N, 4.66%.
[Os(η6-p-cym)(1-CF3-4-Cl-Azpy)I]PF6 (2). [Os(η6-p-cym)I2]2 (50.0 mg, 0.043
mmol) was dissolved in methanol (40 mL). 1-CF3-4-Cl-azpy (24.6 mg, 0.086
mmol) in methanol (10 mL) was added drop-wise, the solution-colour changed
from yellow to red brown immediately. The solution was stirred at ambient
temperature for 72 h. The volume was reduced to about 10 mL by removal of
methanol on a rotary evaporator, and ammonium hexafluorophosphate (28.0 mg.
0.17 mmol) was added. The solution was then left in a freezer (253 K) for 24 h.
Dark coloured crystals formed which were collected by filtration, washed with
cold ethanol and diethyl ether, then finally dried in vacuo. Yield: 54.4 mg
(71.7 %). ESI-MS Calcd for C22H21ClF3IN3Os: m/z 738.0, found 737.8. 1H
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MR((CD3)2CO): δ 8.91 (s, 1H), 8.41 (d, 2H, , J = 6 Hz), 8.06-7.79 (m, 6H), 7.07 
(d, 2H, , J = 6 Hz), 6.46-6.40 (m, 3H), 6.16 (d, 2H, , J = 6 Hz), 2.77 (s, 3H), 2.62-
2.52 (m, 1H), 0.93 (d, 3H, J = 7 Hz), 0.88 (d, 3H, J = 7 Hz). CHN analysis: Found:
C, 29.91%; H, 2.38%; N, 4.83%. Calcd for C22H21ClF9IN3OsP: C, 29.96%; H,
2.40%; N, 4.76%.
[Os(η6-bip)(1-CF3-4-Cl-Azpy)Cl]PF6 (3). [Os(η6-bip)Cl2]2 (50.0 mg, 0.06 mmol)
was dissolved in methanol (40 mL) at 353 K. 1-CF3-4-Cl-azpy (34.3 mg, 0.12
mmol) in methanol (10 mL) was added drop-wise. The solution was stirred at 353
K for 2 h. The volume was reduced to about 10 mL by removal of methanol on a
rotary evaporator, and ammonium hexafluorophosphate (39.1 mg, 0.24 mmol)
was added. The solution was then left in a freezer (253 K) for 24 h. The dark
coloured precipitate was collected by filtration, washed with cold ethanol and
diethyl ether, then finally dried in vacuo. Yield: 71.9 mg (88.7 %). ESI-MS Calcd
for C24H17Cl2F3N3Os: m/z 666.0, found 666.0. 1H NMR((CD3)2CO): δ 9.55 (s, 
1H), 8.84 (d, 1H, J = 2 Hz), 7.99 (d, 2H, J = 8 Hz), 7.76 (t, 1H, J = 8 Hz), 7.66-
7.54 (m, 6H), 7.50-7.47(m, 2H), 7.07 (d, 1H, J = 6 Hz), 6.98-6.92 (m, 3H), 6.54-
6.49 (m, 1H). CHN analysis: Found: C, 36.43%; H, 2.07%; N, 5.17%. Calcd for
C24H17Cl2F9N3OsP: C, 35.56%; H, 2.11%; N, 5.18%.
[Os(η6-p-cym)(1-CF3-4-Cl-Azpy)Cl]PF6 (4). [Os(η6-p-cym)Cl2]2 (50.0 mg,
0.063 mmol) was dissolved in methanol (40 mL). 1-CF3-4-Cl-azpy (36.1 mg,
0.126 mmol) in methanol (10 mL) was added drop-wise, the solution-colour
changed from yellow to red brown immediately. The solution was stirred at
ambient temperature for 12 h. The volume was reduced to about 10 mL by
removal of methanol on a rotary evaporator, and ammonium hexafluorophosphate
(41.2 mg, 0.25 mmol) was added. The solution was then left in the freezer (253 K)
for 24 h. The dark coloured precipitate was collected by filtration, washed with
cold ethanol and diethyl ether, then finally dried in vacuo. Yield: 69.2 mg
(69.5 %). ESI-MS Calcd for C22H21Cl2F3N3Os: m/z 646.1, found 646.0. 1H
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NMR((CD3)2CO): δ 9.80 (s, 1H), 8.88 (s, 1H), 8.18 (m, 2H), 7.96-7.81 (m, 3H), 
7.03 (d, 1H, J = 8 Hz), 6.68 (d, 1H, J = 8 Hz), 6.56 (m, 2H), 2.80 (s, 3H), 2.58-
2.49 (m, 1H), 1.00 (d, 3H, J = 7 Hz), 0.96 (d, 3H, J = 7 Hz). CHN analysis: Found:
C, 33.26%; H, 2.59%; N, 5.24%. Calcd for C22H21Cl2F9N3OsP: C, 33.43%; H,
2.68%; N, 5.32%.
[Os(η6-p-cym)(1-Cl-Azpy)I]PF6 (5). [Os(η6-p-cym)I2]2 (50.0 mg, 0.043 mmol)
was dissolved in methanol (30 mL). 1-Cl-azpy (18.7 mg, 0.086 mmol) in
methanol (10 mL) was added drop-wise. The solution was stirred at 353 K for 4 h.
The volume was reduced to about 10 mL by removal of methanol on a rotary
evaporator, and ammonium hexafluorophosphate (28.0 mg, 0.17 mmol) was
added. The solution was then left in the freezer (253 K) for 24 h. The dark
coloured precipitate was collected by filtration, washed with cold ethanol and
diethyl ether, then finally dried in vacuo. Yield: 28.0 mg (40.0 %). ESI-MS Calcd
for C21H22ClIN3Os: m/z 670.0, found 669.9. 1H NMR((CD3)2CO): δ 9.01 (d, 1H, J 
= 6 Hz), 8.20 (d, 1H, J = 8 Hz), 8.14-8.02 (m, 3H), 7.81 (m, 1H), 7.14 (d, 2H, J =
9 Hz), 6.61 (m, 2H), 6.46 (d, 1H, J = 6 Hz), 6.16 (m, 4H), 2.39 (s, 3H), 2.69-2.64
(m, 1H), 1.05 (d, 3H, J = 7 Hz), 1.01 (d, 3H, J = 7 Hz). CHN analysis: Found: C,
30.38%; H, 2.62%; N, 5.11%. Calcd for C21H22ClF6IN3OsP: C, 30.99%; H,
2.72%; N, 5.16%.
[Os(η6-bip)(1-Cl-Azpy)I]PF6 (6). [Os(η6-bip)I2]2 (30.0 mg, 0.025 mmol) was
dissolved in methanol (40 mL) at 353 K. 1-Cl-azpy (10.8 mg, 0.050 mmol) in
methanol (10 mL) was added drop-wise. The solution was stirred at 353 K for 2 h.
The volume was reduced to about 10 mL by removal of methanol on a rotary
evaporator, and ammonium hexafluorophosphate (16.3 mg, 0.10 mmol) was
added. The solution was then left in a freezer (253 K) for 24 h. The dark coloured
precipitate was collected by filtration, washed with cold ethanol and diethyl ether,
then finally dried in vacuo. Yield: 22.0 mg (52.8 %). ESI-MS Calcd for
C23H18ClIN3Os: m/z 690.0, found 689.9. 1H NMR((CD3)2CO): δ 8.56 (d, 1H, J = 
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6 Hz), 8.33 (t, 1H, J = 8 Hz), 8,19 (d, 1H, J = 6 Hz), 7.87 (d, 2H, J = 8 Hz), 7.66 (t,
1H, J = 8 Hz), 7.52-7.39 (m, 7H), 7.19 (d, 1H, J = 6 Hz), 7.00 (t, 2H, J = 6 Hz),
6.99-6.78 (m, 2H). CHN analysis: Found: C, 32.82%; H, 2.08%; N, 4.75%.
Calcd for C23H18ClF6IN3OsP: C, 33.12%; H, 2.18%; N, 5.04%.
[Os(η6-p-cym)(1-Cl-Azpy)Cl]PF6 (7). [Os(η6-p-cym)Cl2]2 (50.0 mg, 0.063 mmol)
was dissolved in methanol (30 mL). 1-Cl-azpy (27.4 mg, 0.126 mmol) in
methanol (10 mL) was added drop-wise, the solution-colour changed from yellow
to red immediately. The solution was stirred at ambient temperature for 4 h. The
volume was reduced to about 10 mL by removal of methanol on a rotary
evaporator, and ammonium hexafluorophosphate (41.2 mg, 0.25 mmol) was
added. The solution was then left in the freezer (253 K) for 24 h. The dark
coloured precipitate which was collected by filtration, washed with cold ethanol
and diethyl ether, then finally dried in vacuo. Yield: 86.3 mg (94.8 %). ESI-MS
Calcd for C21H22Cl2N3Os: m/z 578.1, found 578.1. 1H NMR((CD3)2CO): δ 8.94 (d, 
1H, J = 8 Hz), 8.41 (t, 1H, J = 8 Hz), 8.30(d, 1H, J = 8 Hz), 8.13(d, 2H, J = 8 Hz),
7.76 (m, 3H), 7.06 (d, 1H, J = 6 Hz), 6.42 (d, 1H, J = 6 Hz), 6.37 (d, 1H, J = 6 Hz),
6.16 (d, 1H, J = 6 Hz), 2.62-2.54 (m, 1H), 2.46 (s, 3H), 1.01 (d, 3H, J = 7 Hz),
0.97 (d, 3H, J = 7 Hz). CHN analysis: Found: C, 34.91%; H, 3.02%; N, 5.75%.
Calcd for C21H22Cl2F6N3OsP: C, 34.91%; H, 3.07%; N, 5.82%.
[Os(η6-bip)(1-Cl-Azpy)Cl]PF6 (8). [Os(η6-bip)Cl2]2 (50.0 mg, 0.060 mmol) was
dissolved in methanol (40 mL) at 353 K. 1-Cl-azpy (26.1 mg, 0.12 mmol) in
methanol (10 mL) was added drop-wise. The solution was stirred at 353 K for 1 h.
The volume was reduced to about 10 mL by removal of methanol on a rotary
evaporator, and ammonium hexafluorophosphate (39.1 mg, 0.24 mmol) was
added. The solution was then left in the freezer (253K) for 24 h. Dark coloured
powder was precipitated which was collected by filtration, washed with cold
ethanol and diethyl ether, then finally dried in vacuo. Yield: 27.8 mg (31.2 %).
ESI-MS Calcd for C23H18Cl2N3Os: m/z 598.0, found 598.0. 1H NMR((CD3)2CO):
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1H NMR((CD3)2CO): δ 8.92 (d, 1H, J = 6 Hz), 8.43 (t, 1H, J = 8 Hz), 8,26 (d, 1H, 
J = 6 Hz), 7.94 (d, 2H, J = 8 Hz), 7.72 (t, 1H, J = 8 Hz), 7.62-7.35 (m, 7H), 7.06 (t,
11H, J = 6 Hz), 6.94 (t, 2H, J = 6 Hz), 6.74 (t, 1H, J = 6 Hz), 6.50 (t, 1H, J = 6 Hz),
CHN analysis: Found: C, 36.95%; H, 2.39%; N, 5.59%. Calcd for
C23H18Cl2F6N3OsP: C, 37.20%; H, 2.44% ; N, 5.66%.
[Os(η6-bip)(2-F-Azpy)I]PF6 (9). [Os(η6-bip)I2]2 (25.0 mg, 0.021 mmol) was
dissolved in methanol (20 mL) at 313 K. 2-F-Azpy (8.4 mg, 0.042 mmol) in
methanol (10 mL) was added drop-wise, the solution-colour changed from yellow
to brown immediately. The solution was heated under reflux (353K) for 12 h. The
volume was reduced to about 10 mL by removal of methanol on a rotary
evaporator, and ammonium hexafluorophosphate (13.7 mg, 0.084 mmol) was
added. The solution was then left in a freezer (253 K) for 24 h. Dark coloured
powder precipitated which was collected by filtration, washed with cold ethanol
and diethyl ether, then finally dried in vacuo. Yield: 15.5 mg (45.0 %). ESI-MS
Calcd for C23H18FIN3Os: m/z 674.0, found 674.1. 1H NMR((CD3)2CO): δ 9.50 (t, 
1H, J = 2 Hz), 8.88 (d of d, 1H), 8,91 (d of d, 2H), 8,32(d of t, 1H), 8,02 (d of d,
1H), 7.95-7.92 (m, 2H), 7.73-7.41 (m, 5H), 7.13-7.09 (m, 2H), 6.96 (t, 1H, J = 7
Hz). 6.79 (d, 1H, J = 7 Hz), 6.65 (t, 1H, J = 7 Hz). CHN analysis: Found: C,
34.17%; H, 2.28%; N, 5.04%. Calcd for C23H18F7IN3OsP: C, 33.79%; H, 2.22%;
N, 5.14%.
[Os(η6-bip)(2-F-Azpy)Cl]PF6 (10) [Os(η6-bip)Cl2]2 (50.0 mg, 0.06 mmol) was
dissolved in methanol (40 mL) and water (10 mL) mixture at 353 K. 2-F-Azpy
(24.1 mg, 0.12 mmol) in methanol (10 mL) was added drop-wise. The solution
was heated under reflux (353K) for 4 h. The volume was reduced to about 10 mL
by removal of methanol on a rotary evaporator, and ammonium
hexafluorophosphate (97.8mg, 0.6 mmol) was added. The solution was then left in
a freezer (253 K) for 24 h. Dark coloured powder precipitated which was
collected by filtration, washed with cold ethanol and diethyl ether, then finally
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dried in vacuo. Yield: 37.5 mg (86.1 %). ESI-MS Calcd for C23H18ClFN3Os: m/z
582.1, found 582.0. 1H NMR((CD3)2CO): δ 9.53 (t, 1H, J = 2 Hz), 9.08 (d of d, 
1H), 8,40 (d of t, 2H), 7.94 (d, 2H J = 8 Hz), 7.73 (t, 1H, J = 8 Hz), 7.63-7.48 (m,
7H), 7.97-7.32 (m, 2H), 6.87 (t, 1H, J = 6 Hz). 6.78 (d, 1H, J = 6 Hz), 6.47 (t, 1H,
J = 6 Hz). CHN analysis: Found: C, 37.69%; H, 2.33%; N, 5.87%. Calcd for
C23H18ClF7N3OsP: C, 38.05%; H, 2.50%; N, 5.79%.
[Os(η6-p-cym)(2-F-Azpy)I]PF6 (11). [Os(η6-p-cym)I2]2 (50.0 mg, 0.043 mmol)
was dissolved in methanol (40 mL) at 313 K. 2-F-azpy (34.8 mg, 0.17 mmol) in
methanol (10 mL) was added drop-wise. The solution was stirred at 313 K for 4 h.
The volume was reduced to about 10 mL by removal of methanol on a rotary
evaporator, and ammonium hexafluorophosphate (70.0 mg, 0.43 mmol) was
added. The solution was then left in a freezer (253 K) for 24 h. Dark coloured
powder precipitated which was collected by filtration, washed with cold ethanol
and diethyl ether, then finally dried in vacuo. Yield: 38.7 mg (48.5 %). ESI-MS
Calcd for C21H22FIN3Os: m/z 654.0, found 654.0. 1H NMR((CD3)2CO): δ 9.70 (s, 
1H), 9.13 (d, 1H, J = 6 Hz), 8.34 (t, 1H, J = 6 Hz), 8.17 (d, 2H, J = 6 Hz), 7.82-
7.73 (m, 3H), 6.84 (d, 1H, J = 6 Hz), 6.52 (d, 1H, J = 6 Hz), 6.45 (d, 1H, J = 6 Hz),
6.35 (d, 1H, J = 6 Hz), 2.83 (s, 3H), 2.65-2.61 (m, 1H), 1.04 (d, 3H, J = 7 Hz),
1.00 (d, 3H, J = 7 Hz). CHN analysis: Found: C, 32.27%; H, 2.81%; N, 5.21%.
Calcd for C21H22F7IN3OsP: C, 31.63%; H, 2.78%; N, 5.27%.
[Os(η6-p-cym)(2-F-Azpy)Cl]PF6 (12). [Os(η6-p-cym)Cl2]2 (25.0 mg, 0.032 mmol)
was dissolved in methanol (20 mL) at 313 K. 2-F-azpy (12.7 mg, 0.063 mmol) in
methanol (10 mL) was added drop-wise. The solution was stirred at ambient
temperature for 4 h. The volume was reduced to about 10 mL by removal of
methanol on a rotary evaporator, and ammonium hexafluorophosphate (20.5 mg,
0.13 mmol) was added. The solution was then left in the freezer (253 K) for 24 h.
Dark coloured powder was precipitated which was collected by filtration, washed
with cold ethanol and diethyl ether, then finally dried in vacuo. Yield: 11.9 mg
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(52.7 %). ESI-MS Calcd for C21H22ClFN3Os: m/z 561.1, found 561.0. 1H
NMR((CD3)2CO): δ 9.70 (s, 1H), 9.12 (d, 1H, J = 6 Hz), 8.43 (t, 1H, J = 6 Hz), 
8.17 (d, 2H, J = 6 Hz), 7.65-7.58 (m, 3H), 6.87 (d, 1H, J = 6 Hz), 6.80 (d, 1H, J =
6 Hz), 6.51 (d, 1H, J = 6 Hz), 6.42 (d, 1H, J = 6 Hz), 2.81 (s, 3H), 2.53-2.49 (m,
1H), 0.99 (d, 3H, J = 7 Hz), 0.94 (d, 3H, J = 7 Hz). CHN analysis: Found: C,
35.07%; H, 2.98%; N, 5.71%. Calcd for C21H22ClF7N3OsP: C, 35.72%; H, 3.14%;
N, 5.95%.
[Os(η6-bip)(2-Cl-Azpy)I]PF6 (13). [Os(η6-bip)I2]2 (30.0 mg, 0.025 mmol) was
dissolved in methanol (10 mL) at 353 K and heated under reflux for 1 h. 2-Cl-
azpy (10.8mg, 0.050 mmol) in methanol (10 mL) was added drop-wise. The
solution was stirred at 353 K for 2 h. The volume was reduced to about 10 mL by
removal of methanol on a rotary evaporator, and ammonium hexafluorophosphate
(16.3 mg, 0.10 mmol) was added. The solution was then left in the freezer (253 K)
for 24 h. Dark coloured crystalline precipitated which was collected by filtration,
washed with cold ethanol and diethyl ether, then finally dried in vacuo. Yield:
24.5 mg (29.3 %). ESI-MS Calcd for C23H18ClIN3Os: m/z 690.0, found 689.9. 1H
NMR((CD3)2CO): δ 9.46 (d, 1H, J = 3 Hz), 8.99 (d, 1H, J = 9 Hz), 8,40 (d of d, 
1H), 7.91 (d, 2H, J = 8 Hz), 7.69 (t, 1H, J = 8 Hz), 7.55-7.47 (m, 3H), 7.44-7.39(m,
4H), 7.13 (d, 1H, J = 6 Hz), 7.09 (t, 1H, J = 6 Hz), 6.89 (t, 1H, J = 6 Hz), 6.82 (d,
1H, J = 6 Hz), 6.72 (t, 1H, J = 6 Hz). CHN analysis: Found: C, 32.92%; H, 2.06%;
N, 5.03%. Calcd for C23H18ClF6IN3OsP: C, 33.21%; H, 2.18%; N, 5.04%.
[Os(η6-p-cym)(2-Cl-Azpy)I]PF6 (14). [Os(η6-p-cym)I2]2 (50.0 mg, 0.043 mmol)
was dissolved in methanol (40 mL) at 313 K. 2-Cl-azpy (18.8 mg, 0.0865 mmol)
in methanol (10 mL) was added drop-wise, the solution-colour changed from
yellow to red immediately. The solution was stirred at ambient temperature for 3 h.
The volume was reduced to about 10 mL by removal of methanol on a rotary
evaporator, and ammonium hexafluorophosphate (28.2 mg, 0.173 mmol) was
added. The solution was then left in a freezer (253 K) for 24 h. The dark coloured
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precipitate was collected by filtration, washed with cold ethanol and diethyl ether,
then finally dried in vacuo. Yield: 45.7 mg (64.8 %). ESI-MS Calcd for
C21H22ClIN3Os: m/z 670.0, found 669.9. 1H NMR((CD3)2CO): δ 9.71 (s, 1H), 
9.05 (d, 1H, J = 9 Hz), 8.45 (d, 1H, J = 6 Hz), 8.16 (d, 2H, J = 6 Hz), 7.83-7.71 (m,
3H), 6.88 (d, 1H, J = 6 Hz), 6.57 (d, 1H, J = 6 Hz), 6.47 (d, 1H, J = 6 Hz), 6.35 (d,
1H, J = 6 Hz), 2.78 (s, 3H), 2.69-2.65 (m, 1H), 1.02 (d, 3H, J = 7 Hz), 0.97 (d, 3H,
J = 7 Hz). CHN analysis: Found: C, 30.95%; H, 2.60%; N, 5.12%. Calcd for
C21H22ClF6IN3OsP: C, 30.99%; H, 2.72%; N, 5.16%.
[Os(η6-bip)(2-Cl-Azpy)Cl]PF6 (15). [Os(η6-bip)Cl2]2 (50.0 mg, 0.060 mmol) was
dissolved in methanol (20 mL) at 353 K and heated under reflux and N2 for 1 h. 2-
Cl-azpy (26.1 mg, 0.120 mmol) in methanol (10 mL) was added drop-wise. The
solution was stirred at 353 K for 1 h. The volume was reduced to about 10 mL by
removal of methanol on a rotary evaporator, and ammonium hexafluorophosphate
(39.1 mg, 0.24 mmol) was added. The solution was then left in a freezer (253 K)
for 24 h. Dark coloured crystals formed which were collected by filtration,
washed with cold ethanol and diethyl ether, then finally dried in vacuo. Yield:
41.3 mg (46.3 %). ESI-MS Calcd for C23H18Cl2N3Os: m/z 598.0, found 598.0. 1H
NMR((CD3)2CO): δ 9.49 (d, 1H, J = 3 Hz), 8.97 (d, 1H, J = 9 Hz), 8,48 (d of d, 
1H), 7.92 (d, 2H, J = 8 Hz), 7.70 (t, 1H, J = 8 Hz), 7.61-7.46 (m, 3H), 7.44-7.38(m,
4H), 6.96 (d, 1H, J = 6 Hz), 6.89 (d, 1H, J = 6 Hz), 6.85 (t, 1H, J = 6 Hz), 6.79 (t,
1H, J = 6 Hz), 6.46 (t, 1H, J = 6 Hz). CHN analysis: Found: C, 36.92%; H, 2.32%;
N, 5.56%. Calcd for C23H18Cl2F6N3OsP: C, 37.20%; H, 2.44%; N, 5.66%.
[Os(η6-p-cym)(2-Cl-Azpy)Cl]PF6 (16). [Os(η6-p-cym)Cl2]2 (50.0 mg, 0.063
mmol) was dissolved in methanol (40 mL) at 313 K. 2-Cl-azpy (27.5 mg, 0.126
mmol) in methanol (10 mL) was added drop-wise, the solution-colour changed
from yellow to red immediately. The solution was stirred at ambient temperature
for 24 h. The volume was reduced to about 10 mL by removal of methanol on a
rotary evaporator, and ammonium hexafluorophosphate (41.2 mg, 0.253 mmol)
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was added. The solution was then left in a freezer (253 K) for 24 h. Dark coloured
crystals formed which were collected by filtration, washed with cold ethanol and
diethyl ether, then finally dried in vacuo. Yield: 41.2 mg (45.2 %). ESI-MS Calcd
for C21H22Cl2N3Os: m/z 578.1, found 578.0. 1H NMR((CD3)2CO): δ 9.68 (s, 1H), 
9.01 (d, 1H, J = 9 Hz), 8.45 (d of d, 1H), 8.13 (d, 2H, J = 6 Hz), 7.83-7.51 (m, 3H),
6.89 (d, 1H, J = 6 Hz), 6.52 (d, 1H, J = 6 Hz), 6.39-6,34 (m, 2H), 2.80 (s, 3H),
2.54-2.46 (m, 1H), 1.00 (d, 3H, J = 7 Hz), 0.96 (d, 3H, J = 7 Hz). CHN analysis:
Found: C, 34.80%; H, 2.98%; N, 5.78%. Calcd for C21H22Cl2F6N3OsP: C, 34.91%;
H, 3.07% N, 5.82%.
[Os(bip)(2-Br-Azpy)I]PF6 (17). [Os(bip)I2]2 (30.0 mg, 0.025 mmol) was
dissolved in methanol (30 mL) and water (10 mL), and the solution was heated
under reflux (T=353 K) for 1.5 h. 2-Br-azpy (13.1 mg, 0.05 mmol) in methanol
(10 mL) was added drop-wise, the solution-colour changed from orange to brown
immediately. The solution was stirred and heated under reflux for 1.5 h further.
The volume was reduced to about 10 mL by removal of methanol on a rotary
evaporator, and ammonium hexafluorophosphate (16.4 mg, 0.2 mmol) was added.
The solution was then left in a fridge for 24 h. The dark coloured precipitate was
collected by filtration, washed with cold ethanol and diethyl ether, then finally
dried in vacuo. Yield: 22.5 mg (51.2 %). ESI-MS Calcd for C23H18BrIN3Os: m/z
733.9, found 733.7. 1H NMR((CD3)2CO): δ 9.50 (d, 1H, J = 2 Hz), 8.91 (d, 1H, J 
= 9 Hz), 8,52 (d of d, 1H), 7.92 (d, 2H, J = 8 Hz), 7.69 (t, 1H, J = 8 Hz), 7.55-7.44
(m, 2H), 7.43-7.39 (m, 5H), 7.16-7.19 (m, 2H), 6.87 (t, 1H, J = 6 Hz), 6.81 (d, 1H,
J = 6 Hz), 6.71 (t, 1H, J = 6 Hz). CHN analysis: Found: C, 31.94%; H, 1.97%; N,
4.74%. Calcd for C23H18BrF6IN3OsP: C, 31.45%; H, 2.07% N, 4.78%.
[Os(η6-p-cym)(2-Br-Azpy)I]PF6 (18). [Os(η6-p-cym)I2]2 (20.0 mg, 0.017 mmol)
was dissolved in methanol (40 mL). 2-Br-Azpy (9.3 mg, 0.035 mmol) in methanol
(10 mL) was added drop-wise. The solution colour changed from yellow to dark
red immediately, it was stirred at ambient temperature for 16 h. The volume was
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reduced to ca 5 mL by removal of methanol on a rotary evaporator and
ammonium hexafluorophosphate (11.3 mg, 0.069 mmol) was added. Then the
solution was left in a freezer (253 K) for 24 h. A dark coloured solid precipitated,
which was filtered off, washed with diethyl ether, dried in vacuo. Yield: 16.2 mg
(54.7%). Anal. ESI-MS Calcd for C21H22BrIN3Os: m/z 714.0, found 713.9. 1H
NMR((CD3)2CO) δ  9.79 (s, 1H), 8.95 (d, 1H, J = 9 Hz), 8.67 (d, 1H, J = 6 Hz), 
8.16 (d, 1H, J = 7 Hz), 7.86-7.78 (m, 3H), 6.93 (d, 1H, J = 6 Hz), 6.57 (d, 1H, J =
6 Hz), 6.39 (m, 2H), 2.56-2.53 (m, 1H), 2.46 (s, 3H), 1.02 (d, 3H, J = 7 Hz), 0.96
(d, 3H, J = 7 Hz). CHN analysis Found: C, 29.98%; H, 2.85%; N, 4.72%, Calcd
for C21H22BrIF6N3OsP: C, 29.38%; H, 2.58%; N, 4.90%.
[Os(bip)(2-Br-Azpy)Cl]PF6 (19). [Os(bip)Cl2]2 (30.0 mg, 0.036 mmol) was
dissolved in methanol (30 mL) and water (10 mL), and the solution was heated
under reflux (T=353 K) for 1 h. 2-Br-azpy (18.9 mg, 0.072 mmol) in methanol (10
mL) was added drop-wise, the solution-colour changed from orange to brown
immediately. The solution was stirred and heated under reflux for 1 h further. The
volume was reduced to about 10 mL by removal of methanol on a rotary
evaporator, and ammonium hexafluorophosphate (59.0 mg, 0.36 mmol) was
added. The solution was then left in a fridge for 24 h. The dark coloured
precipitate was collected by filtration, washed with cold ethanol and diethyl ether,
then finally dried in vacuo. Yield: 19.2 mg (33.8 %). ESI-MS Calcd for
C23H18BrClN3Os: m/z 642.0, found 641.9. 1H NMR((CD3)2CO): δ 9.54 (d, 1H, J = 
2 Hz), 8.88 (d, 1H, J = 9 Hz), 8,61 (d of d, 1H), 7.72 (d, 2H, J = 8 Hz), 7.61 (t, 1H,
J = 8 Hz), 7.50-7.44 (m, 2H), 7.43-7.36 (m, 5H), 6.98 (d, 1H, J = 6 Hz), 7.89-7.80
(m, 3H), 6.47 (t, 1H, J = 6 Hz). CHN analysis: Found: C, 34.84%; H, 2.15%; N,
5.29%. Calcd for C23H18BrClF6N3OsP: C, 35.10%; H, 2.31% N, 5.34%.
[Os(η6-p-cym)(2-Br-Azpy)Cl]PF6 (20). [Os(η6-p-cym)Cl2]2 (30.0 mg, 0.038
mmol) was dissolved in methanol (20 mL) ; 2-Br-Azpy (20.0 mg, 0.076 mmol) in
methanol (10 mL) was added drop-wise, the solution colour changed from yellow
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to dark red immediately. The solution was stirred at ambient temperature for 3 h.
The volume was reduced to ca. 5 mL by removal of methanol on a rotary
evaporator and ammonium hexafluorophosphate (24.7 mg, 0.15 mmol) was added.
Then the solution was left in the freezer (253 K) for 24 h; A dark colour
crystalline precipitated which was filtered off and washed with diethyl ether, then
dried in vacuo. Yield: 39.2 mg (67.3%). Anal. ESI-MS Calcd for C21H22BrClN3Os:
m/z 622.0, found 622.1. 1H NMR((CD3)2CO) δ 9.83 (s, 1H), 9.00 (d, 1H, J = 9 
Hz), 8.61 (d, 1H, J = 6 Hz), 8.22 (d, 1H, J = 6 Hz), 7.80-7.78 (m, 3H), 6.94 (d, 1H,
J = 6 Hz), 6.63 (d, 1H, J = 6 Hz), 6.41 (d, 1H, J = 6 Hz), 6.39 (d, 1H, J = 6 Hz),
2.80 (s, 3H), 2.67-2.64 (m, 1H), 1.04 (d, 3H, J = 7 Hz), 0.99 (d, 3H, J = 7 Hz).
CHN analysis Found: C, 32.85%; H, 2.82%; N, 5.39%, Calcd for
C21H22BrClF6N3OsP: C, 32.89%; H, 2.89%; N, 5.48%.
[Os(η6-bip)(2-I-Azpy)I]PF6 (21). [Os(η6-bip)I2]2 (26.0 mg, 0.022 mmol) was
dissolved in methanol (20 mL) and water (5 mL), and the solution was heated
under reflux (T=353 K) for 1 h. 2-Br-azpy (13.4 mg, 0.043 mmol) in methanol (5
mL) was added drop-wise, the solution-colour changed from orange to brown
immediately. The solution was stirred and heated under reflux for 1 h further. The
volume was reduced to about 10 mL by removal of methanol on a rotary
evaporator, and ammonium hexafluorophosphate (14.3 mg, 0.088 mmol) was
added. The solution was then left in a fridge (253 K) for 24 h. Dark coloured
powder precipitated which was collected by filtration, washed with cold ethanol
and diethyl ether, then finally dried in vacuo. Yield: 19.2 mg (52.0 %). ESI-MS
Calcd for C23H18F6IN3Os: m/z 781.9, found 781.8. 1H NMR((CD3)2CO): δ 9.54 (d, 
1H, J = 2 Hz), 8.74 (d, 1H, J = 9 Hz), 8,64 (d of d, 1H), 7.92 (d, 2H, J = 8 Hz),
7.70 (t, 1H, J = 8 Hz), 7.52-7.46 (m, 3H), 7.44-7.41(m, 4H), 7.15 (d, 1H, J = 6 Hz),
7.09 (d, 1H, J = 6 Hz), 6.83-6.78 (m, 2H), 6.69 (t, 1H, J = 6 Hz). CHN analysis:
Found: C, 29.90%; H, 1.87%; N, 4.51%. Calcd for C23H18F6I2N3OsP: C, 29.85%;
H, 1.96% N, 4.54%.
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[Os(η6-p-cym)(2-I-Azpy)I]PF6 (22). [Os(η6-p-cym)I2]2 (25.0 mg, 0.022 mmol)
was dissolved in methanol (40 mL) at 313 K. 2-I-Azpy (13.4 mg, 0.043 mmol) in
methanol (10 mL) was added drop-wise, the solution-colour changed from orange
to blue immediately. The solution was stirred at ambient temperature for 4 h. The
volume was reduced to about 10 mL by removal of methanol on a rotary
evaporator, and ammonium hexafluorophosphate (14.0 mg, 0.086 mmol) was
added. The solution was then left in a freezer (253 K) for 24 h. Dark coloured
powder precipitated which was collected by filtration, washed with cold ethanol
and diethyl ether, then finally dried in vacuo. Yield: 27.4 mg (70.4 %). ESI-MS
Calcd for C21H22F6IN3Os: m/z 762.0, found 761.8. 1H NMR((CD3)2CO): δ 9.89 (s, 
1H), 9.13 (m, 1H), 8.71 (d of d, 1H), 8.18 (m, 2H), 7.82-7.73 (m, 2H), 6.91 (d, 1H,
J = 6 Hz), 6.59 (d, 1H, J = 6 Hz), 6.41 (d, 1H, J = 6 Hz), 6.35 (d, 1H, J = 6 Hz),
2.83 (s, 3H), 2.65-2.61 (m, 1H), 1.04 (d, 3H, J = 7 Hz), 0.99 (d, 3H, J = 7 Hz).
CHN analysis: Found: C, 27.62%; H, 2.27%; N, 4.64%. Calcd for
C21H22F6I2N3OsP: C, 27.86%; H, 2.45% N, 4.64%.
[Os(η6-bip)(3-Cl-Azpy)I]PF6 (23). [Os(η6-bip)I2]2 (30.0 mg, 0.025 mmol) in
methanol (30 mL) and water (10 mL) was heated under refluxed (T=348 K) for
1.5 h. 3-Cl-Azpy (11.2 mg, 0.052 mmol) in methanol (10 mL) was added drop-
wise. The solution colour changed from orange to dark red immediately, it was
stirred at 348 K for 1.5 h. The volume was reduced to ca. 10 mL by removal of
methanol on a rotary evaporator and ammonium hexafluorophosphate (41.0 mg,
0.25 mmol) was added. Then the solution was left in a fridge for 24 h. A dark
colour powder precipitated, which was filtered off, washed with cold methanol
and diethyl ether, dried in vacuo. Yield: 28.4 mg (68.1%). Anal. ESI-MS Calcd
for C23H18ClIN3Os: m/z 690.0, found 689.9. 1H NMR((CD3)2CO) δ 9.41 (d, 1H, J 
= 6 Hz), 9.14 (d, 1H, J = 2 Hz), 7.96-7.90 (m, 3H), 7.74 (t, 1H, J = 5 Hz), 7.59-
7.41 (m, 7H), 7.13 (d, 1H, J = 6 Hz), 7.05 (t, 1H, J = 6 Hz), 6.92-6.85 (m, 2H),
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6.74 (t, 1H, J = 6 Hz). CHN analysis Found: C, 33.12%; H 2.18%; N 5.04%,
Calcd for C23H18ClF6IN3OsP: C, 32.89%; H, 2.89%; N, 5.48%.
[Os(η6-p-cym)(3-Cl-Azpy)I]PF6 (24). [Os(η6-p-cym)I2]2 (30.0 mg, 0.026 mmol)
was dissolved in methanol (50 mL) . 3-Cl-Azpy (12.5 mg, 0.058 mmol) in
methanol (10 mL) was added drop-wise. The solution colour changed from yellow
to dark red immediately. It was then stirred at ambient temperature for 5 h. The
volume was reduced to ca. 10 mL by removal of methanol on a rotary evaporator
and ammonium hexafluorophosphate (41.8 mg, 0.26 mmol) was added. Then the
solution was left in a freezer (253 K) for 24 h. Dark coloured crystals formed,
which were filtered off, washed with diethyl ether, finally dried in vacuo. Yield:
28.4 mg (67.1%). Anal. ESI-MS Calcd for C21H22ClIN3Os: m/z 670.0, found
670.0. 1H NMR((CD3)2CO) δ  9.59 (d, 1H, J = 6 Hz), 9.16 (s, 1H), 8.18 (m, 2H), 
7.96 (m, 1H), 7.84 (s, 1H), 7.76 (t, 3H), 6.82 (d, 1H, J = 6 Hz), 6.48-6.45 (m, 2H),
6.36 (d, 1H, J = 6 Hz), 2.73 (s, 3H), 2.66 (m, 1H), 1.05 (d, 3H, J = 7 Hz), 0.99 (d,
3H, J = 7 Hz). CHN analysis Found: C, 30.94%; H, 2.60%; N, 5.12%; Calcd for
C21H22ClF6IN3OsP: C, 30.99%; H, 2.72%; N, 5.16%. Single crystals suitable for
X-ray diffraction were obtained by slow evaporation of a methanol solution of
complex 10 at 277 K.
[Os(η6-bip)(3-Cl-Azpy)Cl]PF6 (25). [Os(η6-bip)Cl2]2 (30.0 mg, 0.036 mmol) in
methanol (30 mL) and water (10 mL) was heated under reflux (T=348 K) for 1 h.
3-Cl-Azpy (16.1 mg, 0.073 mmol) in methanol (10 mL) was added drop-wise, the
solution colour changed from orange to dark red immediately. The solution was
stirred at 348 K for 2 h. The volume was reduced to ca. 10 mL by removal of
methanol on a rotary evaporator and ammonium hexafluorophosphate (59.0 mg,
0.36 mmol) was added. Then the solution was left in the fridge for 24 h; A dark
coloured powder precipitated, which was filtered off and washed with cold
methanol and diethyl ether, then dried in vacuo. Yield: 31.0 mg (57.9%). Anal.
ESI-MS Calcd for C23H18Cl2N3Os: m/z 597.6, found 598.0. 1H NMR((CD3)2CO)
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δ 9.05 (d, 1H, J = 6 Hz), 8.87 (s, 1H), 7.73 (d, 1H, J = 6 Hz), 7.39 (d, 2H, J = 6 
Hz), 7.28 (m, 1H), 7.17 (t, 2H, J = 6 Hz), 7.08-7.02 (m, 5H), 6.49 (d, 1H, J = 6
Hz), 6.46 (d, 1H, J = 6 Hz), 6.33 (t, 1H, J = 6 Hz), 6.18 (t, 1H, J = 6 Hz), 5.86 (t,
1H, J = 6 Hz). CHN analysis Found: C, 37.06%; H, 2.38%; N, 5.58%, Calcd for
C23H18Cl2F6N3OsP: C, 37.20%; H, 2.44%; N, 5.66%.
[Os(η6-p-cym)(3-Cl-Azpy)Cl]PF6 (26). [Os(η6-p-cym)Cl2]2 (30.0 mg, 0.038
mmol) was dissolved in methanol (20 mL); 3-Cl-Azpy (16.7 mg, 0.077 mmol) in
methanol (10 mL) was added drop-wise, the solution colour changed from yellow
to dark red immediately. The solution was stirred at ambient temperature for 3 h.
The volume was reduced to ca. 5 mL by removal of methanol on a rotary
evaporator and ammonium hexafluorophosphate (25.0 mg, 0.15 mmol) was added.
Then the solution was left in the freezer (253 K) for 24h; Dark coloured crystals
formed which were filtered off and washed with diethyl ether, dried in vacuo.
Yield: 39.1 mg (71.2%). Anal. ESI-MS Calcd for C21H22Cl2N3Os [M] m/z 578.1,
found 578.1. 1H NMR((CD3)2CO) δ  9.60 (d, 1H, J = 6 Hz), 9.13 (s, 1H), 8.15 (d, 
2H, J = 7 Hz), 8.11 (m, 1H), 7.86-7.79 (m, 3H), 6.84 (d, 1H, J = 6 Hz), 6.46 (d,
1H, J = 6 Hz), 6.38 (s, 2H), 2.56-2.53 (m, 1H), 2.43 (s, 3H), 1.02 (d, 3H, J = 7 Hz),
0.98 (d, 3H, J = 7 Hz). CHN analysis Found: C, 34.80%; H, 2.96%; N, 5.79%,
Calcd for C21H22Cl2F6N3OsP: C, 34.91%; H, 3.07%; N, 5.82%.
[Os(η6-bip)(Abpy)I]PF6 (27). [Os(η6-bip)I2]2 (50.1 mg, 0.0418 mmol) and Abpy
(19.5 mg, 0.105 mmol) were dissolved methanol (30 mL) and heated under reflux
at 353 K for 3 h. The volume was reduced to ca. 10 mL by removal of methanol
on a rotary evaporator. Ammonium hexafluorophosphate (29.3 mg, 0.16 mmol)
was added. Then the solution was left in a freezer (253 K) for 24 h. A dark
coloured precipitate formed, which was filtered off, washed with cold ethanol and
diethyl ether, finally dried in vacuo. Yield: 48.2 mg (72.0%). Anal. ESI-MS Calcd
for C22H18IN4Os: m/z 657.0, found 656.9. 1H NMR((CD3)2CO) δ  9.44 (d, 1H J = 
6 Hz), 9.07 (m, 1H), 8.76 (d, 1H J = 6 Hz), 8.38 (t, 1H, J = 8 Hz), 8.14 (m, 2H),
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7.76 (m, 2H), 7.61 (m, 2H), 7.45 (m, 3H). 7.25 (d, 1H, J = 6 Hz), 7.13 (d, 1H, J =
6 Hz), 7.03 (t, 1H, J = 6 Hz), 6.95 (t, 1H, J = 6 Hz), 6.82 (t, 1H, J = 6 Hz). CHN
analysis Found: C, 32.59%; H, 2.17%; N, 7.07%, Calcd for C20H22 F6IN4OsP: C,
33.01%; H, 2.27%; N, 7.00%.
[Os(η6-p-cym)(Abpy)I]PF6 (28). [Os(η6-p-cym) I2]2 (40.0 mg, 0.035 mmol) was
dissolved in 50 mL of methanol at 313 K; Abpy (16.1 mg, 0.087 mmol) in
methanol (5 mL) was added drop-wise, the solution colour changed from orange
to pink immediately; and was stirred at ambient temperature for 16 h. The volume
was reduced to ca. 10 mL by removal of methanol on a rotary evaporator.
Ammonium hexafluorophosphate (56.2 mg, 0.35 mmol) was added. Then the
solution was left in a freezer (253 K) for 24 h. A dark coloured precipitate formed,
which was filtered off, washed with cold ethanol and diethyl ether, then finally
dried in vacuo. Yield: 35.2 mg (64.5%). Anal. ESI-MS Calcd for C20H22IN4Os:
m/z 637.0, found 637.0. H NMR((CD3)2CO) δ  9.74 (d, 1H, J = 6 Hz), 9.12 (m, 
1H), 8.90 (d, 1H, J = 5 Hz), 8.41 (m, 1H), 8.22 (m, 2H), 7.86 (m, 2H), 6.78 (d, 1H,
J = 6 Hz), 6.72 (d, 1H, J = 6 Hz), 6.57 (d, 1H, J = 6 Hz), 6.51 (d, 1H, J = 6 Hz),
2.72 (s, 3H), 2.39 (m, 1H), 0.95 (d, 3H, J = 7 Hz), 0.91 (d, 3H, J = 7 Hz). CHN
analysis Found: C, 30.91%; H, 2.74%; N, 7.28%, Calcd for C20H22F6IN4OsP: C,
30.78%; H, 2.84%; N, 7.18%.
[Os(η6-bip)(Abpy)Cl]PF6 (29). [Os(η6-bip)Cl2]2 (51.0 mg, 0.064 mmol) and
Abpy (32.0 mg, 0.17 mmol) were dissolved in methanol (30 mL) and heated
under refluxed (T=348 K) for 4 h. The solution colour changed from orange to
pink immediately. The volume was reduced to ca. 10 mL by removal of methanol
on a rotary evaporator and ammonium hexafluorophosphate (40.0 mg, 0.24 mmol)
was added. Then the solution was left in a freezer (253 K) for 24 h. A black
crystalline product precipitated, which filtered off and washed with cold methanol
and diethyl ether, then dried in vacuo. Yield: 56.4 mg (62.6%). Anal. 1H
NMR((CD3)2CO) δ 9.49 (d, 1H, J = 6 Hz), 9.05 (m, 1H), 8.80 (d, 1H, J = 8 Hz), 
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8.46 (t, 1H, , J = 8 Hz), 8.17 (m, 2H), 7.82 (m, 2H), 7.66 (d, 2H, J = 6 Hz), 7.48
(m, 3H). 7.14 (d, 1H, J = 6 Hz), 6.97 (d, 2H, J = 3 Hz), 6.82 (t, 1H, J = 6 Hz), 6.53
(m, 1H). CHN analysis Found: C, 36.91%; H, 2.42%; N, 8.25%, Calcd for
C20H22ClF6N4OsP: C, 37.27%; H, 2.56%; N, 7.90%.
[Os(η6-p-cym)(Abpy)Cl]PF6 (30). [Os(η6-p-cym)Cl2]2 (35.2 mg, 0.0445 mmol)
was dissolved in methanol (25 mL) at RT. Abpy (20.4 mg, 0.11 mmol) in
methanol (5 mL) was added drop-wise, the solution colour changed from orange
to pink immediately. The solution was stirred at RT for 1 h. The volume was
reduced to ca 10 mL by removal of methanol on a rotary evaporator. Ammonium
hexafluorophosphate (73.0 mg, 0.45 mmol) was added. Then the solution was left
in the freezer (253 K) for 24 h. The dark coloured precipitate was filtered off and
washed with cold ethanol and diethyl ether, then finally dried in vacuo. Yield:
41.5 mg (67.7%). Anal. ESI-MS Calcd for C20H22ClN4Os: m/z 545.1, found 545.0.
1H NMR((CD3)2CO) δ 9.72 (d, 1H, J = 5 Hz), 9.07 (m, 1H), 8.94 (d, 1H, J = 4 Hz), 
8.49 (t, 1H, J = 8 Hz), 8.25 (m, 2H), 7.88 (m, 2H), 6.93 (d, 1H, J = 6 Hz), 6.74 (d,
1H, J = 6 Hz), 6.49 (d, 1H, J = 6 Hz), 6.40 (d, 1H, J = 6 Hz), 2.58 (m, 1H), 2.39 (s,
3H), 0.97 (d, 3H, J = 7 Hz), 0.93 (d, 3H, J = 7 Hz). CHN analysis Found: C,
34.69%; H, 3.08%; N, 8.20%, Calcd for C20H22ClPN4OsF6: C, 34.86%; H, 3.22%;
N, 8.13%.
[Os(η6-p-cym)(OH-Azpy-NO2)I]PF6 (31). [Os(η6-p-cym)I2]2 (23.8 mg, 0.020
mmol) was dissolved in methanol (30 mL) . OH-Azpy-NO2 (10.5mg, 0.043 mmol)
in methanol (5 mL) was added drop-wise. The solution was stirred at ambient
temperature for 48 h with 7 drops of HCl (1 M). The volume was reduced to ca. 2
mL by removal of methanol on a rotary evaporator. The complex was purified by
chromatography on a Sephadex LH20 column. Ammonium hexafluorophosphate
(10.0 mg, 0.61 mmol) was added. Then the solution was left in the fridge for 0.5 h.
The dark coloured precipitate was filtered off, washed with cold ethanol and
diethyl ether, then finally dried in vacuo. Yield: 12.7 mg (37.8%). Anal. ESI-MS
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Calcd for C21H22IN4O3Os: m/z 697.0, found 696.9. 1H NMR((CD3)2CO) δ 9.87 (d, 
1H, J = 2 Hz), 9.68 (d, 1H, J = 9 Hz), 9.39 (d, 2H, J = 9 Hz), 9.73 (d, 2H, J = 9
Hz), 8.57 (m, 1H), 7.38 (d, 1H, J = 8 Hz), 7.04 (d, 1H, J = 8 Hz), 6.57 (s, 1H),
4.50 (m, 1H), 3.60 (s, 3H), 0.89 (d, 3H, J = 7 Hz), 0.84 (d, 3H, J = 7 Hz). CHN
analysis Found: C, 31.06%; H, 2.83%; N, 6.44%, Calcd for C21H22F6IN4O3OsP:
C, 30.01%; H, 2.64%; N, 6.67%.
[Os(η6-p-cym)(OH-Azpy-NO2)Cl]PF6 (32). [Os(η6-p-cym) Cl2]2 (31.5 mg, 0.040
mmol) was dissolved in methanol (30 mL). OH-Azpy-NO2 (19.7 mg, 0.081 mmol)
in methanol (10 mL) was added drop-wise, the solution colour changed from
yellow to brown immediately. The solution was stirred at ambient temperature for
4 h. The volume was reduced to about 2 mL by removal of methanol on a rotary
evaporator. The complex was purified by chromatography on a Sephadex LH20
column. Ammonium hexafluorophosphate (26.2 mg, 0.16 mmol) was added. Then
the solution was left in the freezer (253 K) for 1 h. The dark coloured precipitate
was filtered off, washed with diethyl ether, and finally dried in vacuo. Yield: 25.1
mg (41.8%). Anal. ESI-MS Calcd for C21H22ClN4O3Os: 605.1, found 605.1. 1H
NMR((CD3)2CO) δ 9.06 (d, 1H, J = 2 Hz), 8.79 (d, 1H, J = 9 Hz), 8.56 (d, 2H, J = 
9 Hz), 8.33 (d, 2H, J = 9 Hz), 7.80 (d, 1H, J = 8 Hz), 6.74 (d, 1H, J = 8 Hz), 6.36
(d, 2H, J = 8 Hz), 6.22 (d, 1H, J = 8 Hz), 2.57-2.52 (m, 1H), 2.47 (s, 3H), 1.02 (d,
3H, J = 7 Hz), 0.98 (d, 3H, J = 7 Hz). CHN analysis Found: C, 34.35%; H, 2.95%;
N, 7.35%, Calcd for C21H22ClF6N4O3OsP: C, 33.67%; H, 2.96%; N, 7.48%.
4.2.3 Determination of IC50 Values
The concentrations of the osmium complexes that inhibit 50% of the proliferation
of human ovarian A2780 cancer cells were determined using the sulforhodamine
B assay.18 A2780 cells were seeded in 96-well plate (Falcon) at 5000 cells/well,
after the incubation for 48 h. The complexes were solubilised in DMSO (Sigma)
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to provide 10 mM stock solutions. These were serially diluted by cell culture
media to give concentrations four-fold greater than the final concentrations for the
assay. The complexes diluted in cell culture media were added to the 96-well plate
with cells in triplicate. The final DMSO concentration in each well was no more
than 1% (v/v). The media containing the complexes were removed after 24 h. The
cells were washed with phosphate buffered saline once and cell culture medium
was added (150 µL/well). The cells were then allowed to grow for a further 72 h.
The surviving cells were fixed by adding 150 µL/well of 50% (w/v)
trichloroacetic acid and incubated for 1 h in a refrigerator (277 K). The plates
were washed with tap water three times and dried under a flow of warm air, 0.4%
sulforhodamine B (Sigma) solution (100 µL/well) was added, followed by
washing with 1% acetic acid five times and drying under a flow of warm air. The
dye was dissolved in 10 mM Tris buffer (200 µL/well). The absorbance of each
well was determined using a Multiskan Ascent plate reader (Labsystems) at 540
nm. The absorbance of SRB in each well is directly proportional to the cell
number. Then the absorbance was plotted against concentration and the IC50
determined by using Origin software.
4.2.4 NAC or L-BSO Combination Treatments
A2780 cells were treated with 50 μM NAC or L-BSO and various concentrations 
of osmium complexes for 24 h. Then NAC/L-BSO and osmium complexes were
removed at the same time and cells washed with PBS once, then incubated for a
further 72 h for recovery. Cell viability was determined using the SRB assay as
described above.
4.2.5 Cellular Uptake
Chapter 4: OsII Arene R-azopyridine Complexes
111
A2780 cells were seeded 106 cells/well in 6-well plates. After 24 h incubation,
cells were exposed to 4 μM osmium complex. After 1 h, 2 h, 4 h and 24 h of drug 
exposure, the drug-containing medium was removed. Then samples were washed
with PBS twice, trypsinized, collected and stored at 253 K until ICP-MS analysis
for osmium content. The numbers of cells were counted using a cytometer. The
whole cell pellets were digested as described below. Firstly, 0.5 mL of freshly
distilled 72% HNO3 was added to each 1 mL cells pellets, and the samples were
transferred into Wheaton V-Vials The vials were heated in an oven at 373 K for
16 h to digest the samples fully, allowed to cool, and then transferred to Falcon
tubes. The vials were washed with double deionized water three times and diluted
10 times with double deionized water to obtain 6% HNO3 sample solutions. A
blank and the standards were loaded into the sample tray and were run from the
lowest to the highest concentration in a ‘no gas’ mode, followed by the samples.
4.2.6 Separation of Cell Fractions
The A2780 cells were seeded into Petri dishes at a concentration of 5×106
cells/dish. After 24 h incubation, osmium compounds 9 (4 µM) and 23 (4 µM)
were added. The cells were harvested after a further incubation with osmium
compound for 24 h. Then the four cell fractions (cytosol, membrane plus
particulate fraction, nucleus and cytoskeleton) were separated following the
protocol described for the kit (BioVision, Inc, USA). The concentrations of
osmium in different fractions were measured by ICP-MS after digestion following
the same method as for the cellular uptake study. The ICP-MS analysis was
helped by Aida Basri.
4.2.7 Detection of ROS
The vial of DCFH-DA was opened under N2 protection, and contents dissolved in
DMSO to give a 10 mM stock solution . A2780 cells were seeded (5000 cells/well)
into black 96-well plates and incubated for 24 h at 310 K, 5% CO2, high humidity.
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Cells were loaded with DCFH-DA (10 µM) and incubated for 30 min. The probe
was removed and PBS was used to wash the cells twice. The cells were then kept
in PBS solution and osmium compound 9 (4 µM), or NAC (50 µM) with 9 (4 µM),
or L-BSO (50 µM) with 9 (4 µM) were added. Hydrogen peroxide (50 µM) was
added as the positive control. The fluorescence was recorded over a period of 4 h
at 310 K by excitation at 480 nm and emission at 530 nm on a TECAN plate
reader.
4.2.8 Tubulin Polymerization Assay
A cytoskeleton tubulin polymerization assay kit (catalog no BK004) was used in
the tubulin polymerization study. Briefly, 10 μL of general tubulin buffer (80 mM 
PIPES, pH 6.9, 2 mM MgCl2 and 0.5 mM EGTA) containing osmium compound
9, colchicine or taxol was pipetted into the prewarmed 96 well microplate.
Tubulin (defrosted to room temperature from -80 °C and then placed on ice before
use) was diluted with tubulin polymerization buffer with 1 mM GTP to a final
concentration of 4 mg mL-1. Diluted tubulin (100 μL) was added into the wells 
containing osmium compound 9, colchicine or taxol. Diluted tubulin (100 μL) 
mixed with general tubulin buffer (10 μL) served as control. The absorbance at 
340 nm was read immediately with a Tecan microplate reader.
4.2.9 Cell Cycle Analysis
A2780 cells were incubated with osmium compounds 9 or 23 at various
concentrations for 24 h and then harvested. Detached and adherent cells were
washed with PBS and fixed in 70% ethanol. The fixed cells were centrifuged and
washed once with PBS, followed by resuspension in PBS–EDTA containing 7.5
µM propidium iodide (PI) and 10 µg/ml RNase A. After the cells had stood at
room temperature for 30 min, they were analyzed by flow cytometry with
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CellQuest Pro Software (Beckton Dickenson, USA). The cell cycle distribution
was evaluated using the Flowjo 7.6 (Beckton Dickenson, USA).
4.2.10 Immunofluorescence by Confocal Microscopy
A2780 Cells were seeded on Lab-TekTM Chamber Slides (Thermo Scientific
Nunc) 10,000 cells/chamber, after 24 h incubation, osmium compound 9 at
different concentrations were added and incubate for another 24 h. Cells were
fixed with 4% formaldehyde in PBS (20 min, 310 K), then rinsed with PBS (3 × 2
mL×2 min) and permeabilized with 0.1% Triton X-100 solution (PBS solution)
for 15 min at ambient temperature. The cells were blocked with blocking buffer (2
mg/ mL BSA, overnight at 269 K), and then, the cell monolayers were incubated
(1 h, 310 K) with monoclonal anti-α-tubulin-Alexa 488 (4 µg/mL) (Invitrogen 
Molecular Probles, Catalog No. 32-2588) with PI (7.5 µM). After the incubation,
the cells were washed with PBS and the immunofluorescence was detected using
a Leica SP5 fluorescence confocal microscope, with 100× objective.
4.3 Results
In the previous chapter, the synthesis and cancer cell cytotoxicity of twelve
osmium(II) azopyridine complexes containing various substituents on the phenyl
ring were reported.6 The least active compounds in this class contained
unsubstituted one phenyl ring in the chelating ligand.6 In this chapter, an
investigation of whether the latter complexes can be activated by introducing
substituents (R) into the pyridine ring in the class [Os(η6-p-cym)(R-Azpy)X]PF6
was carried out. The effect of changing the arene ligand (from p-cymene to
biphenyl) and the monodentate ligand (X) from Cl to I was also studied. The
exploration of such a family of bioisosteres may allow optimisation of properties
and allow discovery of candidates (‘hits’) suitable for preclinical development.
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In total, 32 novel complexes with nine types of azopyridine chelating ligands
were synthesized in good yields, with PF6
-
as the counter anion, and characterized
by elemental analysis, ESI-MS and NMR spectroscopy (Chart 4.1). For ten
complexes, X-ray crystal structures were determined.
Chart 4.1. Osmium azopyridine arene complexes studied in this chapter.
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Complex Arene R1 R2 R3 R4 R5 X Y
1 bip CF3 H H Cl H I C
2 p-cym CF3 H H Cl H I C
3 bip CF3 H H Cl H Cl C
4 p-cym CF3 H H Cl H Cl C
5 bip Cl H H H H I C
6 p-cym Cl H H H H I C
7* bip Cl H H H H Cl C
8 p-cym Cl H H H H Cl C
9 bip H F H H H I C
10* bip H F H H H Cl C
11 p-cym H F H H H I C
12 p-cym H F H H H Cl C
13* bip H Cl H H H I C
14* p-cym H Cl H H H I C
15 bip H Cl H H H Cl C
16* p-cym H Cl H H H Cl C
17 bip H Br H H H I C
18* p-cym H Br H H H I C
19* bip H Br H H H Cl C
20* p-cym H Br H H H Cl C
21 bip H I H H H I C
22 p-cym H I H H H I C
23 bip H H Cl H H I C
24* p-cym H H Cl H H I C
25 bip H H Cl H H Cl C
26* p-cym H H Cl H H Cl C
27 bip H H H H H I N
28 p-cym H H H H H I N
29 bip H H H H H Cl N
30 p-cym H H H H H Cl N
31 p-cym H H OH H NO2 I C
32 p-cym H H OH H NO2 Cl C
* X-ray structure determined
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4.3.1 X-ray Crystal Structures
Eighteen novel iodido osmium complexes were synthesized and the structures
of [Os(η6-bip)(2-Cl-Azpy)I]PF6 (13), [Os(η6-p-cym)(2-Cl-Azpy)I]PF6 (14),
[Os(η6-p-cym)(2-Br-Azpy)I]PF6 (18) and [Os(η6-p-cym)(3-Cl-Azpy)I]PF6 (24)
were determined by X-ray crystallography. For comparison, fourteen chlorido
analogues were synthesized and the structures of the complexes [Os(η6-bip)(1-Cl-
Azpy)Cl]PF6 (7), [Os(η6-bip)(2-F-Azpy)Cl]PF6 (10), [Os(η6-p-cym)(2-Cl-
Azpy)Cl]PF6 (16), [Os(η6-bip)(2-Br-Azpy)Cl]PF6 (19), [Os(η6-p-cym)(2-Br-
Azpy)Cl]PF6 (20) and [Os(η6-p-cym)(3-Cl-Azpy)Cl]PF6 (26) were also
determined by X-ray crystallography (Fig 4.1, Tables 4.1 and 4.2). All the X-ray
crystal structures adopt the familiar half-sandwich ‘piano-stool’ geometry.
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Figure 4.1. X-ray crystal structures of the cations of [Os(η6-bip)(1-Cl-
Azpy)Cl]PF6 (7) [Os(η6-bip)(2-F-Azpy)Cl]PF6 (10), [Os(η6-bip)(2-Cl-Azpy)I]PF6
(13), [Os(η6-p-cym)(2-Cl-Azpy)I]PF6 (14), [Os(η6-p-cym)(2-Cl-Azpy)Cl]PF6 (16),
[Os(η6-p-cym)(2-Br-Azpy)I]PF6 (18), [Os(η6-bip)(2-Br-Azpy)Cl]PF6 (19), [Os(η6-
p-cym)(2-Br-Azpy)Cl]PF6 (20), [Os(η6-p-cym)(3-Cl-Azpy)I]PF6 (24) and [Os(η6-
p-cym)(3-Cl-Azpy)Cl]PF6 (26) with thermal ellipsoids drawn at 50% probability.
The hydrogen atoms, counterions (PF6
-
) and solvent water molecules have been
omitted for clarity.
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Table 4.1
(A) X-ray crystallographic data for compounds 7, 10, 13 and 14.
7 10 13 14
Formula C23H18Cl2F6N3OsP C23H18ClF7N3OsP C23H18ClF6IN3OsP C21H22ClF6IN3OsP
Molar mass 742.47 726.02 833.92 813.94
Crystal system Monoclinic Triclinic Monoclinic Triclinic
Crystal size /mm 0.35 x 0.25 x 0.08 0.40 x 0.16 x 0.16 0.25 x 0.10 x 0.10 0.50 x 0.40 x 0.08
Space group P2(1)/c P-1 P2(1)/n P-1
Crystal black block brown block black block purple block
a / Å 7.6240(5) 7.4624(2) 6.9574(2) 7.6626(5)
b / Å 28.9718(19) 10.8856(4) 16.7829(6) 11.9693(8)
c / Å 11.0421(14) 14.5449(5 20.7297(7 13.6120(6)
α / deg 90 81.182(3) 90 99.966(5)
β / deg 94.240(8) 84.223(2) 93.182(3) 102.906(5)
γ / deg 90 82.970(3) 90 91.374(5)
T / K 298(2) 100(2) 100(2) 100(2)
Z 4 2 4 2
R [F > 4σ (F)][a] 0.0654 0.0249 0.023 0.0323
Rw[b] 0.1996 0.0569 0.0484 0.0779
GOF[c] 1.044 0.998 1.008 1.018
Δρ max and min/ eÅ-3 3.453 and -4.967 1.152 and -1.411 0.718 and -0.747 1.683 and -1.828
[a] R = Σ||Fo| - |Fc||/Σ|Fo|. [b] Rw = [Σw(Fo2 - Fc2)2/ΣwFo2)]1/2. [c] GOF = [Σw(Fo2
– Fc2)2/(n-p)]1/2. Where n = number of reflections and p = number of parameters.
(B) X-ray crystallographic data for compounds 16, 18 and 19.
16 18 19
Formula C21H22Cl2F6N3OsP C21H22BrF6IN3OsP C23H18BrClF6N3OsP
Molar mass 722.49 858.4 786.93
Crystal system Triclinic Triclinic Triclinic
Crystal size /mm 0.22 x 0.18 x 0.16 0.20 x 0.14 x 0.12 0.40 x 0.18 x 0.05
Space group P-1 P-1 P-1
Crystal green block black block brown block
a / Å 9.1784(2) 7.8035(3) 8.8866(5)
b / Å 10.6711(3) 11.9630(5) 10.0428(4)
c / Å 12.2921(4) 13.6394(6) 14.1695(7
α / deg 93.579(2) 100.216(4) 103.452(4)
β / deg 93.460(2) 102.863(4) 94.374(4)
γ / deg 96.430(2) 90.779(3) 100.802(4)
T / K 100(2) 100(2) 100(2)
Z 2 2 2
R [F > 4σ (F)][a] 0.0214 0.0264 0.0257
Rw[b] 0.0424 0.0608 0.0567
GOF[c] 0.977 1.034 0.99
Δρ max and min/ eÅ-3 0.800 and -0.759 2.450 and -0.866 1.113 and -1.144
[a] R = Σ||Fo| - |Fc||/Σ|Fo|. [b] Rw = [Σw(Fo2 - Fc2)2/ΣwFo2)]1/2. [c] GOF = [Σw(Fo2
– Fc2)2/(n-p)]1/2. Where n = number of reflections and p = number of parameters.
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(C) X-ray crystallographic data for compounds 20, 24 and 25
20 24 26
Formula C21H22BrClF6N3OsP C22H27ClF6IN3O1.50Os C21H22Cl2F6N3OsP
Molar mass 766.95 854.99 722.49
Crystal system Monoclinic Orthorhombic Triclinic
Crystal size /mm 0.30 x 0.10 x 0.05 0.32 x 0.32 x 0.18 0.20 x 0.12 x 0.05
Space group P2(1)/n Pbca P-1
Crystal black block black block black block
a / Å 16.6936(5) 19.4975(4) 7.2224(2)
b / Å 9.0505(3) 14.2729(3) 10.6661(4)
c / Å 16.9583(5) 20.3022(3) 15.8327(6)
α / deg 90 90 79.383(3)
β / deg 107.970(3) 90 78.400(3)
γ / deg 90 90 85.931(3)
T / K 100(2) 173(2) 100(2)
Z 2 2 2
R [F > 4σ (F)][a] 0.0292 0.0324 0.0221
Rw[b] 0.0524 0.073 0.045
GOF[c] 0.926 0.921 0.984
Δρ max and min/ eÅ-3 2.010 and -1.610 1.734 and -1.466 1.287 and -0.795
[a] R = Σ||Fo| - |Fc||/Σ|Fo|. [b] Rw = [Σw(Fo2 - Fc2)2/ΣwFo2)]1/2. [c] GOF = [Σw(Fo2
– Fc2)2/(n-p)]1/2. Where n = number of reflections and p = number of parameters.
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Table 4.2. Selected bond lengths (Å) and angles (°). (A) Iodido complexes
[Os(η6-bip)(2-Cl-Azpy)I]PF6 (13), [Os(η6-p-cym)(2-Cl-Azpy)I]PF6 (14), [Os(η6-
p-cym)(2-Br-Azpy)I]PF6 (18) and [Os(η6-p-cym)(3-Cl-Azpy)I]PF6 (24). (B)
Chlorido complexes [Os(η6-bip)(1-Cl-Azpy)Cl]PF6 (7), [Os(η6-bip)(2-F-
Azpy)Cl]PF6 (10), [Os(η6-p-cym)(2-Cl-Azpy)Cl]PF6 (16), [Os(η6-bip)(2-Br-
Azpy)Cl]PF6 (19), [Os(η6-p-cym)(2-Br-Azpy)Cl]PF6 (20) and [Os(η6-p-cym)(3-
Cl-Azpy)Cl]PF6 (26).
(A) Iodido complexes
bond
length/angle
13 14 18 24
Os(1)-N(8) 2.006(3) 2.033(4) 2.033(3) 2.009(3)
Os(1)-N(1) 2.057(3) 2.065(4) 2.051(3) 2.053(3)
Os(1)-C(15) 2.219(3) 2.213(5) 2.210(4) 2.228(4)
Os(1)-C(19) 2.261(3) 2.230(5) 2.220(4) 2.245(4)
Os(1)-C(18) 2.172(3) 2.240(5) 2.245(4) 2.190(4)
Os(1)-C(16) 2.221(3) 2.239(5) 2.243(4) 2.226(4)
Os(1)-C(20) 2.313(3) 2.219(5) 2.216(4) 2.284(4)
Os(1)-C(17) 2.203(3) 2.260(5) 2.268(4) 2.247(4)
Os(1)-I(1) 2.7063(2) 2.7002(4) 2.7056(3) 2.7007(3)
N(7)-N(8) 1.293(4) 1.296(5) 1.290(5) 1.284(4)
N(8)-Os(1)-N(1) 74.94(10) 75.47(16) 75.15(13) 74.41(13)
N1-Os-I 84.72(7) 84.98(11) 84.91(9) 82.36(9)
I-Os-N8 87.31(7) 88.76(11) 89.49(9) 87.76(9)
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Table 4.2. Selected bond lengths (Å) and angles (°). (A) Iodido complexes
[Os(η6-bip)(2-Cl-Azpy)I]PF6 (13), [Os(η6-p-cym)(2-Cl-Azpy)I]PF6 (14), [Os(η6-
p-cym)(2-Br-Azpy)I]PF6 (18) and [Os(η6-p-cym)(3-Cl-Azpy)I]PF6 (24). (B)
Chlorido complexes [Os(η6-bip)(1-Cl-Azpy)Cl]PF6 (7), [Os(η6-bip)(2-F-
Azpy)Cl]PF6 (10), [Os(η6-p-cym)(2-Cl-Azpy)Cl]PF6 (16), [Os(η6-bip)(2-Br-
Azpy)Cl]PF6 (19), [Os(η6-p-cym)(2-Br-Azpy)Cl]PF6 (20) and [Os(η6-p-cym)(3-
Cl-Azpy)Cl]PF6 (26).
(B) Chlorido complexes
bond
length/angle 7 10 16 19 20 26
Os(1)-N(8) 2.007(7) 2.023(3) 2.012(2) 2.039(3) 2.024(2) 2.0067(17)
Os(1)-N(1) 2.124(9) 2.053(3) 2.059(2) 2.055(3) 2.047(2) 2.0638(18)
Os(1)-C(15) 2.173(10) 2.233(3) 2.227(3) 2.242(4) 2.238(3) 2.246(2)
Os(1)-C(19) 2.227(9) 2.233(3) 2.218(3) 2.181(4) 2.208(3) 2.217(2)
Os(1)-C(18) 2.225(12) 2.239(3) 2.227(3) 2.204(4) 2.228(3) 2.221(2)
Os(1)-C(16) 2.255(10) 2.212(3) 2.173(3) 2.215(4) 2.187(3) 2.177(2)
Os(1)-C(20) 2.230(10) 2.233(3) 2.263(3) 2.278(4) 2.259(3) 2.286(2)
Os(1)-C(17) 2.257(11) 2.242(4) 2.226(3) 2.215(4) 2.238(3) 2.231(2)
Os(1)-Cl(1) 2.387(3) 2.3727(8) 2.3954(6) 2.3896(9) 2.3880(7) 2.3915(5)
N(7)-N(8) 1.276(11) 1.287(4) 1.295(3) 1.283(5) 1.295(3) 1.292(2)
N(8)-Os(1)-
N(1) 73.8(3) 74.52(11) 74.96(9) 74.32(13) 74.88(10) 74.68(7)
N1-Os-Cl 83.5(3) 82.24(8) 84.88(6) 84.69(9) 85.11(7) 84.45(5)
Cl-Os-N8 89.6(2) 88.36(8) 87.82(6) 88.86(9) 86.44(7) 89.63(5)
4.3.2 Stability and Hydrolysis
The hydrolysis (aquation) of two
since this is a potential
complexes in their interactions with biological targets such as DNA.
aqueous behaviour of the highly active complex
moderately active complex
The UV-Vis spectra, showed no change after 24 h, (Fig 4.2) indicating that
complexes 9 and 23
similar to the highly active azopyridine complexes containing unsubstituted
pyridine rings that studied in the previous chapter.
Figure 4.2. UV-Vis spectra for complexes
incubation for 24 h at 310 K in a solution of methanol/ water (5:95 v/v).
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azopyridine complexes were investigated
mechanism for activation of halido osmium arene
9 [Os(η6-bip)(2-F
23 [Os(η6-bip)(3-Cl-Azpy)I]PF6 was studied at 310 K.
remained stable and did not hydrolyze over that period,
6
9 (A) and 23 (B) before and after
122
19 The
-Azpy)I]PF6 and
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4.3.3 Structure-Activity Relationships Based on Bioisosteres
The effect of F, Cl, Br, I and CF3 substituents in the R1-R4 positions of the
pyridine ring of the azopyridine chelating ligand (Chart 4.1) on the cytotoxicity of
the complexes towards human ovarian A2780 cancer cells was investigated (Table
4.3 A).
Their potency covers a wide range of concentrations, from very high potency
with an IC50 of 220 nM for complex 21, [Os(η6-bip)(2-I-Azpy)I]PF6, to >100 µM
and inactivity for complexes 10, 25, 26 and 30 (Table 4.3). The following trends
are observed:
(1) Complexes containing iodide as the monodentate ligand have a higher
activity compared to the chlorido complexes (Table 4.3 B).
(2) Biphenyl complexes are, in general, 10 times more active than p-cymene
complexes (Table 4.3 C).
(3) The effect of chloride as an electron-withdrawing group on the pyridine
ring depends on its position. Within the most active series, which contain biphenyl
as the arene and iodide as the monodentate ligand, anticancer activity decreases
with pyridine ring substitution position in the order R2 > R1 > R3, with [Os(η6-
bip)(2-Cl-Azpy)I]PF6 (13) being the most active, (IC50= 1 µM) (Fig. 4.3 A).
(4) Changing the electron-withdrawing group at the R2 position leads to
increases in activity in the order Cl < Br ≤ F < I (Fig. 4.3 B). 
(5) Changing the phenyl ring in the azopyridine chelating ligand to pyridine,
does not improve the anticancer activity (Table 4.3). Also it is notable that that the
osmium(II) chlorido and iodido complexes with 5-hydroxy-2-(4-
nitrophenylazo)pyridine as the chelating ligand showed similar activity (Table 4.3
A).
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Table 4.3. (A) IC50 values for A2780 cells for complexes 1-32. (B) Comparison
of IC50 values for A2780 cells for monodentate ligand = Cl or I. (C) Comparison
of IC50 values for A2780 cells for arene - p-cym or bip.
(A)
Complex IC50 (µM)
(1)   [Os(η6-bip)(1-CF3-4-Cl-Azpy)I]PF6 5.7(±1.0)
(2)   [Os(η6-p-cym)(1-CF3-4-Cl-Azpy)I]PF6 10.9(±0.3)
(3)   [Os(η6-bip)(1-CF3-4-Cl-Azpy)Cl]PF6 25.2(±0.1)
(4)   [Os(η6-p-cym)(1-CF3-4-Cl-Azpy)Cl]PF6 38.2(±2.8)
(5)   [Os(η6-bip)(1-Cl-Azpy)I]PF6 3.7(±0.3)
(6)   [Os(η6-p-cym)(1-Cl-Azpy)I]PF6 9.0(±4.5)
(7)   [Os(η6-bip)(1-Cl-Azpy)Cl]PF6 42.9(±5.4)
(8)   [Os(η6-p-cym)(1-Cl-Azpy)Cl]PF6 24.0(±0.1)
(9)   [Os(η6-bip)(2-F-Azpy)I]PF6 0.63(±0.1)
(10) [Os(η6-bip)(2-F-Azpy)Cl]PF6 >100
(11) [Os(η6-p-cym)(2-F-Azpy)I]PF6 6.0(±0.4)
(12) [Os(η6-p-cym)(2-F-Azpy)Cl]PF6 13.3(±0.7)
(13) [Os(η6-bip)(2-Cl-Azpy)I]PF6 1.0(±0.1)
(14) [Os(η6-p-cym)(2-Cl-Azpy)I]PF6 33.6(±2.0)
(15) [Os(η6-bip)(2-Cl-Azpy)Cl]PF6 >50
(16) [Os(η6-p-cym)(2-Cl-Azpy)Cl]PF6 30.2(±12.4)
(17) [Os(η6-bip)(2-Br-Azpy)I]PF6 0.59(±0.02)
(18) [Os(η6-p-cym)(2-Br-Azpy)I]PF6 36.6(±0.9)
(19) [Os(η6-bip)(2-Br-Azpy)Cl]PF6 >50
(20) [Os(η6-p-cym)(2-Br-Azpy)Cl]PF6 >50
(21) [Os(η6-bip)(2-I-Azpy)I]PF6 0.22(±0.02)
(22) [Os(η6-p-cym)(2-I-Azpy)I]PF6 2.4(±0.5)
(23) [Os(η6-bip)(3-Cl-Azpy)I]PF6 22.0(±2.0)
(24) [Os(η6-p-cym)(3-Cl-Azpy)I]PF6 48.4(±6.1)
(25) [Os(η6-bip)(3-Cl-Azpy)Cl]PF6 >100
(26) [Os(η6-p-cym)(3-Cl-Azpy)Cl]PF6 >100
(27) [Os(η6-bip)(Abpy))I]PF6 21.3(±6.2)
(28) [Os(η6-p-cym)(Abpy))I]PF6 10.8(±0.11)
(29) [Os(η6-bip)(Abpy)Cl]PF6 22.4(±11.8)
(30) [Os(η6-p-cym)(Abpy))Cl]PF6 >100
(31) [Os(η6- p-cym)(OH-Azpy-NO2)I]PF6 0.29(±0.04)
(32) [Os(η6-p-cym)(OH-Azpy-NO2)Cl]PF6 0.30(±0.05)
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Table 4.3. (A) IC50 values for A2780 cells for complexes 1-32. (B) Comparison
of IC50 values for A2780 cells for monodentate ligand = Cl or I. (C) Comparison
of IC50 values for A2780 cells for arene - p-cym or bip.
(B)
Cl complex / I complex IC50 (Cl) / IC50 (I)
3/1 4.4
4/2 3.5
7/5 11.6
8/6 2.7
10/9 >159
12/11 2.2
15/13 >50
16/14 0.9
19/17 >85
20/18 >1.4
25/23 >4.5
26/24 >2.1
29/27 1.0
(C)
p-Cym Complex /
Bip Complex
IC50 (p-Cym) /
IC50 (Bip)
2/1 1.91
4/3 1.52
6/5 2.43
8/7 0.56
12/10 >7.5
14/13 33.6
18/17 62.0
22/21 10.9
24/23 2.20
28/27 0.51
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(A)
(B)
Figure 4.3. Comparision of the effect of different pyridine ring substitutions on
IC50 values for A2780 cells. Different colours are employed to show different sub-
families of these complexes: green (arene = biphenyl, monodentate ligand=iodide),
orange (arene = biphenyl, monodentate ligand = chloride), blue (arene = para-
cymene, monodentate ligand = iodide), red (arene = para-cymene, monodentate
ligand = chloride). (A) Chloride substituent at R1, R2 and R3 positions. (B)
Fluoride, chloride, bromide or iodide substituent at R2 position.
4.3.4 Partition Coefficients (Log P)
Octanol/water partition coefficients (log
lipophilicity of compounds and are often a useful indication of the likely extent of
drug uptake by cells.20
F), 13 (2-Cl), 17 (2-Br
25 (3-Cl) were studied by using the “shake tube method”. The log P values for
these complexes (Table 4.4) decrease along the series: complex
ligand Cl/substituent
25 (Cl/3-Cl) (Fig. 4.4),
octanol) to -1.446 (partitioning preferentially into water).
Figure 4.4. Comparison of octanol/water partition
cytotoxicity towards A2780 cells.
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P values) provide a measure of the
The log P values for four iodido biphenyl complexes
), and 23 (3-Cl), and two chlorido complexes
19
2-Br) > 17 (I/2-Br) > 13 (I/2-Cl) > 23 (I/3-
ranging from 0.1330 (partitioning preferentially into
coefficients (log P values) and
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9 (2-
19 (2-Br), and
(monodentate
Cl) > 9 (I/2-F)>
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Table. 4.4. Comparison of octanol/water partition coefficients (log P values) and
cytotoxicity towards A2780 cells. Data are the mean of three experiments and are
reported as mean ± standard error of the mean (SEM).
Complex Log P IC50/µM
9 -0.99 (± 0.28) 0.63 (±0.1)
13 -0.09 (± 0.06) 1.0 (±0.1)
17 0.08 (± 0.07) 0.59 (±0.02)
19 0.13 (± 0.06) >50
23 -0.59 (± 0.32) 22.0 (±2.0)
25 -1.45 (± 0.37) >100
4.3.5 Cellular Uptake and Distribution in A2780 Cells
Time-dependent cellular uptake studies of the biphenyl/iodido complexes 9
[Os(bip)(2-F-Azpy)I]PF6 and 23 [Os(bip)(3-Cl-Azpy)I]PF6 showed that the
accumulation of osmium from 9 is much higher than that of 23 after 24 h (Table
4.5 and Fig. 4.6 A) The distribution of Os in A2780 cells was investigated after
incubation with 4 µM complex 9 or 23 (the concentration was selected based on
the IC50 values of 9 and 23 against A2780 cells). The cytosol, membrane-plus-
particulate fraction, nucleus and cytoskeleton fractions were separated and their
Os contents were determined by ICP-MS (Fig. 4.5 and Fig 4.6 B). Complex 9
gave rise an uptake of osmium into the cytosol, membrane plus particulate
fraction and nucleus ca. 23 times higher than for 23 (Fig. 4.6 B). It is interesting
that for 23 there is a very high percentage of osmium in the cytoskeleton, up to 43 %
of the total cellular Os (Fig 4.5).
Table 4.5. Time dependent accumulation of O
A2780 human ovarian cancer cells.
Time / h
0.5
1
4
24
Figure. 4.5 Distribution of osmium in A2780 cells as a percentage of total
osmium for compounds
are reported as mean
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s from complexes 9
9/ppt Os/104 cells 23/ppt Os/104 cells
40.6 (±1.6) 64.8 (±5.6)
51.8 (±2.8) 67.4 (±0.3)
263.8 (±12.7) 67.9 (±1.8)
399.4 (±20.9) 35.1 (±2.2)
9 and 23. All data are the mean of three experiments and
± standard error of the mean (SEM)
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and 23 in
(A)
(B)
Figure 4.6. Uptake of osmium into A2780 human ovarian cancer cells.
dependence for complexes
complexes 9 and 23 in cell fractions: cytosol, membrane plus particulate fraction,
nucleus and cytoskeleton. Data are the mean of three experiments and are reported
as mean ± standard error of the mean (SEM).
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9 and 23 (B) Osmium distribution of Os from
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(A) Time
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4.3.6 Detection of ROS in A2780 Cancer Cells
To detect changes in general oxidative stress,21 the level of reactive oxygen
species (ROS, including O2-, OH∙, H2O2) in A2780 cells was determined by using
the probe 2′,7′-dichlorodihydrofluorescein-diacetate (DCFH-DA). When taken up 
by live cells, DCFH-DA hydrolyzes to 2′,7′-dichlorodihydrofluorescein (DCFH), 
which in turn is oxidized to 2′,7′-dichlorofluorescein (DCF) in the presence of 
ROS and detected by its intense fluorescence.22, 23 The change in ROS level
induced by 9 was monitored, [Os(η6-bip)(2-F-Azpy)I]PF6, one of the most active
compounds. The relative increase in DCF fluorescence was detected over time
after exposure to 9 alone (1 μM), 9 (1 μM) with L-buthionine sulfoximine (Chart 
4.2, 50 μM, an inhibitor of glutamylcysteine synthetase),24 and, for comparison,
H2O2 (50 μM). For 9, an increase in intracellular ROS level was observed, but it
was lower than that observed for H2O2 (50 μM) after 4 h of incubation. 
Chart 4.2. Structure of L-buthionine sulfoximine (L-BSO).
Exposure of A2780 cells to 9 (1 μM) in the presence of the antioxidant thiol 
N-acetyl-L-cysteine (NAC, 50 μM)25 gave no increase in ROS level compared to
the control. However, for 9 (1 μM) with L-BSO (50 μM), the increase in ROS 
level was even higher than that for H2O2 (50 μM) (Fig 4.7A). The increase of 
fluorescence over time after exposure of A2780 cells preloaded with DCFH-DA
to 1 µM of 9, indicates that 9 causes a build-up of ROS inside A2780 cancer cells.
(A)
(B)
Figure 4.7. (A) Relative changes in DCF fluorescence detected over time after
exposure to 1 μM 9, 1 μM 
μM H2O2. For each compound, the fluorescence was averaged over 6 wells (
(B) Percentage cell survival after 24
L-BSO (C+L-BSO), 1 μM 
50 μM L-BSO (9+ L
effects of combination treatment of complex
[Os(η6-bip)(2-Br-Azpy)I]PF
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9 with 50 μM NAC, 1 μM 9 with 50 μM
h exposure to 50 μM NAC (C+NAC), 50
9 (9), 1 μM 9 with 50 μM NAC (9+NAC),
-BSO) and 96 h recovery for A2780 ovarian cancer cells;
[Os(η6-bip)(2-F-Azpy)I]PF
6 (17) with NAC or L-BSO.
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L-BSO, or 50
n = 6).
 μM 
1 μM 9 with
6 (9) or
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4.3.7 Relationship of Cytotoxicity to ROS
In order to further investigate the possible involvement of ROS in the
cytotoxicity of the azopyridine osmium arene complexes studied here, the
combined effects of either complex 9 or 17 with the reductant NAC which can
deplete ROS or with L-BSO which depletes glutathione levels and can lead to an
increase in levels of ROS in cells were investigated.
The cytotoxicity assays showed that complex 9 (1 μM) in combination with 
the reductant (antioxidant) NAC (50 μM) did not increase the survival of A2780 
cells compared to those treated with 9 alone for 24 h (Fig 4.7 B). This suggests
that ROS are not implicated in cell death induced by complex 9. In contrast,
combination treatment of 9 with the oxidant L-BSO, which resulted in an increase
in the ROS level, blocked the anticancer activity.
The effect of combination treatment with the reductant (antioxidant) NAC (50
μM) on IC50 values for complex 9 was investigated for both A2780 (ovarian) and
A549 (lung) human cancer cell lines (Table 4.6). A2780 cells were treated with
various concentrations of 9 or 17 together with NAC (50 μM). Combination 
treatment with NAC decreased the cytotoxicity of both 9 and 17, slightly.
However, combination treatment with L-BSO raised the IC50 values for 9 and 17
more than 10 times for A2780 cells. For the A549 cell line, the IC50 value of 9
was raised from 1.8 µM to more than 100 µM, and for 17 the IC50 values
increased more than 70-fold (Table 4.6). Although the combination treatment of 9
or 17 with L-BSO then increase ROS block the anticancer acitivty is still need
further investigations, these data resemble those reported for the effects of
combination treatment on the organic drug Paclitaxel (Taxol) intriguingly which
is in clinical use for the treatment of ovarian, breast and non-small cell lung
cancer. Taxol is known to target tubulin in microtubules.14
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Table 4.6. IC50 values of combination treatment with NAC or L-BSO. (A) Effect
of L-BSO treatment (24 h) on IC50 values for A549 human lung cancer cells. (B)
Effect of L-BSO and NAC treatment (24 h) on IC50 values for IC50 values for
A2780 human ovarian cancer cells. The error bars are standard deviations from an
average of three wells.
(A)
Complex IC50/µM
+ L-BSO
IC50 /µM
9 1.8 (±1.4) >100
17 3.6 (±0.2) 30.5 (±2.6)
(B)
Complex IC50/µM
+ L-NAC
IC50 /µM
+ L-BSO
IC50 /µM
9 0.63 (±0.10) 0.97 (±0.01) 12.6 (±1.9)
17 0.59 (±0.02) 1.14 (±0.22) 8.4 (±0.9)
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4.3.8 Prevention of the Polymerization of Tubulin in Vitro
In order to investigate whether the osmium azopyridine complexes can
influence the polymerization process of tubulin, a variety of osmium complexes (1,
5, 9, 10 and 23) were incubated with purified and unpolymerized tubulin, the
polymerization processes of tubulin were monitored at 37°C for 60 min. Taxol
(microtubule stabilizer) and colchicine (microtubule de-stabilizer) were used as
comparisons. The process of polymerization was facilitated with the treatment of
taxol but completely halted by clochicine`s inhibition on the contrary. It was
found that 9 was able to reduce the total amount of polymerization of tubulin in a
dose-dependent manner during the 1h incubation time, the IC50 of tubulin
polymerization of 9 is ca. 20 µM (Figure 4.8 A). With the treatment with 9 at 20
µM, the tubulin polymerization process had one elongated nucleation phase which
lasted for 14 min (Figure 4.8 A). All the osmium anticancer complexes which
were tested for tubulin polymerization showed the inhibitive effect at different
extents; among them, complex 9 demonstrated the most potent inhibition to the
polymerization process of tubulin (Fig. 4.8 B).
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(A)
(B)
Osmium Compounds at 10 µM Inhibition of Tubulin Polymerisation/%
1 12.96
5 11.36
9 20.96
10 8.08
23 19.68
Figure 4.8. Inhibition of tubulin polymerization by osmium complexes in vitro.
(A) Inhibition of [Os(η6-bip)(2-F-Azpy)I]PF (9) on tubulin polymerization over a
period of 1 hour at 310 K. (2) The inhibition extents of tubulin polymerization
after 1 h incubation at 310 K for different osmium complexes: 1, 5, 9, 10 and 23.
Chapter 4: OsII Arene R-azopyridine Complexes
137
4.3.9 Complex 9 Inhibits the Formation of Microtubules in Cells
The microtubule assembly status in A2780 cells was examined by confocal
microscopy after the treatment with various concentrations of 9 at different time
points (2h and 24h). The A2780 cells were fixed, then the microtubules were
stained by anti-α-tubulin-Alexa 488 (monoclonal antibody which can react with 
all forms of alpha tubulin with a conjugation of green-fluorescent dye) and nuclei
were counterstained with propidium iodide (DNA intercalating agent and red-
fluorescent dye). After 2 h incubation with 9 at high concentrations (10 μM and 
20 μM), chromosome separation disruption in A2780 cells was observed (Fig 4.9 
A). After 24 h of treatment, most of the cells have long microtubule fragments
scattered throughout the cytoplasm in the control cells; however, the inhibition of
forming microtubules were even observed with the incubation with 9 at low
concentrations (1 µM), moreover there was a complete loss of microtubules with
only a diffuse stain visible throughout the cytoplasm at higher concentrations (5,
10 and 20 µM).
(A)
(B)
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(C)
Figure 4.9. Confocal microscopy of A2780 cells treated with different
concentrations of 9
magnification; (B) 24 h treatment and under 100×
and under 100× objective plus 4× magnification. Microtubules were stained by
anti-α-tubulin-Alexa 488 (green) and nuclei were dyed with propidium iod
(red). Results are representative of two independent experiments.
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. (A) 2 h of treatment under 100× objective plus 4×
objective; (C) 24 h treatment
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ide
4.3.10 Complexes 9 and 23 Induce G
Since inhibition of forming microtubules can affect the cell divisions in
mitosis phase, the changes of distributions in different cell cycle phases on A2780
cells after incubated with
A2780 cells were incubated with
selected to be comparable to their IC
dependent accumulation of A2780 cells with G
concomitant decrease with G
treatment with 9 or 23
cells in G2/M phase, an increase in subdiploid cells at highest concentr
both 9 and 23 was also observed (Fig 4.10). An S phase arrest induced by
also observed during the cell cycle which is not observed after the treatment with
23.
Figure 4.10. (A) Cell cycle distributions of A2780 cells after t
various concentrations of
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2/M Phase Cell Cycle Arrest
9 or 23 were monitored by using flow cytometer. The
9 or 23 at different concentrations which were
50 values respectively (Table 4.3). A dose
2/M phase (4N DNA content) and a
0/G1 phase (2N DNA content) were found after the
for 24 h (Fig. 4.10). Together with the accumulation of
9 or 23 for 24 h.
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ations for
9 was
he treatment of
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4.4 Discussions
The replacement of the N,N-chelating ligand ethylenediamine (en) by
azopyridine in [Ru(η6-arene)(N,N)X]+ complexes introduced some dramatic
changes in their chemical and biological properties was already found.8
Azopyridine ligands are not only σ-donors (like en), but also strong π-acceptors. 
The chlorido azopyridine complexes [Ru(η6-arene)(Azpy)Cl]+ (arene: p-cymene
(p-cym), benzene (bz), or biphenyl (bip)) readily underwent slow decomposition
via hydrolysis and/or arene loss. They were inactive (non-cytotoxic) towards
cancer cells but activated by the introduction of electron-donating substituents
into the phenyl ring, e.g. OH and NMe2. The π-acceptor property of the 
azopyridine ligand results in highly acidic aqua complexes. For example, the pKa
of the coordinated water in [Ru(η6-p-cym)(Azpy-NMe2)OH2]2+ is 4.60.26 Most
dramatic was the effect of changing the monodentate leaving group from chloride
to iodide which conferred on the complexes remarkable inertness towards ligand
substitution.8 Moreover these iodido complexes with substituents on the phenyl
ring were highly cytotoxic to A2780 human ovarian and A549 human lung cancer
cell lines with IC50 values of 2 - 6 µM. The mechanism of cytotoxicity appeared to
involve ligand-based redox reactions.8
These findings for RuII complexes appear to be mirrored to some extent for OsII
complexes. The chlorido OsII azopyridine complex [Os(η6-p-cym)(Azpy)Cl]PF6 is
inactive towards A2780 human ovarian cancer cells but active with electron-donor
NMe2 or OH substituents on the phenyl ring.6 The iodido complexes are more
active and complexes with moderate activity e.g. [Os(η6-p-cym)(Azpy)I]PF6 (IC50
= 10.3 µM in A2780 cell line) become potently cytotoxic at nanomolar
concentrations towards a panel of human cancer cell lines when substituents are
introduced into the phenyl ring, e.g. IC50 = 140 nM for [Os(η6-bip)(Azpy-
NMe2)I]PF6 towards A2780 ovarian cancer cells.6
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The aim of this chapter was to investigate the effects on anticancer activity of
introducing substituents into the pyridine ring especially when the phenyl ring is
left unsubstituted. 32 novel organometallic osmium azopyridine complexes were
synthesized and characterized (Chart 4.1). All the osmium complexes adopted the
familiar piano-stool geometry in the crystalline state, with bond lengths and
angles within the expected ranges.6 X-ray crystallographic data, selected bond
lengths and angles for these structures are listed in table 4.1 and table 4.2. For the
iodido osmium complexes, the Os-C (arene) bond lengths are in the range of
2.172-2.284 Å, and the Os-I bond lengths from 2.7002-2.7063 Å (Table 4.2). For
the chlorido osmium complexes, the Os-C (arene) bond lengths are in the range of
2.173-2.286 Å, and Os-Cl bond lengths are 2.3727-2.3954 Å (Table 4.2). A
relatively longer bond length for Os(1)-N(1)(pyridine) compared to Os(1)-
N(8)(azo) was observed in all the 10 crystal structures. This can be attributed to
the back-bonding competition for the osmium 5d6 electron density by the
azopyridine and arene -acceptor ligands. A similar trend was also observed for
ruthenium arene azopyridine complexes.26
Three of the structures show π-π stacking. [Os(η6-bip)(2-F-Azpy)Cl]PF6 (10)
exhibits intramolecular π-π stacking between the phenyl ring of the biphenyl arene 
ligand and the phenyl ring of the 2-F-Azpy ligand. There is also intermolecular π-
π stacking involving the same groups, but between symmetry-related molecules. 
For [Os(η6-p-cym)(3-Cl-Azpy)I]PF6 (24), there is π-π stacking between the p-
cymene and a phenyl ring in a symmetry-related molecule. There is an
intermolecular π-π stacking interaction between 2-Cl-Azpy ligands that lie in a 
head-to-tail dimer fashion related by an inversion centre in [Os(η6-p-cym)(2-Cl-
Azpy)I]PF6 (14). The distances between the planes of the stacked rings (ca. 3.3 Å)
are within the normal range for such interactions.27
Remarkably electron-withdrawing substituents on the pyridine ring can give
rise to highly potent complexes with IC50 values in the nano-molar range (Table
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4.3 and Fig. 4.3). The structure-activity relationships show that potency is higher
for biphenyl versus p-cymene as the arene (Table 4.3 C), and for iodide compared
to chloride as the monodenate ligand (Table 4.3 B). Biphenyl is a stronger π-
acceptor than p-cymene (back-donation of electron density from RuII) whereas p-
cym is the stronger electron donor. When RuII arene complexes bind to DNA, the
uncoordinated phenyl ring of bip can intercalate between DNA bases whereas
DNA distortions caused by p-cymene are steric in origin.28 The arene can also
have a major effect on interactions with protein targets, as demonstrated for
interactions between serum albumin and biphenyl and p-cymene RuII
complexes.29
The inertness of the most active complexes to hydrolysis suggests direct
binding to DNA is not the major mechanism of action and that a novel target for
these metal arene complexes is involved. Studies on OsII azopyridine complexes
containing unsubstituted pyridine and substitutions of the phenyl ring also lead to
the same conclusion.
Reactive oxygen species (ROS) play important roles in regulating cell
proliferation, death, and senescence, they can also play significant roles in the
mechanism of action of anticancer agents.30 The cytotoxicity mechanism for
osmium arene azopyridine iodido complexes containing unsubstituted (R1 – R4 =
H) pyridine rings and their ruthenium analogues was found to be related to ROS
generation.8 However, the complexes investigated in this chapter containing
substituted pyridine rings do not appear to share a mechanism dependent to the
formation of ROS. Down-regulation of ROS by increasing intracellular GSH,
does not block the anticancer activity of 9 and 17 (Table 4.6). It is also known that
cisplatin resistance is partly related to an increase of GSH levels,31 and the data
for complexes 9 and 17 suggests that they have potential for the treatment of
cisplatin-resistant tumours.32
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The mechanism of action of complexes 9 and 17 appears to be GSH-
dependent. L-buthionine sulfoximine (L-BSO) depletes intracellular glutathione
levels by inhibiting the enzyme glutamylcysteine synthetase. L-BSO is on clinical
trial for combination treatment with Melphalan,33 and increases the cytotoxicity of
a number of therapeutic agents, including cisplatin, especially towards resistant
cancer cell lines.34, 35 The only reported exception in which the L-BSO can block
the cytotoxicity of a drug appears to be taxol.14
For the structure activity relationships, it is evident that when biphenyl is the
arene and iodide is the monodentate ligand, the osmium complexes in this class
show the highest anticancer activity towards A2780 cells, consistent with our
previous work on azopyridine complexes with unsubstituted pyridine rings.6
Introducing biphenyl as the arene instead of p-cymene not only provides a
potential DNA intercalator but also increases the hydrophobicity for interaction
with proteins which may contribute to the increased activity.36, 37
Consideration of the substituents on the pyridine ring shows that changing
from chloride at R3 to fluoride causes the cellular accumulation of osmium to
increase dramatically and is accompanied by an improvement in anticancer
activity. The difference in the extent of cellular accumulation within this family
may contribute to the observed variations in anticancer activity, as may
interactions with targets (which may be proteins) .37
To investigate whether there is a link between lipophilicity and anticancer
activity for these complexes. The log P values were determined; they cover a
broad range from -1.446 to 0.1330 (Table 4.4). These values can be compared to
those for the less lipophilic clinical PtII drug cisplatin (log P = -2.36)38 and to the
RuIII drug NAMI-A (log P = -0.25)39 which is on clinical trials as an
antimetastatic agent. The sequence of potency towards A2780 human ovarian
cancer cells for the osmium azopyridine complexes is: 17 > 9 > 13 > 23 > 19 > 25,
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whereas lipophilicity decreases in the order 9 (monodentate ligand Cl/ pyridine
substituent 2-Br) > 17 (I/2-Br) > 13 (I/2-Cl) > 23 (I/3-Cl) > 9 (I/2-F)> 25 (Cl/3-
Cl). Hence there appears to be little correlation between lipophilicity (log P), and
anticancer activity (Fig. 4.4 and Table. 4.4). The introduction of bioisosterism into
the design has led to the discovery of compounds with different pharmaceutical
properties, potential candidates for further pharmacokinetic studies.
The cell distribution studies showed a dramatic increase in accumulation of
osmium in the membrane and particulate fraction of A2780 cells for 9 compared
to 23, and 9 is > 50 times more active than 23 (Fig. 4.5 and 4.6). Whether the
critical target site is in the membrane and particulate fraction remains to be
investigated further. However, to identify and determine the contribution of the
individual binding sites is a complex task, for example, only ca. 1 % of Pt from
intracellular cisplatin binds to its target, DNA,40,41 Further work is required to
validate the target for this sub-family of osmium arene azopyridine complexes.
Since the anticancer activity of osmium arene azopyridine complexes can be
blocked by the combination treatment with L-BSO, a similar effect which was
only observed on the combination treatment of L-BSO with taxol which can show
its anticancer effect through affecting the polymerization of tubulin, osmium
arene complexes were studied on the influence of the formation of microtubules
for the first time. There are two common types of tubulins (α-tubulin and β-
tubulin) which are able to polymerize to form microtubules; they and their
inherent dynamicity is vital for the cell division process especially in G2/M cell
cycle phase. Two classes of drugs which are targeting the polymerization process
of tubulin are now in clinical uses: (1) microtubule stabilizers (eg. taxol); (2)
microtubule de-stabilizers like Vinca alkaloids (eg. vincristine, vinblastine, and
vinorelbine). Both of these two types of anticancer drugs work by interfering with
the cell’s ability to form mitotic spindles appropriately by inducing or preventing
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the normal polymerization of microtubules in the G2/M phase during the cell cycle
process.42 The design of tubulin-targeting anticancer drugs was mainly based on
natural products (eg. taxol and vinca alkaloids) with more than 30 drug candidates
in different phases of clinical trials now.43 A lot of progresses have also been
made based on organic structures to design new tubulin polymerization
inhibitors,44-48 however, there is still no report showing any organometallic
complex can inhibit the polymerization of tubulin, although an osmium carbonyl
cluster was found to hyperstabilize microtubules in 2009.49
The results showed an inhibition effect of osmium arene complexes on the
tubulin polymerization process which was determined in vitro (Fig. 4.8). Complex
9 which showed the best inhibition effect in vitro and was selected for a further
cellular test in A2780 cells, the confocal microscopy images showed less
microtubules formed in A2780 cells after the treatment with 9 in a dose-dependent
manner (Fig. 4.9). However, for complex 9, the IC50 value of polymerization of
tubulin (ca. 20 µM) is much higher than the IC50 of anticancer activity (0.63 µM).
It is also noted that an S phase arrest together with G2/M phase arrest was induced
by complex 9, it suggested another anticancer mechanism involved for complex 9
which should be investigated in the future (Fig. 4.10).
The substitution of hydrogen by fluorine (most electronegative element) is one
of the most commonly employed monovalent isosteric replacements (e.g. 5-
fluorouracil) to improve the pharmacological properties.13 The major reason is
that fluorine substitution may cause an interaction with a biological target (for
example: hydrogen bond) as well as its effect on the metabolism of the drug in
vivo. Following this design, the osmium complex 9 was developed and showed
nanomolar anticancer activity, the mechanism for anti-proliferation is found
through cell cycle arrest and apoptosis. The mechanism of action of 9 involves the
inhibition of tubulin polymerization. Tubulin is possibly not the only target in this
case; more work will be carried out to search for the target(s) of osmium arene
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azopyridine complexes with potent anticancer activity. However, complex 9
demonstrated the first example of an organometallic complex which inhibits
tubulin polymerization.
4.5 Summary
The synthesis and characterisation of 32 half sandwich azopyridine OsII arene
complexes [Os(η6-arene)(azopyridine)X]+ in which X is chloride or iodide, the
arene is p-cymene or biphenyl and the pyridine and phenyl rings contain a variety
of substituents (F, Cl, Br, I, CF3, OH or NO2) were reported. Ten X-ray crystal
structures have been determined. Cytotoxicity towards A2780 human ovarian
cancer cells ranges from high potency at nanomolar concentrations to inactivity.
In general the introduction of an electron-withdrawing group (e.g. F, Cl, Br or I)
at specific positions on the pyridine ring significantly increases cytotoxic activity
and aqueous solubility. Changing the arene from p-cymene to biphenyl and the
monodentate ligand X from chloride to iodide also increases the activity
significantly. Activation by hydrolysis and DNA binding appears not to be the
major mechanism of action since both the highly active complex [Os(η6-bip)(2-F-
Azpy)I]PF6 (9) and the moderately active complex [Os(η6-bip)(3-Cl-Azpy)I]PF6
(23) are very stable and inert towards aquation. Studies of octanol/water partition
coefficients (log P) and subcellular distributions of osmium in A2780 human
ovarian cancer cells suggested that cell uptake and targeting to cellular organelles
play important roles in determining activity. Although complex 9 induced the
production of reactive oxygen species (ROS) in A2780 cells, the ROS level did
not appear to play a role in the mechanism of anticancer activity. This class of
organometallic osmium complexes has new and unusual features worthy of
further exploration for the design of novel anticancer drugs, their mechanism of
action may involve the inhibition of forming microtubules.
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5.1 Introduction
Recently, non-organometallic osmium (VI) complexes were reported to show
good anticancer activity in vivo.1 Certain half-sandwich organometallic iodido
osmium (II) arene azopyridine complexes were also found to exhibit potent in
vitro and in vivo anticancer activity (Chapter 2).2, 3 The mechanism of action is
different from that found previously for osmium(II) arene picolinate complexes
which can hydrolyze and then bind to DNA bases,4 with DNA believed to be the
target as is it for cisplatin.5, 6
Anticancer agents which target DNA will encounter an activated DNA repair
system which is driven by ATP energy.7 Reduced nicotinamide adenine
dinucleotide (NADH) is an important intermediate for energy metabolism
(through glycolysis and mitochondrial respiration8) and is therefore vital for
DNA-damage repair. Therefore, the depletion of NADH may have severe effects
on the bioenergetics of cells. NADH is not only an important intermediate in
mitochondrial respiration and glycolysis which can provide energy for cancer
cells, but also together with nicotinamide adenine dinucleotide (NAD+) is a part of
redox balance system.9 Under physiological conditions, the ratio of free
[NADH]/[NAD+] in cells is very low (in Hela cells, it was found to be 0.0016)
and the free NADH has cellular concentration in the range of nano molar,10 which
makes it a potential target in cancer cells.
Early work by Steckhan's group11 and Fish's group12 reported on an
economical process for regeneration of NADH from NAD+ by rhodium catalysts.
In previous work from Sadler's group, ruthenium arene anticancer complexes
were found to regioselectively reduce NAD+ to NADH through hydrogenation
transfer under physiological conditions in the presence of formate as hydride
donor.13 Though osmium is in the same group of ruthenium, no osmium
complexes have been reported to catalytically react with NAD+ or NADH to the
best of my knowledge.
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There are some intriguing differences between the chemical properties of
organometallic RuII and OsII arene complexes even though their three-dimensional
structures can be almost identical.14 For example, osmium complexes are often
considered to be relatively inert (a common characteristic of low-spin d6 metal
ions and especially 3rd row transition metals).4, 15 Probably due to the intriguing
difference between ruthenium and osmium, several organometallic osmium
anticancer complexes have been designed based on their ruthenium analogues.6, 16
However, the osmium complexes in this chapter were not designed based on
the work on ruthenium.2 Osmium(II) arene azopyridine complexes [Os(η6-
arene)(Azpy-R)X]PF6 (arene = biphenyl, p-cymene; X= Cl, I) were found to show
anticancer activity in nanomolar range in vitro,2 and resulted in the first
organometallic osmium complex ([Os(η6-p-cym)(Azpy-NMe2)I]PF6, FY026)
showing anticancer activity in vivo.3 An efficient approach to the study of the
anticancer activity17 of osmium arene complexes employed here uses
bioisosterism, which is a term coined to describe the wide application of
modifying biological activity by isosterism. The different biological behaviours
achieved by changing from the azo bond (N=N) to the imine bond (C=N) on the
osmium arene azopyridine complexes are explored. With this aim, derivatives of
osmium arene complexes containing iminopyridine as the N, N-chelating ligand
were prepared and the iodido and chlorido analogues of FY026 were mainly
studied in this chapter. The results indicate higher anticancer activity for the
iminopyridine complexes which also show good anticancer activity in the NCI 60
cell lines screen. Additionally, unlike the azopyridine complexes, the
iminopyridine complexes do not only undergo hydrolysis and then bind with 9-
ethylguanine, but also they can catalytically oxidize NADH to NAD+. For that
reason, the combination of both processes could contribute to the enhanced
anticancer activity of these complexes. It is therefore conceivable to develop a
strategy to combine both the nucleobase binding capability with NADH oxidizing
ability in one compound to improve its anticancer activity.
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5.2 Experimental
5.2.1 Synthesis of Iminopyridine ligands. Syntheses of iminopyridine ligand
were based on literature reports.18
5.2.2 Syntheses of Osmium Iminopyridine Complexes
(1) [Os(η6-bip)(Impy)I]PF6. [Os(η6-bip)I2]2 (50.0 mg, 0.042 mmol) was
dissolved in methanol (30 mL) at 353 K. Ligand Impy (15.3mg, 0.84 mmol) in
methanol (10 mL) was added drop-wise, the solution-colour changed from orange
to red immediately. The solution was stirred at 353 K for 3 h. The volume was
reduced to about 10 mL by removal of methanol on a rotary evaporator, and
ammonium hexafluorophosphate (27.4 mg. 0.17 mmol) was added. Then the
solution was left in the freezer (253K) for 24 h. Dark coloured powder was
precipitated which was collected by filtration, washed with cold ethanol and
diethyl ether, then finally dried in vacuum. Yield: 51.0 mg (78.1%) ESI-MS Calcd
for C24H20IN2Os: m/z 655.0, found 655.3. 1H NMR((CD3)2CO): δ 9.38 (d, 1H, 
J=5 Hz), 9.19 (s, 1 H), 8.55 (d, 1H, J=8 Hz), 8.25 (t, 1H, J=8 Hz), 7.70 (d, 2H, J=9
Hz),7.55-7.48 (m, 7H). 7.40 (d, 2H, J=9 Hz), 6.68 (d, 1H, J=6 Hz), 6.63 (t, 1H,
J=6 Hz), 6.58 (t, 1H, J=6 Hz), 6.47 (t, 1H, J=6 Hz), ), 6.34 (t, 1H, J=6 Hz), CHN
analysis: Found: C 34.91%, H 2.41%, N 3.34%. Calcd. for C24H20F6IN2OsP: C
36.10%, H 2.52%, N 3.51%.
(2) [Os(η6-p-cym)(Impy)I]PF6. [Os(η6-p-cym)I2]2 (30.0 mg, 0.026 mmol) was
dissolved in methanol (20 mL) at 313 K. Ligand Impy (9.4mg, 0.052 mmol) in
methanol (10 mL) was added drop-wise, the solution-colour changed from orange
to red immediately. The solution was stirred at ambient temperature for 2 h. The
volume was reduced to about 10 mL by removal of methanol on a rotary
evaporator, and ammonium hexafluorophosphate (17.0 mg. 0.1 mmol) was added.
Then the solution was left in the freezer (253K) for 24 h. Dark coloured powder
was precipitated which was collected by filtration, washed with cold ethanol and
diethyl ether, then finally dried in vacuum. Yield: 30.2 mg (74.8 %). ESI-MS
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Calcd for C22H24IN2Os: m/z 635.1, found 635.0. 1H NMR((CD3)2CO): δ 9.65 (d, 
1H, J=6 Hz), 9.31 (s, 1 H), 8.59 (d, 1H, J=8 Hz), 8.32 (t, 1H, J=8 Hz), 7.97-7.95
(m, 2H), 7.86 (t, 1H, J=8 Hz), 7.68-7.65 (m, 2H), 6.37 (d, 1H, J=8 Hz), 6.08 (d,
1H, J=6 Hz), 5.98 (d, 1H, J=6 Hz), 5,83 (d, 1H, J=6 Hz), 2.81 (s, 3H), 2.75-2.68
(m, 1H), 2.63 (s, 6H), 1.09 (d, 3H, J=7 Hz) 1.07 (d, 3H, J=7 Hz). CHN analysis:
Found: C, 34.29%; H, 3.10%; N, 3.57%. Calcd for C22H24F6IN2OsP: C, 33.94%
H, 3.11% N, 3.60%.
(3) [Os(η6-bip)(Impy-OH)I]PF6. [Os(η6-bip)I2]2 (50.0 mg, 0.042 mmol) was
dissolved in methanol (30 mL) and water (10 mL) mixture at 353 K. Ligand
Impy-OH (16.6 mg, 0.084mmol) in methanol (10 mL) was added drop-wise, The
solution was stirred at 353 K for 4 h. The volume was reduced to about 10 mL by
removal of methanol on a rotary evaporator, and ammonium hexafluorophosphate
(52.2 mg. 0.32 mmol) was added. Then the solution was left in the fridge (277K)
for 24 h. Dark coloured powder was precipitated which was collected by filtration,
washed with cold ethanol and diethyl ether, then finally dried in vacuum. Yield:
29.0 mg (17.2 %). ESI-MS Calcd for C22H24IN2OOs: m/z 651.0, found 651.0. 1H
NMR((CD3)2CO): δ 9.37 (d, 1H, J=6 Hz), 9.10 (s, 1 H), 8.49 (d, 1H, J=8 Hz), 
8.20 (t, 1H, J=8 Hz), 7.66 (t, 1H, J=9 Hz),7.59 (d, 2H, J=8 Hz), 7.49-7.41 (m,
5H), 6.91 (d, 2H, J=9 Hz), 6.89 (d, 1H, J=6 Hz), 6.65 (t, 1H, J=6 Hz), 6.55 (d, 1H,
J=6 Hz), 6.48 (t, 1H, J=6 Hz), 6.34 (t, 1H, J=6 Hz), CHN analysis: Found: C,
34.92%; H, 2.65%; N, 3.29%. Calcd for C22H24F6IN2OOsP: C, 35.39% H, 2.47%
N, 3.44%.
(4) [Os(η6-p-cym)(Impy-OH)I]PF6. [Os(η6-p-cym)I2]2 (50.0 mg, 0.043 mmol)
was dissolved in methanol (30 mL) at 313 K. Ligand Impy-OH (17.1 mg, 0.086
mmol) in methanol (10 mL) was added drop-wise, the solution-colour changed
from orange to red immediately. The solution was stirred at ambient temperature
for 48 h. The volume was reduced to about 10 mL by removal of methanol on a
rotary evaporator, and ammonium hexafluorophosphate (26.1 mg. 0.16 mmol)
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was added. Then the solution was left in the freezer (253K) for 24 h. Dark
coloured powder was precipitated which was collected by filtration, washed with
cold ethanol and diethyl ether, then finally dried in vacuum. Yield: 43.7 mg (64.0
%). ESI-MS Calcd for C22H24IN2OOs: m/z 651.0, found 651.1. 1H
NMR((CD3)2CO): δ 9.61 (d, 1H, J=5 Hz), 9.22 (s, 1 H), 8.51 (d, 1H, J=7 Hz), 
7.85(t, 1H, J=6 Hz), 7.80 (t, 1H, J=7 Hz), 7.07 (d, 2H, J=9 Hz), 6.40 (d, 1H, J=6
Hz),, 6.07 (d, 1H, J=6 Hz), 5.97 (d, 1H, J=6 Hz), 5.88 (d, 1H, J=6 Hz), 5.66 (s,
1H), 2.81 (s, 3H), 2.74-2.66 (m, 1H), 2.09 (s, 6H), 1.13 (d, 3H, J=7 Hz) 1.09 (d,
3H, J=7 Hz).. CHN analysis: Found: C, 33.01%; H, 3.15%; N, 3.41%. Calcd for
C22H24F6IN2OOsP: C, 33.26% H, 3.04% N, 3.53%. Crystals for X-ray diffreaction
were obtained by crystallization of a concentrated solution of [(η6-p-
cym)Os(Impy-OH)I]PF6 in a mixture of DCM and MeOH at 253K.
(5) [Os(η6-bip)(Impy-NMe2)I]PF6. [Os(η6-bip)I2]2 (50.0 mg, 0.042 mmol) was
dissolved in methanol (30 mL) at 353 K. Ligand Impy-NMe2 (18,8mg, 0.84
mmol) in methanol (10 mL) was added drop-wise, the solution-colour changed
from orange to red immediately. The solution was stirred at 353K for 4 h. The
volume was reduced to about 10 mL by removal of methanol on a rotary
evaporator, and ammonium hexafluorophosphate (27.3 mg. 0.17 mmol) was
added. Then the solution was left in the freezer (253K) for 24 h. red coloured
powder was precipitated which was collected by filtration, washed with cold
ethanol and diethyl ether, then finally dried in vacuum. Yield: 35.1 mg (49.8 %).
ESI-MS Calcd for C26H25IN3Os: m/z 698.1, found 698.1. 1H NMR((CD3)2CO): δ 
9.29 (d, 1H, J=5 Hz), 9.02 (s, 1 H), 8.42 (d, 1H, J=8 Hz), 8.18 (t, 1H, J=8 Hz),
7.65 (d, 2H, J=9 Hz), 7.51-7.38 (m, 7H). 6.88 (d, 1H, J=6 Hz), 6.74 (d, 2H, J=9
Hz), 6.62 (t, 1H, J=6 Hz), 6.55 (d, 1H, J=6 Hz), 6.50 (t, 1H, J=6 Hz), 6.34 (t, 1H,
J=6 Hz), CHN analysis: Found: C, 41.54%; H, 3.31%; N, 5.61%. Calcd for
C24H29ClF6N3OsP: C, 41.63% H, 3.36% N, 5.60%.
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(6) [Os(η6-p-cym)(Impy-NMe2)I]PF6. [Os(η6-p-cym)I2]2 (50.0 mg, 0.043 mmol)
was dissolved in methanol (30 mL) at 313 K. Ligand Impy-NMe2 (19.5mg, 0.086
mmol) in methanol (10 mL) was added drop-wise, the solution-colour changed
from orange to red immediately. The solution was stirred at ambient temperature
for 2 h. The volume was reduced to about 10 mL by removal of methanol on a
rotary evaporator, and ammonium hexafluorophosphate (141.8 mg. 0.87 mmol)
was added. Then the solution was left in the freezer (253K) for 24 h. Dark
coloured powder was precipitated which was collected by filtration, washed with
cold ethanol and diethyl ether, then finally dried in vacuum. Yield: 50.7 mg (72.9
%). ESI-MS Calcd for C24H28IN3Os: m/z 678.1, found 678.0. 1H
NMR((CD3)2CO): δ 9.55 (d, 1H, J=5 Hz), 9.12 (s, 1 H), 8.45 (d, 1H, J=7 Hz), 
8.24 (t, 1H, J=7 Hz), 7.83 (d, 2H, J=9 Hz), 7.73 (t, 1H, J=5 Hz), 6.89 (d, 2H, J=9
Hz), 6.38 (d, 1H, J=6 Hz), 6.04 (d, 1H, J=6 Hz), 5.92-5.87 (m, 2H), 3.15 (s, 6H),
2.65 (s, 3H), 2.21-2.13 (m, 1H), 1.09 (d, 3H, J=6 Hz) 1.07 (d, 3H, J=6 Hz). CHN
analysis: Found: C, 34.53%; H, 3.36%; N, 5.06%. Calcd for C24H28F6IN3OsP: C,
35.08% H, 3.56% N, 5.11%.
(7) [Os(η6-bip)(OMe-Impy-NMe2)I]PF6. [Os(η6-bip)I2]2 (50.0 mg, 0.042 mmol)
was dissolved in methanol (30 mL) and water (10 mL) mixture at 353 K. Ligand
OMe-Impy-NMe2 (21.3 mg, 0.84 mmol) in methanol (10 mL) was added drop-
wise, the solution-colour changed from orange to red immediately. The solution
was stirred at 353K for 4 h. The volume was reduced to about 10 mL by removal
of methanol on a rotary evaporator, and ammonium hexafluorophosphate (27.3
mg. 0.17 mmol) was added. Then the solution was left in the freezer (253K) for
24 h. red coloured powder was precipitated which was collected by filtration,
washed with cold ethanol and diethyl ether, then finally dried in vacuum. Yield:
18.0 mg (24.0 %). ESI-MS Calcd for C27H27IN3OOs: m/z 728.08, found 727.9. 1H
NMR((CD3)2CO): δ 9.00 (s, 1H), 8.18 (t, 1H, J=8 Hz), 7.99 (d, 1H, J=8 Hz), 7.60 
(d, 2H, J=9 Hz), 7.49-7.39 (m, 5H), 7.34 (d, 1H, J=8 Hz), 6.91 (d, 1H, J=6 Hz),
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6.74 (d, 2H, J=9 Hz), 6.56 (d, 1H, J=6 Hz), 6.51 (d, 1H, J=6 Hz), 6.48 (d, 1H, J=6
Hz), 6.21 (d, 1H, J=6 Hz), 4.10 (s, 3H), 3.12 (s, 6H), CHN analysis: Found: C,
37.17%; H, 2.98%; N, 5.04%. Calcd for C27H27F6IN3OOsP: C, 37.21% H, 3.12%
N, 4.82%.
(8) [Os(η6-p-cym)(OMe-Impy-NMe2)I]PF6. [Os(η6-p-cym)I2]2 (50.0 mg, 0.043
mmol) was dissolved in methanol (30 mL) at 313 K. Ligand OMe-Impy-NMe2
(22.0 mg, 0.086 mmol) in methanol (10 mL) was added drop-wise, the solution-
colour changed from orange to red immediately. The solution was stirred at
ambient temperature for 2 h. The volume was reduced to about 10 mL by removal
of methanol on a rotary evaporator, and ammonium hexafluorophosphate (28.0
mg. 0.172 mmol) was added. Then the solution was left in the freezer (253K) for
24 h. Dark coloured powder was precipitated which was collected by filtration,
washed with cold ethanol and diethyl ether, then finally dried in vacuum. Yield:
35.2 mg (49.2 %). ESI-MS Calcd for C25H31IN3OOs: m/z 708.1, found 708.0. 1H
NMR((CD3)2CO): δ 9.10 (s, 1 H), 8.23 (t, 1H, J=8 Hz), 8.03 (d, 1H, J=8 Hz), 7.83 
(d, 2H, J=8 Hz), 7.64 (d, 1H, J=8 Hz), 6.89 (d, 2H, J=8 Hz), 6.51 (d, 1H, J=6 Hz),
5.96 (d, 1H, J=6 Hz), 5.91(d, 1H, J=6 Hz), 5.75 (d, 1H, J=6 Hz), 4.40 (s, 3H), 3.16
(s, 6H), 2.84 (s, 3H), 2.70-2.61 (m, 1H), 1.11 (d, 3H, J=6 Hz) 1.09 (d, 3H, J=6
Hz).. CHN analysis: Found: C 35.20%, H 3.61%, N 5.01%. Calcd for
C25H31F6IN3OOsP: C, 35.26 % H, 3.67 % N, 4.93 %.
(9) [Os(η6-bip)(Impy)Cl]PF6. [Os(η6-bip)Cl2]2 (50.0 mg, 0.060 mmol) was
dissolved in methanol (30 mL) at 353 K. Ligand Impy (21.9mg, 0.12 mmol) in
methanol (10 mL) was added drop-wise, the solution-colour changed from orange
to red immediately. The solution was stirred at 353 K for 4 h. The volume was
reduced to about 10 mL by removal of methanol on a rotary evaporator, and
ammonium hexafluorophosphate (39.1 mg. 0.24 mmol) was added. Then the
solution was left in the freezer (253K) for 24 h. Dark coloured powder was
precipitated which was collected by filtration, washed with cold ethanol and
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diethyl ether, then finally dried in vacuum. Yield: 64.0 mg (75.3 %). ESI-MS
Calcd for C24H20ClN2Os: m/z 563.1, found 563.0. 1H NMR((CD3)2CO): δ 9.42 (d, 
1H, J=5 Hz), 9.28 (s, 1 H), 8.53 (d, 1H, J=8 Hz), 8.34 (t, 1H, J=8 Hz), 7.80 (t, 1H,
J=8 Hz), 7.62 (d, 2H, J=9 Hz), 7.58(d, 2H, J=9 Hz), 7.54-7.45 (m, 6H). 6.71 (d,
1H, J=6 Hz), 6.45 (d, 1H, J=6 Hz), 5.45-5.40 (m, 2H). 6.36 (t, 1H, J=6 Hz), CHN
analysis: Found: C, 40.77%; H, 2.79%; N, 3.91%. Calcd for C24H20ClF6N2OsP: C,
40.77% H, 2.85% N, 3.96%.
(10) [Os(η6-p-cym)(Impy)Cl]PF6. [Os(η6-p-cym)Cl2]2 (30.0 mg, 0.042 mmol)
was dissolved in methanol (30 mL) at 313 K. Ligand Impy (15.2mg, 0.085 mmol)
in methanol (10 mL) was added drop-wise, the solution-colour changed from
yellow to red immediately. The solution was stirred at ambient temperature for 2
h. The volume was reduced to about 10 mL by removal of methanol on a rotary
evaporator, and ammonium hexafluorophosphate (27.6 mg. 0.17 mmol) was
added. Then the solution was left in the freezer (253K) for 24 h. Dark coloured
powder was precipitated which was collected by filtration, washed with cold
ethanol and diethyl ether, then finally dried in vacuum. Yield: 27.4 mg (77.4%).
ESI-MS Calcd for C22H24ClN2Os: m/z 543.1, found 543.1. 1H NMR((CD3)2CO):
δ 9.63 (d, 1H, J=6 Hz), 9.37 (s, 1 H), 8.54 (d, 1H, J=8 Hz), 8.37 (t, 1H, J=8 Hz), 
7.90 (d, 2H, J=9 Hz), 7.66 (d, 2H, J=8 Hz), 7.86 (d, 2H, J=8 Hz), 6.44 (d, 1H, J=6
Hz), 6.02 (d, 1H, J=6 Hz), 5,96 (d, 1H, J=6 Hz), 5,79 (d, 1H, J=6 Hz), 2.79 (s,
3H), 2.69-2.55 (m, 1H), 2.39 (s, 6H), 1.09 (d, 3H, J=7 Hz) 1.07 (d, 3H, J=7 Hz).
CHN analysis: Found: C 38.44%, H 3.38%, N 4.06% Calcd. for
C22H24ClF6N2OsP: C 38.46%, H 3.52%, N 4.08%.
(11) [Os(η6-bip)(Impy-OH)Cl]PF6. [Os(η6-bip)Cl2]2 (50.0 mg, 0.060 mmol) was
dissolved in methanol (20 mL) and water (10 mL) mixture at 353 K. Ligand
Impy-OH (23.8mg, 0.012mmol) in methanol (10 mL) was added drop-wise, The
solution was stirred at 353 K for 4 h. The volume was reduced to about 10 mL by
removal of methanol on a rotary evaporator, and ammonium hexafluorophosphate
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(97.8 mg. 0.6 mmol) was added. Then the solution was left in the freezer (253K)
for 24 h. Dark coloured powder was precipitated which was collected by filtration,
washed with cold ethanol and diethyl ether, then finally dried in vacuum. Yield:
15.3 mg (17.2 %). ESI-MS Calcd for C24H20ClN2OOs: m/z 579.1, found 579.0. 1H
NMR((CD3)2CO): δ 9.36 (d, 1H, J=6 Hz), 9.18 (s, 1 H), 8.47 (d, 1H, J=8 Hz), 
8.29 (t, 1H, J=8 Hz), 7.76 (t, 1H, J=9 Hz),7.58 (d, 2H, J=8 Hz), 7.54-7.43 (m,
5H), 6.92 (d, 2H, J=9 Hz), 6.74 (d, 1H, J=6 Hz), 6.64 (d, 1H, J=6 Hz), 6.45 (t, 1H,
J=6 Hz), 6.42 (t, 1H, J=6 Hz), 6.35 (t, 1H, J=6 Hz), CHN analysis: Found: C,
39.44%; H, 2.84%; N, 3.71%. Calcd for C24H20ClF6N2OOsP: C, 39.87% H,
2.79% N, 3.87%.
(12) [Os(η6-p-cym)(Impy-OH)Cl]PF6. [Os(η6-p-cym)Cl2]2 (50.0 mg, 0.063
mmol) was dissolved in methanol (30 mL) at 313 K. Ligand Impy-OH (25.0 mg,
0.12 mmol) in methanol (10 mL) was added drop-wise, the solution-colour
changed from orange to red immediately. The solution was stirred at ambient
temperature for 2 h. The volume was reduced to about 10 mL by removal of
methanol on a rotary evaporator, and ammonium hexafluorophosphate (41.2 mg.
0.25 mmol) was added. Then the solution was left in the freezer (253K) for 24 h.
Dark coloured powder was precipitated which was collected by filtration, washed
with cold ethanol and diethyl ether, then finally dried in vacuum. Yield: 53.8 mg
(63.7 %). ESI-MS Calcd for C22H24ClN2OOs: m/z 559.1, found 559.1. 1H
NMR((CD3)2CO): δ 9.60 (d, 1H, J=5 Hz), 9.35 (s, 1 H), 8.50 (d, 1H, J=7 Hz), 
8.34 (t, 1H, J=7 Hz), 7.84(t, 1H, J=6 Hz), 7.75 (d, 2H, J=9 Hz), 7.08 (d, 2H, J=9
Hz), 6.46 (d, 1H, J=6 Hz), 6.00 (d, 1H, J=6 Hz), 5.84 (d, 1H, J=6 Hz), 2.81 (s,
3H), 2.65-2.55 (m, 1H), 2.41 (s, 6H), 1.10 (d, 3H, J=7 Hz) 1.08 (d, 3H, J=7 Hz).
CHN analysis: Found: C, 37.82%; H, 3.33%; N, 3.91%. Calcd for
C22H24ClF6N2OOsP: C, 37.58% H, 3.44% N, 3.98%.
(13) [Os(η6-bip)(Impy-NMe2)Cl]PF6. [Os(η6-bip)Cl2]2 (50.0 mg, 0.060 mmol)
was dissolved in methanol (20 mL) at 313 K. Ligand Impy-NMe2 (27.1mg, 0.12
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mmol) in methanol (10 mL) was added drop-wise, the solution-colour changed
from orange to red immediately. The solution was stirred at 353K for 12 h. The
volume was reduced to about 10 mL by removal of methanol on a rotary
evaporator, and ammonium hexafluorophosphate (39.1 mg. 0.24 mmol) was
added. Then the solution was left in the freezer for 24 h. red coloured powder was
precipitated which was collected by filtration, washed with cold ethanol and
diethyl ether, then finally dried in vacuum. Yield: 52.0 mg (57.8 %). ESI-MS
Calcd for C24H20ClN2Os: m/z 563.1, found 563.0. 1H NMR((CD3)2CO): δ 9.31 (d, 
1H, J=5 Hz), 9.09 (s, 1 H), 8.39 (d, 1H, J=8 Hz), 8.25 (t, 1H, J=8 Hz), 7.70 (t, 1H,
J=9 Hz),7.61-7.44 (m, 7H). 6.77 (d, 2H, J=9 Hz), 6.74 (d, 1H, J=6 Hz), 6.62 (d,
1H, J=6 Hz), 6.63-6.45 (m, 2H), 6.34 (t, 1H, J=6 Hz), CHN analysis: Found: C,
41.54%; H, 3.31%; N, 5.61%. Calcd for C24H20ClF6N2OsP: C, 41.63% H, 3.36%
N, 5.60%.
(14) [Os(η6-p-cym)(Impy-NMe2)Cl]PF6. [Os(η6-p-cym)Cl2]2 (50.0 mg, 0.063
mmol) was dissolved in methanol (30 mL) at 313 K. Ligand Impy-NMe2 (28.5mg,
0.126 mmol) in methanol (10 mL) was added drop-wise, the solution-colour
changed from orange to red immediately. The solution was stirred at ambient
temperature for 2 h. The volume was reduced to about 10 mL by removal of
methanol on a rotary evaporator, and ammonium hexafluorophosphate (41.2 mg.
0.253 mmol) was added. Then the solution was left in the freezer for 24 h. Dark
coloured powder was precipitated which was collected by filtration, washed with
cold ethanol and diethyl ether, then finally dried in vacuum. Yield: 67.2 mg (85.6
%). ESI-MS Calcd for C24H29ClN3Os: m/z 586.2, found 586.1. 1H
NMR((CD3)2CO): δ 9.55 (d, 1H, J=5 Hz), 9.20 (s, 1 H), 8.44 (d, 1H, J=7 Hz), 
8.31 (t, 1H, J=7 Hz), 7.82(t, 1H, J=6 Hz), 7.76 (d, 2H, J=9 Hz), 6.92 (d, 2H, J=9
Hz), 6.44 (d, 1H, J=6 Hz), 6.04 (d, 1H, J=6 Hz), 5.97 (d, 1H, J=6 Hz), 5.85 (d, 1H,
J=6 Hz), 3.16 (s, 6H), 2.42 (s, 3H), 2.21-2.11 (m, 1H), 1.09 (d, 3H, J=7 Hz) 1.07
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(d, 3H, J=7 Hz). CHN analysis: Found: C 39.43%, H 3.89%, N 5.75%. Calcd. for
C24H29ClF6N3OsP: C 39.48%, H 4.00%, N 5.75%.
(15) [Os(η6-bip)(OMe-Impy-NMe2)Cl]PF6. [Os(η6-bip)Cl2]2 (50.0 mg, 0.060
mmol) was dissolved in methanol (20 mL) and water (10 mL) at 313 K. Ligand
OMe-Impy-NMe2 (30.6 mg, 0.12 mmol) in methanol (10 mL) was added drop-
wise, the solution-colour changed from orange to red immediately. The solution
was stirred at 353K for 12 h. The volume was reduced to about 10 mL by removal
of methanol on a rotary evaporator, and ammonium hexafluorophosphate (39.1
mg. 0.24 mmol) was added. Then the solution was left in the freezer (253K) for
24 h. red coloured powder was precipitated which was collected by filtration,
washed with cold ethanol and diethyl ether, then finally dried in vacuum. Yield:
72.1 mg (77.0 %). ESI-MS Calcd for C27H27ClN3OOs: m/z 636.2, found 636.0. 1H
NMR((CD3)2CO): δ 9.00 (s, 1H), 8.24 (t, 1H, J=8 Hz), 7.95 (d, 1H, J=8 Hz), 7.60-
7.56 (m, 5H), 7.50-7.41 (m, 5H), 6.77 (d, 2H, J=9 Hz), 6.60 (d, 1H, J=6 Hz), 6.37-
6.32 (m, 2H), 4.14 (s, 3H), 3.12 (s, 6H), CHN analysis: Found: C, 41.04%; H,
3.32%; N, 5.28%. Calcd for C27H27ClF6N3OOsP: C, 41.57 % H, 3.49 % N, 5.39
%.
(16) [Os(η6-p-cym)(OMe-Impy-NMe2)Cl]PF6. [Os(η6-p-cym)Cl2]2 (50.0 mg,
0.063 mmol) was dissolved in methanol (30 mL) at 313 K. Ligand OMe-Impy-
NMe2 (32.2 mg, 0.126 mmol) in methanol (10 mL) was added drop-wise, the
solution-colour changed from orange to red immediately. The solution was stirred
at ambient temperature for 2 h. The volume was reduced to about 10 mL by
removal of methanol on a rotary evaporator, and ammonium hexafluorophosphate
(41.2 mg. 0.253 mmol) was added. Then the solution was left in the freezer
(253K) for 24 h. Dark coloured powder was precipitated which was collected by
filtration, washed with cold ethanol and diethyl ether, then finally dried in
vacuum. Yield: 58.7 mg (61.3 %). ESI-MS Calcd for C25H31ClN3OOs: m/z 616.2,
found 616.0. 1H NMR((CD3)2CO): δ 9.10 (s, 1 H), 8.25 (t, 1H, J=8 Hz), 7.98 (d, 
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1H, J=8 Hz), 7.72 (d, 2H, J=8 Hz), 7.53 (d, 1H, J=8 Hz), 6.90 (d, 2H, J=8 Hz),
6.54 (d, 1H, J=6 Hz), 5.98 (d, 1H, J=6 Hz), 5.82 (dd, 2H, J=6 Hz), 4.38 (s, 3H),
2.86 (s, 6H), 2.61-2.51 (m, 1H), 2.38 (s, 3H), 1.11 (d, 3H, J=7 Hz) 1.08 (d, 3H,
J=7 Hz). CHN analysis: Found: C 38.66%, H 4.00%, N 5.29%. Calcd. for
C25H31ClF6N3OOsP: C 39.50%, H 4.11%, N 5.53%.
(14A) [Os(η6-p-cym)(Impy-NMe2)OH]PF6. [Os(η6-p-cym)Cl2]2 (100.0 mg, 0.126
mmol) and AgNO3 (85.9 mg, 0.506 mmol) was stirred in water (20 mL) at 313 K
for 12h, a white precipitate was filtered off. Ligand Impy-NMe2 (57.0 mg, 0.25
mmol) was added to the yellow clear solution, the solution-colour changed from
yellow to red immediately. The solution was stirred at ambient temperature for 12
h. Ammonium hexafluorophosphate (205 mg. 1.26 mmol) was added. Then the
solution was left in the fridge (277K) for 24 h. Dark coloured powder was
precipitated which was collected by filtration, washed with cold ethanol and
diethyl ether, then finally dried in vacuum. Yield: 105 mg (58.5 %). ESI-MS
Calcd for C24H31N3OOs: m/z 569.2, found 569.1. 1H NMR(D2O): δ 9.29 (d, 1H, 
J=5 Hz), 8.98 (s, 1 H), 8.15 (d, 1H, J=7 Hz), 8.12 (t, 1H, J=7 Hz), 7.67 (t, 1H, J=6
Hz), 7.52 (d, 2H, J=9 Hz), 6.96 (d, 2H, J=9 Hz), 6.17 (d, 1H, J=6 Hz), 5.81 (d, 1H,
J=6 Hz), 5.66 (d, 1H, J=6 Hz), 5.54 (d, 1H, J=6 Hz), 2.98 (s, 6H), 2.25 (s, 3H),
2.23-2.16 (m, 1H), 0.83 (d, J=7 Hz, 3H), 0.74 (d, J=7 Hz, 3H). CHN analysis:
Found: C 39.59%, H 3.87%, N 6.23%. Calcd. for C24H30F6N3OOsP: C 40.50%, H
4.25%, N 5.90%.
5.2.3 X-ray Crystallography. X-ray diffraction data for  [Os(η6-p-cym)(Impy-
OH)I]PF6 (3), was obtained on an Oxford Diffraction Gemini four-circle system
with a Ruby CCD area detector using Mo Kα radiation.19 Absorption corrections
were carried out using ABSPACK. The crystals were mounted in oil and held at
100(2) K with the Oxford Cryosystem Cryostream Cobra. The structures were
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solved by direct methods using SHELXS (TREF) with additional light atoms
found by Fourier methods.20 Refinement used SHELXL 97.21
5.2.4 NCI Cell Tests. The cells were treated for 48 h at five concentrations
ranging from 0.01 to 100 µM. Three endpoints were determined: IC50 (the
concentration that inhibits cell growth by 50 %); TGI (the concentration that
inhibits cell growth by 100 %); LC50 (the concentration that kills original cells by
50 %). Cisplatin data are from NCI/DTP screening: Oct 2009.
5.2.5 Hydrolysis. A solution of 6 or 14 in 10% MeOD-d4/90% D2O phosphate
buffer (v/v) was prepared by dissolution in MeOD-d4 followed by a dilution with
D2O phosphate buffer (pH*=7.2). NMR spectra were recorded after 24 h
incubation at 310K. The extent of hydrolysis was determined from 1H NMR peak
integrals.
5.2.6 pH* Measurements. The pH* values of NMR samples in D2O (pH meter
reading without correction for effects of deuterium on glass electrode) were
measured at 298 K using a chloride-free electrode calibrated with Sigma-Aldrich
buffer solutions at pH 4, 7 and 10.
5.2.7 Determination of pKa* Value of 14. The pKa* value (pKa value in D2O
solution) was determined by pH* titration of 14A with diluted solutions of NaOH
and HClO4 in D2O. The 1H NMR spectra at different pH* values ranging from c.a.
1.5 to 13 were recorded and chemical shifts against pH* values were plotted. The
pH titration curves were fitted according to the Henderson-Hasselbalch equation
with the assumption that the observed chemical shifts are weighted averages
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according with the populations of the protonated and deprotonated species. This
work was helped by Dr. Maria. J. Romero-Castro (Chemistry Department,
University of Warwick).
5.2.8 Interaction with 9-Ethylguanine. 14A and 9-Ethylguanine (1 equiv) were
mixed in D2O phosphate buffer (pH*=7.4) and incubated at 310 K. The 1H NMR
spectra were recorded after different time intervals. This work was helped by Dr.
Maria. J. Romero-Castro (Chemistry Department, University of Warwick).
5.2.9 Catalytic Reaction with NADH. Osmium iminopyridine complexes: 6, 8,
14, 14A and 16 were incubated with different equivalents of NADH in a solution
of 10% MeOD-d4/90% D2O phosphate buffer (pH*=7.4). 1H-NMR spectra were
recorded at different time intervals under incubations at 310 K. The analysis using
UV-Vis spectroscopy was carried out under similar conditions but with non-
deuterated solvents.
5.2.10 ROS Detection in A549 Cells. The ROS accumulation induced by
complex 6 (4 μM) and 14 (4 μM) without or with L-BSO (50 μM) was monitored 
by using a method reported in chapter 3.22
5.2.11 Combination Treatment with L-BSO. To determine the effect of
decreased GSH levels on the cytotoxicity of osmium iminopyridine complexes,
A549 human lung cancer cells were co-incubated with 50 μM L-BSO and various 
concentrations of complexes for 24 h, then followed by 72 h recovery. Cell
viability was then determined by using the sulforhodamine (SRB) assay (details in
chapter 3).
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5.2.12 Electrochemistry. The electrochemical study was carried out using the
similar conditions as for the ruthenium azopyridine analogues reported
previously:22 Electrochemical studies were performed with a CHI730A
bipotentiostat (CH Instrument, USA) system. All of the electrochemical
techniques used a three-electrode configuration with all the electrodes in solution.
A 2 mm diameter platinum disc electrode was used as the working electrode with
a chloridized silver wire as the quasi-reference electrode and a Pt counter
electrode (CH Instrument, USA). The reference electrode was Ag/AgCl in a
solution of 0.1 M [TBA][BF4] in DMF against which E1/2 for the
ferrocinium/ferrocene couple was measured to be +0.55 V.
5.2.13 Liquid Chromatography–Mass Spectrometry Analysis. NADH (0.5
mM) with or without complex 14A (0.5 mM) were incubated at 310 K for 24 h,
NADH and NAD+ were incubated under the same conditions and LC-MS was
employed to analyze the 3 samples.
5.2.14 Detection of H2 by Gas Chromatography (GC). Solutions containing
complex 14 [(η6-p-cym)Os(Impy-NMe2)OH]PF6 and NADH (Os, 100 µM,
NADH, 2 mM, 100 mM phosphate buffer, pH 7.4, 10% MeOH/90% H2O) was
incubated at 310 K for 18 h before sampling. Aliquot of the head space (10 µl)
was removed by using a gas-tight syringe and analyzed on an Agilent GC 7890A
instrument equipped with a thermal conductivity detector, using N2 as the carrier
gas. Under these conditions H2 had a retention time of 0.4 min and O2 a retention
time of 0.8 min. This work was helped by Dr. Andrew Crombie and Prof. Colin
Murrell (Biology Department, University of Warwick).
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5.2.15 Cell Cycle Analysis. A2780 cells were incubated with complex 14 at
various concentrations for 24 h and then harvested. Detached and adherent cells
were washed with PBS and fixed in 70% ethanol (253 K). The fixed cells were
centrifuged and washed once with PBS, followed by resuspension in PBS
containing 7.5 µM propidium iodide (PI) and 100 µg/ml RNase A. They were
analyzed by flow cytometry (FACS-Calibur, Beckton Dickenson). The cell cycle
distribution was evaluated using the Flow Jo (Version 7.6, Software from Tree
Star).
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5.3 Results
5.3.1 Synthesis and Characterization
Sixteen osmium(II) arene iminopyridine complexes (Chart 5.1) of general
formula [Os(η6-arene)(R1-Impy-R2)X]PF6 (arene = biphenyl or p-cymene; X = Cl
or I) containing different chelating iminopyridine ligands (Impy, Impy-OH, Impy-
NMe2 and OMe-Impy-NMe2) were synthesized. The general method involves
stirring the mixture of osmium dimer and appropriate chelating iminopyridine
ligand which was synthesized following a method based on literature18 in a
methanol solution, which is similar to that reported before for the synthesis of
their azopyridine analogues.2 In general, the iminopyridine complexes were
obtained in good yields and well characterized by 1H-NMR spectroscopy, mass
spectrometry and CHN elemental analysis.
For organometallic metal arene complex with the piano-stool structure which
contains an unsymmetrical chelating ligand and another monodentate ligand, the
metal atom is a chiral centre.23 1H NMR spectra (CDCl3, 298 K) were taken
before and after adding the chiral anionic chiral shift-reagent (Δ–trisphat) to the 
solution of complex 14 in chloroform-d. The even splits of peaks were observed
(Fig. 5.1) which indicated that there were two osmium enantiomers in ca. 1:1
ratio, consistent with the previous report on osmium/ruthenium arene anticancer
complexes.5
Recrystallization of [Os(η6-p-cym)(Impy-OH)I]PF6 (4) in DCM and methanol
mixed solvent (Fig 5.2) gave purple single crystals corresponding to
40.5CH2Cl2H2O (Fig 5.3) suitable for the study by X-ray diffraction.
Crystallographic data are listed in Table 5.1 and selected bond lengths and angles
in Table 5.2. The asymmetric unit comprises a mixture of enantiomers of the
cation [Os(η6-p-cym)(Impy-OH)I]+ with (R)- and (S)- configuration respectively
at the metal centre (Fig. 5.3) and two molecules of PF6- acting as counterions.
Cahn–Ingold–Prelog priority rules (CIP system) were used to define the priority
sequence of ligands attached to osmium: I > η6-C6 > N (imine) > N (pyridine).
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Additionally, the two enantiomers are solvated by one dichloromethane and two
water molecules. The osmium complex shows the usual pseudo-octahedral
“piano-stool” structure with the p-cymene ligand -bonded to the metal ion and
the iminopyridine chelating ligand Impy-OH coordinated through the pyridine and
imine nitrogen atoms. The imine bond in the chelating ligand Impy-OH adopts an
E conformation to minimise the steric hindrance with the bulky phenol group. The
coordination sphere of the osmium(II) ion is completed with a terminal iodide
atom behaving as monodentate ligand. The Os-N, Os-I and Os-arene bond lengths
in this complex are similar to those found in the azopyridine analogues previously
reported.2 The crystal structure of complex 40.5CH2Cl2H2O shows dissimilarities
with the crystal structure of [Os(η6-bip)(Azpy-OH)I]PF6 which was reported
previously in Chapter 3. In complex 40.5CH2Cl2H2O there is no deprotonation of
the hydroxyl group on the chelating ligand which allows each enantiomer to
establish an intramolecular hydrogen bond between the phenol OH group of the
iminopyridine ligand and one water molecule [O115-H11HO400 1.84 Å, O215-
H21HO300 1.89 Å] as shown in Figure 5.3 B. Additional intermolecular
hydrogen bonds are observed between one water molecule and both PF6-
counterions [O300-H30AF33 2.10(3) Å, x+1, y, z; O300-H30BF21 2.36(3) Å,
-x+1, -y, -z].
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Os
PF6
X
N CH
N
R2
Arene
R1
Chart 5.1. Osmium (II) arene iminopyridine complexes synthesized and studied
in this chapter.
Complex Arene R1 R2 X Chelating ligand
1 bip H H I Impy
2 p-cym H H I Impy
3 bip H OH I Impy-OH
4 p-cym H OH I Impy-OH
5 bip H NMe2 I Impy-NMe2
6 p-cym H NMe2 I Impy-NMe2
7 bip OMe NMe2 I OMe-Impy-NMe2
8 p-cym OMe NMe2 I OMe-Impy-NMe2
9 bip H H Cl Impy
10 p-cym H H Cl Impy
11 bip H OH Cl Impy-OH
12 p-cym H OH Cl Impy-OH
13 bip H NMe2 Cl Impy-NMe2
14 p-cym H NMe2 Cl Impy-NMe2
15 bip OMe NMe2 Cl OMe-Impy-NMe2
16 p-cym OMe NMe2 Cl OMe-Impy-NMe2
Figure 5.1. 1H NMR spectrum before and after adding 2 mol equivalents of Δ
trisphat in chloroform
Figure 5.2. X-ray crystal structure of the cation of the enantiomer (S)
cym)(Impy-OH)I]PF6
ellipsoids are drawn at 50% probability. The hydrogen atoms, counterion (PF
and solvent molecules have been omitted for clarity.
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(A)
(B)
Figure 5.3. (A) Crystal structures of the enantiomers (S)-[Os(η6-p-cym)(Impy-
OH)I]PF6 (left) and (R)-[Os(η6-p-cym)(Impy-OH)I]PF6 (right) of complex 4
0.5CH2Cl2H2O showing the atomic numbering scheme. Thermal ellipsoids are
drawn at the 50% probability level. Lattice CH2Cl2 and H2O molecules are not
shown. Hydrogen atoms and PF6- counterions are omitted for clarity. (B) There is
an hydrogen bond interaction between the phenol group of the chelating
iminopyridine ligand in the enantiomer (R)-[Os(η6-p-cym)(Impy-OH)I]PF6 and
one water molecule.
O21
5
H21H
O30
0
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Table 5.1. Crystal data and structure refinement for [Os(η6-p-cym)(Impy-
OH)I]PF6 0.5CH2Cl2H2O (4 0.5CH2Cl2H2O )
4 0.5CH2Cl2H2O
Empirical formula C22.50 H27ClF6IN2O2OsP
Crystal size [mm] 0.200.200.20
Formula weight 854.98
Crystal system Triclinic
Space group P-1
a [Å] 11.3168(3)
b [Å] 13.0498(3)
c [Å] 19.2278(4)
 [º] 95.3980(19)
β [º] 103.654(2)
 [º] 97.2625(19)
Volume [Å3] 2714.50(11)
Temperature [K] 100(2)
Z 4
 [mm-1] 6.057
Reflections collected 12572
Independent reflections [Rint] 9981 [0.0222]
R1, wR2 [I>2σ(I)] 0.0332, 0.0793
R1, wR2 (all data) 0.0450, 0.0817
Table 5.2. Selected bond lengths [Å] and angles [º] for [Os(η6-p-cym)(Impy-
OH)I]PF6· 0.5CH2Cl2H2O (4 0.5CH2Cl2H2O )
4 0.5CH2Cl2H2O
Os1-N108 2.077(4) Os2-N208 2.078(4) Os1-6-arene centroid 1.6962(2)
Os1-N101 2.087(4) Os2-N201 2.080(4) Os2-6-arene centroid 1.6845(2)
Os1-C120 2.182(5) Os2-C220 2.169(5) N108-Os1-N101 76.05(14)
Os1-C116 2.189(5) Os2-C216 2.184(5) N101-Os1-I1 84.80(11)
Os1-C117 2.206(5) Os2-C221 2.201(6) N208-Os2-N201 76.59(15)
Os1-C121 2.209(5) Os2-C217 2.209(5) N208-Os2-I2 85.06(12)
Os1-C119 2.219(4) Os2-C219 2.212(5)
Os1-C118 2.256(4) Os2-C218 2.245(5)
Os1-I1 2.7091(4) Os2-I2 2.7247(4)
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5.3.2 Hydrolysis and Binding with 9-Ethylguanine
The possible activation of these complexes by hydrolysis and their interaction
with 9-ethylguanine (9-EtG) which is a DNA nucleobase model were studied by
following the reactions by 1H NMR. The osmium iminopyridine complexes
[Os(η6-p-cym)(Impy-NMe2)I]PF6 (6) and [Os(η6-p-cym)(Impy-NMe2)Cl]PF6 (14)
which are mainly studied here can undergo hydrolysis, after incubation of the
samples at 310 K for 24 h in D2O, they can reach the hydrolysis extent of 49.5 %
and 99.5%, respectively. The formation of the aqua product (14A) was confirmed
by the presence of new signals in the 1H NMR spectra shifted with respect to the
signals observed for 6 and 14.
To study the potential of DNA binding, the reaction of the hydrolyzed product
of 14 (14A) with 9-ethylguanine (9-EtG) was monitored at different time intervals
by 1H NMR after incubation of the solution at 310 K in 0.1 M phosphate buffer
(D2O, pH* = 7.4). The 9-EtG binding was evidenced by the appearance of new
signals assignable to the 14-9-EtG adduct which are shifted in comparison with
the signals of 14A and the free nucleobase. The binding extent reached only 14%
after 18 hours and the ratio increase slightly to 19% after another 20 h of
incubation at 310 K (Fig. 5.4 A).
5.3.3 pKa Measurement
The pKa value for the hydrolysed product of 6 and 14 (14A) was determined
by 1H NMR spectroscopy after variations of the pH* values of a solution of 14A
in D2O (Fig. 5.4 B). The chemical shifts of the 1H NMR signals were gradually
shifted upfield after increasing the pH* value from c.a. pH* 1.5 to 13 which is
consistent with the behaviour of an aqua adduct. Plots of the chemical shifts of the
pyridine proton Ha against pH* were fitted to the Henderson-Hasselbalch
equation, giving a pKa* value of 5.1 (pKa= 5.2) corresponding to the coordinated
water molecule. The low value of pKa found in the aqua adduct indicates that the
hydroxy adduct is possibly the predominant species in aqueous solution under
Chapter 5: OsII Arene Iminopyridine Complexes
176
physiological conditions. The pKa value of the dimethylamine substituent on the
iminopyridine chelating ligand Impy-NMe2 (pKa*=2.3, pKa= 2.6) which is the first
reported pKa for this type of ligand bound to metal.
Figure 5.4. (A) Interaction of the hydroxo complex 14A (1 mM) with the 9-
ethylguanine (2 mM, 2 equiv.) followed by 1H NMR. The spectra were recorded
10 min after preparing the mixture in a 10%D2O/90%H2O phosphate buffer
solution (pH*=7.4) and after incubation of the sample during 18 h and 38 h at 310
K; (B) Dependence of the 1H NMR chemical shifts with pH* for the pyridine
proton Ha in the complex 14A. The pKa* values were determined by fitting the
data points to the Henderson-Hasselbalch equation, corresponding to pKa1*= 5.1
for the coordinated water and pKa2* = 2.3 for the dimethylamine substituent.
These values were converted to pKa values (pKa1=5.2, pKa2= 2.6) using the
equation pKa = 0.929pKa*+0.42.
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5.3.4. Anticancer Activity
All the sixteen osmium arene iminopyridine complexes were tested on the
A2780 cell line and some were tested on the A549 human lung cancer cell line
(Table 5.3). The results showed they had a broad range of anticancer activity from
0.14 µM to 35.5 µM (IC50 values) to A2780 cells (Table 5.3A). Anticancer
efficacy was also seen on A549 cells and a significant increase of anticancer
activity by combination treatment enhancement with L-buthionine-sulfoximine
(L-BSO, a specific inhibitor of gamma-glutamylcysteinesynthetase, depletes
intracellular glutathione which plays important role for maintaining the redox
balance in cancer cells) was achieved (Table 5.3B).
The complexes [Os(η6-p-cym)(Impy-NMe2)I]PF6 (6) and [Os(η6-p-cym)(Impy-
NMe2)Cl]PF6 (14) showed anticancer activity in the same range of cisplatin
against A2780 cancer cells. Moreover, complexes 6 and 14 were selected for the
study of anticancer activity screening towards the human tumour 60-cell line
panel of the Developmental Therapeutics Program of the National Cancer Institute
(DTP of NCI) which includes nine tumour type subpanels. The mean values of
IC50 (the concentration that inhibits cell growth by 50 %), TGI (the concentration
which that cell growth by 100 %) and LC50 (the concentration that kills original
cells by 50 %) are listed in Table 5.3C. Both of them showed anticancer activity
within the same range of cisplatin.
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Table 5.3. In vitro anticancer activity towards A2780 human ovarian cancer cells
(A); A549 human lung cancer cells and combination treatment with 50 µM L-
BSO (B); 60-cell line screening results from the NCI (C).
(A)
Complex IC50(µM)
(1)   [Os(η6-bip)(Impy)I]PF6 18.6(±0.9)
(2)   [Os(η6-p-cym)(Impy)I]PF6 29.4(±5.3)
(3)   [Os(η6-bip)(Impy-OH)I]PF6 5.4(±1.1)
(4)   [Os(η6-p-cym)(Impy-OH)I]PF6 31.8(±3.8)
(5)   [Os(η6-bip)(Impy-NMe2)I]PF6 0.14(±0.01)
(6)   [Os(η6-p-cym)(Impy-NMe2)I]PF6 0.80(±0.05)
(7)   [Os(η6-bip)(Ome-Impy-NMe2)I]PF6 9.14(±0.93)
(8)   [Os(η6-p-cym)(Ome-Impy-NMe2)I]PF6 35.5(±3.2 )
(9)   [Os(η6-bip)(Impy)Cl]PF6 4.6(±0.4)
(10) [Os(η6-p-cym)(Impy)Cl]PF6 26.2(±2.8)
(11) [Os(η6-bip)(Impy-OH)Cl]PF6 2.4(±1.1)
(12) [Os(η6-p-cym)(Impy-OH)Cl]PF6 5.5(±0.6)
(13) [Os(η6-bip)(Impy-NMe2)Cl]PF6 0.44(±0.01)
(14) [Os(η6-p-cym)(Impy-NMe2)Cl]PF6 1.5(±0.047)
(15) [Os(η6-bip)(Ome-Impy-NMe2)Cl]PF6 9.5(±0.22)
(16) [Os(η6-p-cym)(Ome-Impy-NMe2)Cl]PF6 32.9(±1.2)
Cisplatin 1.8(±0.1)
(B)
Complex IC50(µM) IC50(µM) with L-BSO
(3)   [Os(η6-bip)(Impy-OH)I]PF6 4.55(±1.09) 1.59(±0.36)
(6)   [Os(η6-p-cym)(Impy-NMe2)I]PF6 3.7(±0.2) 0.73(±0.10)
(9)   [Os(η6-bip)(Impy)Cl]PF6 >100 25.88(±12.29)
(10) [Os(η6-p-cym)(Impy)Cl]PF6 0.9(±0.09) NA
(13) [Os(η6-bip)(Impy-NMe2)Cl]PF6 2.55(±1.35) NA
(14) [Os(η6-p-cym)(Impy-NMe2)Cl]PF6 8.68(±2.11) 2.34(±1.18)
Cisplatin 6.65(±0.06) NA
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Table 5.3. In vitro anticancer activity towards A2780 human ovarian cancer cells
(A); A549 human lung cancer cells and combination treatment with 50 µM L-
BSO (B); 60-cell line screening results from the NCI (C).
(C)
Complex IC50(µM) TGI(µM) LC50(µM)
(6)     [Os(η6-p-cym)(Impy-NMe2)I]PF6 3.72 13.2 49
(14)   [Os(η6-p-cym)(Impy-NMe2)Cl]PF6 8.3 33.9 75.8
Cisplatin[*] 10.3 50.7 90.5
[*] Data from NCI/DTP screening. 6 = NSC755639; 14 = NSC755640. Mean-
graph midpoint (MG-MID) for IC50, TGI and LC50 values of NCI all cell panels.
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5.3.5. Accumulations of Reactive Oxygen Species (ROS)
In Chapter 3, osmium(II) arene azopyridine complexes were found to cause an
increase in ROS levels in cancer cells. For comparison, whether the cellular ROS
level was affected by iminopyridine complexes was also investigated. The level of
ROS was monitored in A549 human lung cancer cells induced by osmium
complexes (6 and 14) using the probe 2,7-dichlorodihydrofluorescein-diacetate
(DCFH-DA). It can be hydrolyzed to 2,7-dichlorodihydrofluorescein (DCFH) in
live cells, which in turn is oxidized to 2,7-dichlorofluorescein (DCF) in the
presence of ROS and exhibits a green fluorescence. Using this probe, the level of
general oxidative stress induced in A549 cells by 6 and 14 was determined. The
ROS accumulations of combined exposure to 6 or 14 with L-BSO were also
studied. In A549 cells, the relative increase in DCF fluorescence was detected
over a period of 4 h after treating the cells with 6 (4 µM), 14 (4 µM), 6 (4 µM)
plus L-BSO (50 µM), 14 (4 µM) plus L-BSO (50 µM) or 10 µM H2O2 (Fig. 5.5).
After a treatment only with 6 or 14, the ROS level increased dramatically
compared to the control and even the positive control (H2O2, 10µM). This level
increased further in the presence of L-BSO in addition to 6 or 14. The further
increase of ROS by the combination treatment may explain why L-BSO can
enhance the cytotoxicity of complex 6 and 14 towards A549 cancer cells
significantly (Table 5.3B). L-BSO alone at a dose of 50 µM had no significant
effect on the increase of ROS and the growth of A549 cancer cells, but greatly
enhanced the cytotoxicity of osmium iminopyridine complexes to A549 cancer
cells. These data implied the increasing ROS might be the basis of combination
treatment strategy of 6 or 14 with L-BSO which is opposite to our recent report on
azopyridine complexes with substituent on the pyridine ring in Chapter 4.24
Figure 5.5. Changes of ROS levels
treatment of 6 (4 µM),
BSO (50 µM), and H
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14 (4 µM), L-BSO (50 µM), 6 or 14 combined with L
2O2 (10 uM, positive control) during 4 h at 310 K.
181
-
Chapter 5: OsII Arene Iminopyridine Complexes
182
5.3.6. Catalytic Oxidation of NADH
Following the indication of an increase of ROS in cells induced by osmium
iminopyridine complexes, whether they can react with important cellular reducing
agents directly was examined. It was found that 6 and 14 could not catalytically
oxidize GSH which is different from their ruthenium azopyrdine iodido
analogues.22 Since NADH forms a redox pair with NAD+ to play an important
role in maintaining the redox balance in cells, the reaction with NADH was also
studied. The reactions of NADH with complexes 6, 8, 14, 14A and 16 were
followed by 1H NMR spectroscopy. They were found to catalytically oxidize
NADH to NAD+ to different extents after incubation in a 10%MeOD/90%D2O
phosphate buffer solution (pH*=7.4) over 24 h at 310 K (Fig. 5.6 and Fig. 5.7),
whereas the control (NADH) was stable towards the NAD+ formation under the
same conditions. More than one equivalent of NADH was found to be oxidized by
osmium complexes; it implies that this is a catalytic oxidation. The recording of
the 1H NMR spectra for the reaction with 14A after 3 h and 6 h of incubation at
310 K (10%D2O/90%H2O phosphate buffer) in lead to the detection of a weak
hydride signal at –4.20 ppm, as shown in Figure 5.8. This signal is indicative of
the formation of an osmium hydride adduct during the catalytic reaction.
(A)
(B)
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Figure 5.6. 1H NMR spectra corresponding to the reaction between the osmium
complex (0.1 mM) and NADH (0.4 mM, 4 equivalents).
recorded in a 10%MeOD /90%D
h of incubation of the sample at 310 K. (A) Control: NADH at time 0 and time 24
h (310 K oven) (B)
cym)(Impy-NMe2)Cl]PF
[Os(η6-p-cym)(OMe-
catalytic oxidation by osmium iminopyridine complexes:
NMR spectra at 0 h were NMR recorded immediately after preparing the samples.
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2O phosphate buffer solution (pH*=7.4) after 24
(6) [Os(η6-p-cym)(Impy-NMe2)I]PF6. (C) (
6. (D) (8) [Os(η6-p-cym)(Ome-Impy-NMe
Impy-NMe2)Cl]PF6. (F) Summary of extent of NADH
6, 8, 14, and
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14) [Os(η6-p-
2)I]PF6. (E) (16)
16. The 1H
Chapter 5: OsII Arene Iminopyridine Complexes
186
Figure 5.7. 1H NMR spectra corresponding to the reaction between the hydroxo
complex 14A (2 mM) and NADH (8 mM, 4 mol equivalents). The spectra were
recorded in a 10%D2O/90%H2O phosphate buffer solution (pH* 7.4) at t = 0 h
and after 20 h of incubation of the sample at 310 K. The 1H NMR spectra at 0 h
were NMR recorded immediately after preparing the samples.
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Figure 5.8. Detection of hydride signals by 1H NMR for the reaction of 4 mol
equivalents of NADH with the hydroxo complex 14A (2.5 mM) at different time
points.
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LC-MS was also employed to analyse the reaction between NADH (0.5 mM)
and 14A (0.5 mM) after the incubation at 310 K for 24 h. The decrease of the
peak with a retention time 11-12 min (identified by MS as NADH) and the
appearance of a new peak with a retention time at 4.8-5.2 min (identified by MS
as NAD+ and also comfirmed by a comparison with the retention time of NAD+
control) were observed by LC after the treatment with 14A (Fig. 5.9A). The MS
results showed the correct masses of NADH (Calcd for C21H30N7O14P2: m/z =
666.1 and found m/z = 666.1) and NAD+ (Calcd for C21H28N7O14P2: m/z = 664.1
and found m/z = 664.1) which is consistent with the LC results. The MS results of
the two controls (NADH and NAD+) are also shown in Figure 5.9 D and E,
respectively, other than the MS of 14A, a phosphate adduct was also detected by
MS (Fig. 5.9 F and 5.9 G).
(A)
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Figure 5.9. NADH (0.5 mM) with or without Complex 14A (0.5 mM) were
incubated at 310 K for 24 h, NAD+ were incubated under the same conditions and
LC-MS was employed to analyze the 3 samples. (A) HPLC separation of NADH
(0.5 mM, green line), NADH with complex 14A (blue line) and NAD+ (0.5 mM,
red line). (B) MS of first two appearing peaks from HPLC of NADH with
complex 14A (blue line). (C) MS of second appearing peak from HPLC (green
line). (D) MS of third appearing peak from HPLC of NADH with Complex 14A
(blue line). (E) MS of NAD+. (F) MS of 14A. (G) MS of phosphate adduct of
14A.
The catalytic reaction of the chlorido complex 14 with NADH (8 mol equiv)
was monitored by UV-Vis over 18 h at 310 K using a phosphate buffer solution in
H2O (pH = 7.4, Fig. 5.10A). The kinetic experiment showed one isosbestic point
at 300 nm corresponding to the oxidation from NADH to NAD+ and another
isosbestic point at 432 nm due to the hydrolysis of 14 in an aqueous solution,
suggesting that the hydrolysis of the chloride complex 14 occurred during the
catalytic reaction. The formation of NAD+ was confirmed by the decrease of the
characteristic band of the NADH at 338 nm and the simultaneous increase of the
band at 260 nm. Additionally, the dependence of the catalytic activity of 14 on the
concentration of NADH in solution was studied by following the conversion of 2
and 8 mol equivalents of NADH into NAD+ (Fig. 5.10B) under the same
conditions described above. The results indicate that in the presence of 25 M of
14, the conversion of NADH into NAD+ is slightly higher for 2 equiv than for 8
equiv of NADH. In these experiments a slight decomposition of the NADH
control was observed under these conditions due to the effect of phosphate buffer
which is consistent with previous reports.25, 26
Figure 5. 10. (A)
between the chlorido complex
spectra were recorded in phosphate buffer solution (pH
Inset: (B) Conversion of 2 and 8 mol equiv of NADH into NAD
of complex 14 (0.025 mM) plotted versus time during 18 h.
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Monitored UV-Vis spectra corresponding to the reaction
14 (0.025 mM) and NADH (0.2 mM, 8 equiv). The
* 7.4) during 18h at 310 K.
+
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in the presence
To elucidate the mechanism
step following the form
chromatography (GC) was used for
potential product from osmium hydride. However, no H
GC, indicating that the hydride is not transferred from th
to the medium to form hydrogen gas.
The reaction between the osmium complex
was studied under aerobic condition or after degassing with argon for 10 min, the
corresponding 1H NMR spectra were recorded
a 10%MeOD/90%D2
NAD+ product from 17% to 3% under argon atmosphere was observed (Fig. 5.11).
Figure 5.11. 1H NMR spectra corresponding to the reaction between the osmium
complex 14 (0.1 mM) and NADH (0.4 mM, 4 equivalents) under aerobic
conditions (top spectrum) or degassed (bottom spectrum) with argon for 10 min.
The spectra were recorded
(pH*=7.4) after 18 h incubation of the sample at 310 K.
Chapter 5: OsII Arene Iminopyridine Complexes
of the catalytic of action of these compounds, the
ation of the osmium-hydride adduct was investigated. Gas
the detection of H2 gas which
2 peak was detected
e osmium
14 (0.1 mM) and NADH (0.4 mM)
after 18 h of incubation at 310 K in
O phosphate buffer solution (pH* = 7.4). A decrease in the
in a 10%MeOD /90%D2O phosphate buffer solution
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could be a
by
-hydride adduct
When the reaction between
after the oxygen saturation for 10 min. the NAD
(reaction under aerobic
the control had no obvious NAD
without osmium complex
Figure 5.12. 1H NMR spectra corresponding to the reaction between the osmium
complex 14 (0.1 mM) and NADH (0.5 mM, 5 equivalents) under oxygen
saturation condition (top spectrum), aerobic condition (middle spectrum) and the
NADH control under oxygen saturation condition
were recorded in a 10%MeOD /90%D
after 18 h incubation of the sample at 310 K.
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14 (0.1 mM) and NADH (0.5 mM) was performed
+ product increased from 10%
condition) to 25% (saturated oxygen condition)
+ formation (under oxygen saturation for 10 min
, then incubate for 18 h at 310K) (Fig. 5.12).
(bottom spectrum). The spectra
2O phosphate buffer solution (pH
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5.4. Discussions
5.4.1. Hydrolysis and Binding with 9-Ethylguanine
The chlorido complex (14) achieved higher hydrolysis extent than the iodido
complex (6), which is in agreement with the more inert character of iodide as a
ligand for osmium. To study the potential of DNA binding, the reaction of the
hydrolyzed product of 14 (14A) with 9-EtG (model DNA nucleobase) was
monitored at different time intervals by 1H NMR. The binding process with 9-EtG
was found to be much slower than the previously reported osmium DNA-targeted
complexes4 probably due to the low pKa value (pKa = 5.2) found in this complex.
This value indicates the tendency of compound 14 to form the hydroxyl adduct
14A under physiological conditions. For this reason, the predominant inert
hydroxyl adduct (14A) interacts slowly with DNA nucleobases and consequently
slows down the reaction4 with 9-EtG reaching only 14% of binding with 9-EtG
after 18 hours of incubation at 310K; the binding ratio only increased to 19% after
another 20 h of incubation at 310K.
5.4.2. Structure Activity Relationships (SARs) on A2780 Cell Line
Comparing the anticancer activity of osmium arene iminopyridine complexes
with their azopyridine analogues, the correlation coefficient of SAR is low (R2=
0.0673), which indicates that the mechanism of action could be different for these
two families of osmium anticancer complexes (Fig. 5.13). The major differences
between them are: (1) the iminopyridine complexes can hydrolyze and bind to a
DNA base; (2) the iminopyridine complexes can catalytically oxidize NADH to
NAD+.
It was found that all the iminopyridine complexes bearing biphenyl arene
showed better anticancer activity to A2780 cells than their p-cymene analogues.
The reasons might be the intercalation of the extended biphenyl arene with the
DNA and/or the increase of hydrophobility which can facilitate the cellular
uptake. In general, the chlorido complexes showed better or similar anticancer
Chapter 5: OsII Arene Iminopyridine Complexes
196
activity compared to iodido analogues which is contrary to the trend observed for
their azopyridine analogues except for those with a –NMe2 electron withdrawing
substituent in the phenyl moiety of the iminopyridine ligand. The
functionalization of these compounds with a methoxy group in the ortho position
on the pyridine ring of iminopyridine ligand decreased the anticancer activity
significantly. This effect may due to the steric effect introduced by the methoxy
group, and indicates that the binding site on osmium of the monodentate ligand is
important for the mechanism of action.
It was noted that the anticancer activity of 6 and 14 is better than those
obtained for ruthenium and osmium anticancer complexes reported previously4, 27
which could bind DNA bases to greater extents and/or in faster speeds. This
suggests that a different mechanism of action is involved in the biological activity
of these iminopyridine complexes other than targeting DNA.
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Figure 5.13. Correlations of structure-activity-relationships of osmium arene
iminopyridine complexes with their azopyridine analogues. Each plot represents
the IC50 value of one iminopyridine complex (y axis) labelled with number and its
azopyridine analog (x axis).
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5.4.3. Accumulations of Reactive Oxygen Species (ROS)
ROS are highly reactive O2 metabolites that include superoxide radicals (O2
-
·),
hydrogen peroxide (H2O2) and hydroxyl radicals (OH·).28 Because cancerous cells
have increased ROS levels compared to normal cells, this difference can be
exploited as a biochemical basis for therapeutic selectivity.29, 30 Increasing the
ROS level in cancer cells can reach the threshold to induce cell death but can be
tolerated by normal cells.30 Because the GSH concentration is higher (100-10,000
fold) compared to other reductants (NADH, NADPH and thioredoxin) of redox
couples in cells, the level of GSH usually determines the steady-state value of
intracellular redox potentials.31 However, it was found that 6 and 14 cannot
catalytically oxidize GSH similarly as their ruthenium azopyridine analogues. The
cyclic voltammetry studies of 6 and 14 together with 3 and 10 showed that these
compounds underwent an irreversible electrochemical reduction in
dimethylformamide. Two reduction peaks during cyclic voltammetry study were
found for all the four complexes, the first from –0.58 to –0.76 V and the second
from –0.82 to –1 V. All the reduction peaks are more negative than -0.5 V and the
processes are not reversible (no reverse scan peak at 0.1 Vs−1 as shown in figure
5.14). The overlapped reduction peaks make it hard to identify whether there is a
one-electron reduction and calculate the redox potentials. However the reduction
peaks are more negative than the ruthenium azopyridine complexes, indicating
that the imine bonds in the osmium complexes are harder to reduce than the azo
bonds within ruthenium azopyridine complexes. These results might explain why
no GSH oxidation was observed for osmium arene iminopyridine complexes.22
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Complex Reduction Peak /V
(3)   [Os(η6-bip)(Impy-OH)I]PF6 -0.58 and -0.95
(6)   [Os(η6-p-cym)(Impy-NMe2)I]PF6 -0.65 and -0.82
(10) [Os(η6-p-cym)(Impy)Cl]PF6 -0.67 and -1.0
(14) [Os(η6-p-cym)(Impy-NMe2)Cl]PF6 -0.76 and -1.0
Figure 5.14. Cyclic voltammograms for 3, 6, 10 and 14 (in 0.1 M
tetrabutylammonium BF4 DMF, sweep from 0 to -1.5 to 0 V or 0 to -1.0 to 0 V at
scan rate 0.1 V/s). Reduction peaks were also listed in the table.
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5.4.4. Catalytic Oxidation of NADH
Following the evidence for generation of ROS and with the aim of
rationalizing the surprisingly good anticancer activity of these osmium (II)
iminopyridine complexes, a catalytic reaction employing the reducing agent
NADH was discovered. The reaction between the iminopyridine complexes and
NADH was monitored by 1H NMR for 6, 8, 14 and 16, LC-MS for 14A and UV-
Vis spectroscopy for 14. All these data consistently showed the oxidation of
NADH and their behaviours as catalysts.
The 1H NMR studies show that 6 and 14 can oxidize a greater amount of
NADH than 8 and 16 after 24 h incubation at 310K. This could be due to the
steric hindrance exerted by the methoxy substituent on the ortho-position of the
iminopyridine chelating ligand for 8 and 16 (Fig. 5.6). This trend is also in
agreement with the anticancer activity of these compounds (6 and 14 are more
active than 8 and 16). It was noted that the complexes with the methoxy
substituent exhibit 20 times less anticancer activity than 8 and 16, indicating that
the catalytic reaction with NADH is involved in the mechanism of action for
osmium iminopyridine anticancer complexes.
During the catalytic conversion from NADH to NAD+ in the presence of 14A,
an osmium-hydride peak was detected by 1H NMR at –4.20 ppm. This value is in
agreement with previous reports of osmium-hydride peaks identified at similar
chemical shifts by NMR.32 Although several examples of hydride transfer have
been published for osmium(II) complexes, this is still the first time an osmium(II)
hydride peak has been detected in an aqueous solution by NMR. This is also the
first example of an osmium compound which is able to transfer the hydride from a
biomolecule as one hydride source (NADH). This evidence indicated the potency
of using osmium complexes as catalysts to interfere in biological systems. The
hydride transfer initiated by 14A during the reaction with NADH was
demonstrated with the detection of the Os(II)-hydride signal after 3 h and 6 h by
1H NMR experiment, using a sample preincubated for 24 h at 310 K. However,
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no hydride peak was detected after 21 h, which indicated that the hydride adduct
is not stable enough but its formation is important for the catalytic oxidation
reaction with NADH.
LC-MS was also performed to determine the product of 14A with NADH after
24 hours of incubation at 310 K. NADH and NAD+ references were incubated
under the same conditions for comparison. For the sample of NADH with 14A,
one peak appeared at the same retention time of NAD+ reference and also the
mass spectrum showed one peak at 664.1 m/z corresponding to the NAD+ which
confirmed the oxidation of the NADH. It must be noticed that a small peak
appeared before the appearance of the NAD+ peak, which follows the same pattern
of NAD+ in the MS suggesting an isomer of NAD+, but further tests are needed to
confirm its chemical structure (Fig. 5.9). Further investigation of the chlorido
complex 14 showed that it can catalytically oxidize NADH even when sodium
chloride was added to suppress its hydrolysis. This study demonstrated that the
Os-Cl complex can transfer hydride directly and that hydrolysis is not a
prerequisite step for the formation of osmium hydride using NADH as a hydride
source (Fig. 5.15).
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Figure 5.15. Effect of adding Cl- on NADH catalytic oxidation by complex 14 in
a solution of 10% MeOD-d4/90% D2O phosphate buffer (pH*=7.4) after 24 h
incubation at 310 K.
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For the elucidation of the catalytic mechanism, it was firstly checked whether
the osmium hydride can form hydrogen gas, but no H2 was detected after the
incubation of NADH with 14 or 14A after 24 h at 310 K. It was also studied
whether air was involved in the catalytic reaction. 1H-NMR experiments were
used to monitor the influence of the aerobic atmosphere on the catalytic reaction.
It was found that the catalytic oxidation of NADH by 14 is significantly depressed
after degassing the solution with argon (Fig 5.11). On the contrary, oxidation of
NADH by 14 was facilitated in oxygen-saturated solution (Fig. 5.12). This
suggested the involvement of oxygen in the oxidation of NADH, and it is very
likely to be oxygen in the air who takes part in this catalytic reaction facilitating
the generation of ROS. Taking all this evidence into account, A possible catalytic
mechanism of action was proposed based in the interaction of these compounds
with the NADH through a hydride transfer process with the concomitant
formation of a osmium-hydride adduct and NAD+ (Chart 5.2), the regeneration of
the osmium iminopyridine catalyst would take place after the hydrogenation of
dissolved molecular oxygen to produce H2O2. Further investigations will be
necessary to uncover the details of this mechanism of action.33-35
Finally, a concentration dependent cell cycle arrest on S phase (increase from
10% to 21%) was also detected on A2780 cancer cells induced by complex 14
(Fig. 5.16). This indicated that a consequence after DNA was damaged; the cancer
cells will be halted at S phase for DNA repairs.
Under physiological conditions, the aqua osmium complex has a tendency to
form the Os-OH hydroxyl adduct, which is an inert ligand that can stop the
poisoning of the catalyst for NADH oxidation. With DNA nucleobase (9-
ethylguanine) binding and a catalytic NADH oxidation induced by the osmium
iminopyridine complexes, the combined mechanism may explain the reason why
this family of osmium complexes showed good anticancer activity.
Figure 5.16. S phase cell cycle arrest induced complex
concentrations after incubation of 24 h on A2780 human ovarian cancer cell line
Chart 5.2. Proposed catalytic mechanism for the oxidation of NADH to NAD
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14 at different
.
+.
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5.5. Conclusions
Based on the previous work on osmium azopyridine complexes, the
iminopyridine complexes were designed and were found to show a good potential
for anticancer activity. However, different from their azopyridine analogues, they
can hydrolyze and bind to 9-EtG, the mechanism involves DNA base binding and
a novel catalytic oxidation of NADH. This is the first example of an osmium
compound showing the capability to transfer hydride from a biomolecule: NADH.
This evidence indicated the potency of using osmium complexes as catalysts to
interfere in biological systems.
5.6 Summary
Previously, the first organometallic osmium arene complex [Os(η6-p-
cym)(Azpy-NMe2)I]PF6 (FY026) showing potent anticancer activity in vivo was
reported. In this work, its bioisosteres by changing the azopyridine chelating
ligand to iminopyridine were mainly investigated. Sixteen osmium arene
iminopyridine complexes were synthesized, well characterized and showed
anticancer activity in the same range of cisplatin against A2780 cancer cells.
Totally different structure-activity relationships comparing iminopyridine
complexes with azopyridine complexes were identified which suggested a
different anticancer mechanism. Dissimilarly from FY026, [Os(η6-p-cym)(Impy-
NMe2)I]PF6 (6) and [Os(η6-p-cym)(Impy-NMe2)Cl]PF6 (14) were found to be
able to undergo hydrolysis and the binding of the hydrolyzed product (14A) to 9-
ethylguanine was observed. Moreover, an osmium hydride intermediate in a
catalytic process to form NAD+ was discovered. This process might be involved
in the anticancer mechanism of action. A mechanism of action based in the
interaction of these compounds with DNA nucleobase and catalytically oxidizing
NADH is proposed.
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6.1 Introduction
After the tragedy of severe birth defects caused by the S isomer of thalidomide
in the 1950s (thalidomide was originally used as a sedative drug then found to be
an inhibitor of angiogenesis in recent years),1, 2 it had been compulsory for all the
drug candidates to purify the isomers and identify their toxicities. For
organometallic arene complexes with the three-legged piano-stool structure which
contain an unsymmetrical chelating ligand and an additional monodentate ligand,
the metal atom becomes a chiral centre.3 It is also necessary to investigate the
stability, biological activity and toxicity of chiral-at-metal4 organometallic drug
candidates. Some early work has been done: the chirality of a ruthenium centre
was found to be able to affect the inhibition of glycogen synthease kinase 3β;5 the
first purification of Z/E isomers of chiral osmium arene paullone complexes by
crystallization demonstrated that Z/E isomers are able to undergo an exchange in
solution.6
In 1911, Werner successfully isolated the first enantiomerically pure metal
complex,4 this discovery paved the way for the study on chiral metal complexes in
enantioselective catalysis over the last 40 years.7-9 Nevertheless, reports on the
stabilities and anticancer activites of chiral osmium arene complexes are scarce.
The reasons may be chiral enantiomers are not easy to purify, chiral columns are
expensive with relatively small yield and chirality-selective synthesis for a metal
centre is still not always easily applicable.
In this Chapter, two chiral iminopyridine chelating ligands were used: N-(2-
pyridylmethylene)-(S)-1-phenylethylamine (Impy-S) and N-(2-
pyridylmethylene)-(R)-1-phenylethylamine (Impy-R) (Fig. 6.1), chiral osmium
complexes obtained were isolated by crystallizations and were studied for
anticancer activity against A2780 human ovarian cancer cell line; in addition, the
NCI 60-cell line screening results were also reported.
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6.2 Experimental
6.2.1 Materials
OsCl3.3H2O was purchased from Alfa-Aesar. Ethanol and methanol were
dried over Mg/I2 or anhydrous quality was used (Aldrich). All other reagents used
were obtained from commercial suppliers and used as received. The preparation
of the starting material [Os(η6-p-cym)Cl2]2 has been previously reported.10 The
synthesis of the chirally pure iminopyridine ligands was carried out as reported.11
The A2780 human ovarian carcinoma cell line was purchased from European
Collection of Animal Cell Cultures (Salisbury, UK), RPMI-1640 media and
trypsin were purchased from Invitrogen, bovine serum from Biosera, penicillin,
streptomycin, trichloroacetic acid (TCA) and sulforhodamine B (SRB) from
Sigma-Aldrich, and tris[hydroxymethyl]aminomethane from Formedium.
6.2.2 Syntheses
[Os(η6-p-cym)(Imine-S)Cl]PF6 (1). [Os(η6-p-cym)Cl2]2 (50.0 mg, 0.063 mmol)
was dissolved in methanol (20 mL) at 313 K. Imine-S (26.9 mg, 0.12 mmol) in
methanol (10 mL) was added drop-wise; the solution-colour changed from orange
to red immediately. The solution was stirred at ambient temperature for 2 h.
Ammonium hexafluorophosphate (41.2 mg. 0.24 mmol) was added. Then the
solution was left in the fridge (277 K) for 24 h. Dark coloured crystals
precipitated which were collected by filtration, washed with diethyl ether, finally
dried in vacuum. Yield: 54.0 mg (58.7 %). ESI-MS Calcd for C24H28ClN2Os: m/z
571.2, found 571.1. 1H NMR((CD3)2CO): δ 9.59 (d, 1H, J = 6 Hz), 9.32 (s, 1 H), 
8.47 (d, 1H, J = 8 Hz), 8.32 (t, 1H, J = 6 Hz), 7.73 (t, 2H, J = 6 Hz), 7.62-7.55 (m,
3H), 6.55 (d, 1H, J = 6 Hz), 6.16 (d, 1H, J= 6 Hz), 6.06 (qd, 1H, J = 6 Hz), 5.89
(d, 2H, J = 6 Hz), 2.65 (s, 3H), 2.54-2.42 (m, 1H), 2.38 (s, 6H), 1.93 (d, 3H, J = 6
Hz), 1.07 (d, 3H, J = 7 Hz), 0.94 (d, 3H, J = 7 Hz). CHN analysis: Found: C,
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40.30%; H, 3.87%; N, 3.90%. Calcd for C24H28ClF6N2OsP: C, 40.31% H, 3.95%
N, 3.92%.
[Os(η6-p-cym)(Imine-S)I]PF6 (2). [Os(η6-p-cym)I2]2 (50.0 mg, 0.043 mmol) was
dissolved in methanol (20 mL) at 313 K. Imine-S (19.3 mg, 0.086 mmol) in
methanol (10 mL) was added drop-wise, the solution-colour changed from orange
to red immediately. The solution was stirred at ambient temperature for 24 h.
Ammonium hexafluorophosphate (28.0 mg. 0.17 mmol) was added. Then the
solution was left in the fridge (277 K) for 24 h. Dark coloured crystals
precipitated which were collected by filtration, washed with diethyl ether, finally
dried in vacuum. Yield: 28.9 mg (33.8 %). ESI-MS Calcd for C24H28IN2Os: m/z
663.1, found 663.0. 1H NMR((CD3)2CO): δ 9.57 (d, 1H, J = 6 Hz), 9.43 (s, 1 H), 
8.48 (d, 1H, J = 8 Hz), 8.25 (t, 1H, J = 6 Hz), 7.77 (t, 2H, J = 6 Hz), 7.52-7.48 (m,
3H), 6.49 (d, 1H, J = 6 Hz), 6.26 (d, 1H, J= 6 Hz), 6.08 (qd, 1H, J = 6 Hz), 6.04 (d,
1H, J = 6 Hz), 5.83 (d, 1H, J= 6 Hz), 2.84 (s, 3H), 2.67-2.602 (m, 1H), 2.65 (s,
6H), 2.13 (d, 3H, J = 7 Hz), 1.09 (d, 3H, J = 7 Hz), 0.96 (d, 3H, J = 7 Hz). CHN
analysis: Found: C, 35.76%; H, 3.53%; N, 3.36%. Calcd for C24H28F6IN2OsP: C,
35.74 % H, 3.50 % N, 3.47 %.
[Os(η6-p-cym)(Imine-R)Cl]PF6 (3). [Os(η6-p-cym)Cl2]2 (50.0 mg, 0.063 mmol)
was dissolved in methanol (20 mL) at 313 K. Imine-R (26.9 mg, 0.12 mmol) in
methanol (10 mL) was added drop-wise, the solution-colour changed from orange
to red immediately. The solution was stirred at ambient temperature for 2 h.
Ammonium hexafluorophosphate (41.2 mg. 0.24 mmol) was added. Then the
solution was left in the fridge (277K) for 24 h. Dark coloured crystals precipitated
which were collected by filtration, washed with diethyl ether, finally dried in
vacuum. Yield: 25.5 mg (27.7 %). ESI-MS Calcd for C24H28ClN2Os: m/z 571.2,
found 571.1. 1H NMR((CD3)2CO): δ 9.59 (d, 1H, J = 6 Hz), 9.32 (s, 1 H), 8.47 (d, 
1H, J = 8 Hz), 8.32 (t, 1H, J = 6 Hz), 7.73 (t, 2H, J = 6 Hz), 7.62-7.55 (m, 3H),
6.55 (d, 1H, J = 6 Hz), 6.16 (d, 1H, J= 6 Hz), 6.06 (qd, 1H, J = 6 Hz), 5.89 (d, 2H,
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J = 6 Hz), 2.65 (s, 3H), 2.54-2.42 (m, 1H), 2.38 (s, 6H), 1.93 (d, 3H, J = 6 Hz),
1.07 (d, 3H, J = 7 Hz), 0.94 (d, 3H, J = 7 Hz).. CHN analysis: Found: C, 40.16 %;
H, 3.80%; N, 3.90%. Calcd for C24H28ClF6N2OsP: C, 40.31% H, 3.95% N, 3.92%.
[Os(η6-p-cym)(Imine-R)I]PF6 (4). [Os(η6-p-cym)I2]2 (50.0 mg, 0.043 mmol) was
dissolved in methanol (20 mL) at 313 K. Imine-R (19.3 mg, 0.086 mmol) in
methanol (10 mL) was added drop-wise, the solution-colour changed from orange
to red immediately. The solution was stirred at ambient temperature for 24 h.
Ammonium hexafluorophosphate (28.0 mg. 0.17 mmol) was added. Then the
solution was left in the fridge (277K) for 24 h. Dark coloured crystals precipitated
which were collected by filtration, washed with diethyl ether, finally dried in
vacuum. Yield: 25.2 mg (35.6 %). ESI-MS Calcd for C24H28IN2Os: m/z 663.1,
found 663.0. 1H NMR((CD3)2CO): δ 9.57 (d, 1H, J = 6 Hz), 9.43 (s, 1 H), 8.48 (d, 
1H, J = 8 Hz), 8.25 (t, 1H, J = 6 Hz), 7.77 (t, 2H, J = 6 Hz), 7.52-7.48 (m, 3H),
6.49 (d, 1H, J = 6 Hz), 6.26 (d, 1H, J= 6 Hz), 6.08 (qd, 1H, J = 6 Hz), 6.04 (d, 1H,
J = 6 Hz), 5.83 (d, 1H, J= 6 Hz), 2.84 (s, 3H), 2.67-2.602 (m, 1H), 2.65 (s, 6H),
2.13 (d, 3H, J = 7 Hz), 1.09 (d, 3H, J = 7 Hz), 0.96 (d, 3H, J = 7 Hz). CHN
analysis: Found: C, 35.63%; H, 3.47%; N, 3.33%. Calcd for C24H28F6IN2OsP: C,
35.74 % H, 3.50 % N, 3.47 %.
6.2.3 Circular Dichroism (CD). The CD spectra of 0.5 mM solutions (MeOH) of
1, 2, 3 or 4 at ambient temperature in CD cuvettes (path: 1mm, Starna, UK) were
recorded on J-815 circular dichroism spectropolarimeter (Jasco, UK).
6.2.4 Stability and Hydrolysis. A 100 µM solution of 1, 2, 3 or 4 in 10%
MeOD-d4/90% D2O phosphate buffer (v/v) was prepared by dissolution of 1, 2, 3
or 4 in MeOD-d4 followed by a dilution with D2O/100 mM phosphate buffer
(pH*=7.4). The NMR spectra were recorded after 24 h incubation at 310 K in an
oven. The extent of hydrolysis was determined by 1H NMR peak integrals.
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6.2.5 Data Evaluation and Mean Graph Analysis of NCI Screening.
Complexes 2 and 4 (Fig. 6.1) were selected for study for activity towards the
human tumour 60-cell line panel of the Developmental Therapeutics Program of
the National Cancer Institute (DTP of NCI, USA) which includes nine tumour
type subpanels (leukemia, lung, colon, central nervous system, melanoma, ovarian,
renal, prostate, and breast cancer). The cells were treated for 48 h at five
concentrations ranging from 0.01 to 100 µM. Three endpoints were calculated:
IC50 (the concentration that inhibits cell growth by 50 %); TGI (the concentration
that inhibits cell growth by 100 %) and LC50 (the concentration that kills original
cells by 50 %).
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6.3 Results and Discussions
6.3.1 Syntheses and Cyrstallizations
In Chapter 5, it was found that two osmium arene iminopyridine enantiomers
coexisted in a ca. 1:1 ratio. In this chapter, in order to isolate chirally pure chiral-
at-metal iminopyridine complexes, a classical resolution was employed by
introducing an additional carbon chiral centre in the chelating iminopyridine
ligand. By doing this, a racemic mixture is converted into a pair of
diastereoisomers. The solubility difference between the diastereoisomers may be
used for the isolation of optically pure products by crystallization. Since
diastereomers usually show different 1H NMR spectra, the purification process
can be easily monitored without the need of chiral shift-reagents (eg. Δ-trisphat: 
[Tetrabutylammonium] [Δ-tris(tetrachloro-1,2-benzenediolato)phosphate(V)]). In 
this Chapter, all the four osmium complexes were synthesized and crystallized to
obtain pure chirality at the osmium centre (Fig. 6.1).
For the two osmium iminopyridine iodido complexes 2 and 4, the synthesis
and crystallization were reproduced more than three times, and single crystals (Fig.
6.1) of chirally pure osmium complex were grown overnight in the fridge from a
concentrated methanol solution of 2 and 4 respectively. The crystallographic data
and selected bond lengths are summarized in Table 6.1 and Table 6.2. Although
similar method has been widely used for organometallic chiral catalysts,7, 12-14 the
application to metal arene anticancer complexes is demonstrated for the first time
in this Chapter.
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Figure 6.1. Solid state structure of one of the crystallographically independent
molecules of (SOs, SC)-1 (A), (SOs, SC)-2 (B), (ROs, RC)-3 (C) and (ROs, RC)-4 (D)
with atom numbering (PF6 counter ion is omitted for clarity).
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Table 6.1. X-ray crystallographic data for complexes (A) 1 and 3; (B) 2 and 4.
(A)
1 3
Formula C24H28ClF6N2OsP C24H28ClF6N2OsP
Molar mass 715.1 715.1
Crystal system Monoclinic Monoclinic
Crystal size /mm 0.25 x 0.18 x 0.16 0.24 x 0.20 x 0.20
Space group P2(1) P2(1)
Crystal brown block orange block
a / Å 10.19773(12) 10.19210(18)
b / Å 11.79001(13) 11.78829(18)
c / Å 10.99917(13) 10.99531(18)
α / deg 90 90 
β / deg 103.0453(12) 103.0937(17)  
γ / deg 90 90 
T / K 100(2) 100(2)
Z 2 2
R [F > 4σ (F)][a] 0.0241 0.0184
Rw[b] 0.0526 0.0391
GoF[c] 1.017 1.022
Δρ max and min/ eÅ-3 1.217 and -0.796 1.046 and -0.718
(B)
2 4
Formula C24H28F6IN2Os P C24H28F6IN2OsP
Molar mass 806.55 806.55
Crystal system Monoclinic Monoclinic
Crystal size /mm 0.18 x 0.18 x 0.06 mm 0.35 x 0.35 x 0.12
Space group P2(1) P2(1)
Crystal brown block brown block
a / Å 9.1232(2) 9.1232(2)
b / Å 15.0439(4) 15.0439(4)
c / Å 9.6304(2) 9.6304(2)
α / deg 90 90 
β / deg 97.591(3) 97.591(3) 
γ / deg 90 90 
T / K 100(2) 100(2)
Z 2 2
R [F > 4σ (F)][a] 0.0427 0.028
Rw[b] 0.0992 0.0698
GoF[c] 1.02 1.03
Δρ max and min/ eÅ-3 2.220 and -1.676 1.904 and -1.058
[a] R = Σ||Fo| - |Fc||/Σ|Fo|.
[b] Rw = [Σw(Fo2 - Fc2)2/ΣwFo2)]1/2.
[c] GoF = [Σw(Fo2 – Fc2)2/(n-p)]1/2
where n = number of reflections and p = number of parameters.
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Table 6.2. Selected bond lengths (Å) and angles (°) for complexes 1, 3, 2 and 4.
(A)
bond length/angle 1 3
Os(01)-N(101) 2.082(3) 2.086(2)
Os(01)-N(108) 2.124(9) 2.086(2)
Os(01)-Arene Centroid 1.685 1.682
Os(1)-Cl(1) 2.3913(8) 2.3892(7)
N(101)-Os(01)-N(108) 76.61(10) 76.43(9)
(B)
bond length/angle 2 4
Os(1)-N(1) 2.084(6) 2.090(4)
Os(1)-N(8) 2.089(7) 2.074(5)
Os(01)-Arene Centroid 1.689 1.695
Os(1)-I(1) 2.7068(6) 2.7078(4)
N(1)-Os(1)-N(8) 75.9(3) 76.17(17)
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All the four osmium complexes were well characterized by NMR, MS and
CHN analysis. However, these techniques could not provide evidence for the
purity of the two pairs of diastereoisomers. In that, X-ray crystallography was
used to determine the chirality at the osmium centre. Only one type of osmium
chirality was found in cubic single crystals for all the four osmium complexes
which were different from that found for iminopyridine osmium complexes in
Chapter 5. A type of intermolecular interaction was found for both of the chiral
chlorido complexes (1 and 3) between the chloride (monodentate lignad) and
nitrogen in the pyridine ring of the chiral chelating iminopyrdine ligand (Fig. 6.2).
Figure 6.2. Similar intermolecular interaction within the crystal structures of
complexes 1 (left) and 3 (right), the distance between chloride (monodentate
lignad) and nitrogen in the pyridine ring of chelating iminopyrdine ligand is 3.279
Å for 1 and 3.388 Å for 3.
Chapter 6: Chiral Osmium Iminopyridine Complexes
220
To assign the chirality at the metal centre, Cahn–Ingold–Prelog priority rules
(CIP system) were used to define the priority sequence of ligands attached on the
osmium centre: η6-C6 > Cl > N (imine) > N (pyridine) or I > η6-C6 > N (imine) >
N (pyridine). According to the sequence rule of the R/S system, the configurations
of the osmium centre in these four chiral osmium arene iminopyridine complexes
are: 1 = SOs, 2 = SOs, 3 = ROs and 4 = ROs. It was noticed that there are two pairs of
osmium diastereoisomers among the 4 complexes: (SOs, SC)-1/(ROs, RC)-3 and
(SOs, SC)-2/(ROs, RC)-4.
Circular dichroism which can give rise to absorption bands for optically active
chiral molecules was used to compare the two pairs of osmium complexes which
are mirror images. The results show complementary CD spectra recorded at
ambient temperature for 1 versus 3 and 2 versus 4 indicating the presence of
mirror images, which is consistent with the crystal structure data (Fig. 6.3).
During the synthesis of chiral iodido complexes, two complexes with chiral-
at-osmium of R or S can co-exist. However, only one isomer is crystallized under
the conditions used in this chapter, another type of crystals was observed after
leaving the solutions of 2 or 4 in fridge for another several days, which indicates
antoher isomer co-existed for both of 2 and 4. DFT geometry optimizations and
energy calculations (by Dr. Luca Salassa, University of Warwick) were performed
on the iodido osmium complexes 2 and 4 and their corresponding enantiomers.
Such calculations were run at the b3lyp/LANL2DZ/6-31G** level in gas phase
using the program Gaussian 03. The sequence of thermodynamic stability is: (SOs,
RC) > (ROs, SC) > (SOs, SC)-2 = (ROs, RC)-4. According to computational results,
the (ROs, SC) configuration is only 0.0015753 KJ/mol less stable than the (SOs, RC)
configuration, while (SOs, SC)-2 and (ROs, RC)-4 are 10.0627518 KJ/mol less
stable than the (SOs, RC) configuration. On the basis of the computational results,
2 and 4 are not thermodymanic favoured isomers. Since complexes 2 and 4 were
still reproducibly obtained and crystallized, suggesting that they are the kinetically
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favoured isomers in the reactions between osmium dimer with the chiral
iminopyridine ligands.
Figure 6.3. CD spectra for the two pairs of osmium arene iminopyridine
complexes. (A) 1 and 3; (B) 2 and 4 in methanol.
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6.3.2 Stability and Hydrolysis
Although chiral metal centres are usually stable in the solid state at ambient
temperature and physiological temperature, they can still behave differently in
solutions: some are configurationally stable whereas others are very labile.4, 15, 16
Early work on the ruthenium iodido complexes [Ru(η6-p-cym)(LL*)I] (LL*=(SC)-
(-)-dimethyl(1-phenylethyl)amine) showed that they were even more
configurationally labile than their chlorido analogues.17 Considering the
possiblilites of different bahaviors in solutions between chlorido and iodide
complexes and there is still no report on the the comparisions on osmium
complexes, it is therefore necessary to study the stability of the osmium
complexes in this chapter especially under biologically-relevant conditions.
Since hydrolysis followed by targeting DNA is an important mechanism for
the ruthenium and osmium arene anticancer complexes, the hydrolysis of all the
four complexes was also studied in 10% MeOD/90% D2O phosphate buffer (pH*=
7.4). About 10 % hydrolysis was observed after 24 h at 310 K for chlorido
complexes 1 and 3, which can be suppressed by the presence of excess Cl- (Fig
6.4). After incubation for 24 h at 310 K, the two idodido complexes (2 and 4)
were found to be very stable in water and no hydrolysis was observed by 1H NMR.
Since there is a very high chloride concentration ca. 10 mM in human blood, it
was investigated whether the iodide ligand can be replaced by choride. Even if at
very high concentration of Cl- (5000 mol equivalent) present, no replacement of
iodide by chloride was observed for both 2 and 4 (Fig 6.4). In summary, there is
no isomerisation at the osmium centre during an incubation time of 24 h at 310 K
for both the osmium arene chlorido and iodido osmium iminopyridine complexes;
it indicates good stability on the chiral osmium centre for these complexes under
physiological conditions.
(A)
(B)
Figure 6.4. 1H NMR spectra of complexes
MeOD/90% D2O phosphate buffer (pH
The time 0 h NMR spectra were recorded immediately (within 10 min) after
preparation of the samples.
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(C)
(D)
Figure 6.4. 1H NMR spectra of complexes 1 (A), 2 (B), 3 (C) and 4 (D) in 10%
MeOD/90% D2O phosphate buffer (pH*= 7.4) after incubation for 24 h at 310 K.
The time 0 h NMR spectra were recorded immediately (within 10 min) after
preparation of the samples.
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6.3.3 Anticancer Activity
The anticancer activity in vitro of the four chiral osmium arene iminopyrdine
complexes was studied. After 24 h incubation followed by 72 h recovery, the two
chlorido osmium complexes (1 and 3) did not show very good anticancer activity
(their IC50 values are larger than 10 µM (Table 6.3) and are significantly higher
than that of cisplatin (2 µM). On the contrary, the two iodido osmium complexes
(2 and 4) showed anticancer activity in the same range of cisplatin (Table 6.3).
The two iodido complexes were selected by NCI (National Cancer Institute of
USA) for 60 cell line screening. Both 2 and 4 showed anticancer activity as good
as cisplatin over the average of all the cell lines screened. The results of MG-MID
(full-panel mean-graph midpoint) values of IC50 (the concentration inhibits cell
growth by 50 %): TGI (the concentration inhibits cell growth by 100 %) and LC50
(the concentration kills original cells by 50 %) are listed in Table 6.3B. The
details for each cell line are shown in Table 6.4. As opposed to cisplatin, these
two osmium complexes showed a broad range of anticancer activity towards
different cell lines, with IC50 values ranging from nanomolar to 100 micromolars.
Further analysis of the in vitro anticancer efficacy of complexes 2 and 4 by the
NCI revealed a selectivity pattern reflecting a characteristic distribution of
sensitive and resistant tumours. Complex 2 and 4 showed a broad spectrum of
activity and a particular selectivity for melanoma and breast cancer, with
particular activity against MDA-MB-468 breast cancer cell line giving IC50 values
in the nanomolar range (703 nM for 2 and 530 nM for 4). It was also noted that
complexes 2 and 4 are highly inactive towards renal cancer cell lines with IC50
values larger than 100 µM towards most of the renal cancer cell lines.
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Table 6.3. IC50 values against A2780 ovarian cancer cell line.
(A)
Complex IC50(µM)
 [Os(η6-p-cym)(Impy-S)Cl]PF6 (1) 22.3 (± 1.6)
[Os(η6-p-cym)(Impy-S)I]PF6 (2) 1.9 (± 0.2)
 [Os(η6-p-cym)(Impy-R)Cl]PF6 (3) 18.3 (± 1.7)
 [Os(η6-p-cym)(Impy-R)I]PF6 (4) 0.60 (± 0.02)
Cisplatin 2.0 (± 0.2)
(B)
Compound IC50/ µM TGI/ µM LC50/ µM
[Os(η6-p-cym)(Impy-S)I]PF6 (2) 9.55 61.7 91.2
[Os(η6-p-cym)(Impy-R)I]PF6 (4) 7.58 53.7 89.1
Cisplatin 10.3 50.7 90.5
Cisplatin Data from NCI/DTP screening: Oct 2009, 48 h incubation.
6.4 Conclusions
In this chapter, four chiral-at-osmium arene iminopyridine complexes were
synthesized. All of them showed good configurational stability under
physiological conditions, with no isomerisation observed at the chiral metal centre
over 24 h at 310 K. The two iodido complexes, [Os(η6-p-cym)(Imine-S)I]PF6 (2)
and [Os(η6-p-cym)(Imine-R)I]PF6 (4) showed promising anticancer activity, as
good as or better than cisplatin. From the 60-cell line screening of National
Cancer Institute (NCI), the two iodide complexes, 2 (FY175A, NSC: D-758116/1)
and 4 (FY178A, NSC: D-758118/1) also showed promising anticancer activity
and dramatic selectivity between different cell lines. However, further work is
also needed to investigate the difference in pharmacological action, metabolism,
toxicity, plasma disposition, and urinary excretion kinetics of the osmium
diastereoisomers.18
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Table 6.4. Anticancer activity in the NCI 60-cell line screen. (A) complex 2, (B)
complex 4. The meanings of GI50 and IC50 value are the same: the concentration
that inhibits cell growth by 50 %.
(A) Complex 2
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(B) Complex 4
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This chapter explores possible areas of future work for this project which has the
potential to provide an osmium anticancer complex as a candidate for clinical
trials. This chapter is mainly based on the results described in the previous
chapters or preliminary data obtained which is not included in previous chapters.
7.1 Absorption, Distribution, Metabolism, and Excretion Analysis
In Chapter 3 and 4, the drug properties of osmium (II) arene azopyridine
complexes were evaluated in vitro and in vivo. In the future work, more
absorption, distribution, metabolism, and excretion (ADME) studies should be
carried on with two purposes: (1) to tune the drug properties without losing the
anticancer activity; (2) to obtain a lead compound for further testing and even
clinical trials. In order to setup one sensitive method for analysis, LC/MS/MS was
employed and the response of the osmium azopyridine compounds was analyzed.
Then it is possible to analyze, evaluate and optimize the most important
pharmaceutical indexes of osmium (II) arene azopyridine anticancer complexes.
For example, the in vitro intrinsic clearance (CLint) values and the inhibition of
cytochrome P450 (CYP) are very important indices. The CLint values of drug
candidates are helpful to confirm whether metabolism is the main clearance
pathway and to project the metabolic clearance of drug candidates in humans.1
Investigations of whether the drug candidates have the effect of decreasing the
activity of various CYP isozymes are also important for evaluations of drug
candidates. Because inhibitions of CYP enzymes activity may affect the
metabolism and clearance of various other drugs and result in drug accumulation
and reaching toxic levels; this CYP enzyme inhibition test is also important for
selection of drugs for combination therapy in the future. After the screening of
ADME in vitro, the ADME study of the promising complexes from screening in
vitro should be explored in vivo.
7.2 Designs for Improved Anticancer Activity
Based on knowledge of structure activity relationships (SARs) gained in the
study of osmium azopyridine complexes, the preliminary conclusions are that the
anticancer activity can be increased
and dimethylamino
phenyl ring of the chelating ligand respectively. The most active osmium complex
achieved so far is [Os(
by NCI. Its IC50 value is 60 nM (mean value for 60 cell lines). Following the
SARs, one osmium complex can be proposed to have even better anticancer
activity (Fig. 7.1A). For comparison, its iminopyr
phenyldiazenyl benzothiazole
Figure 7.1. Osmium azopyridine (A), iminopyridine (B) and phenyldiazenyl
benzothiazole (C) complexes which may obtain improved anticancer activity
based on the knowledge of SARs.
Chapter
dramatically with extended arene, fluoride
substituents at specific position in the pyridine ring and
η6-bip)(Azpy-NMe2)I]PF6 which was selected and screened
idine analogue and
2 analogues should be investigated as well ( Fig. 7.1).
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7.3 Separation of Enantiomers of Osmium Anticancer Complexes
The most common chiral centre is carbon, however, it is notable that a chiral
osmium centre is created when four non
osmium. The two osmium complexes with non
structures are called enantiomers. In Chapter 5, it was found that two enantiomers
of osmium arene iminopyridine complex exist in ca 1:1 ratio (a racemic misture).
The requirement of resolving chiral racemic mixtures for drugs is co
after the thalidomide tragedy
mixtures is the effective pharmaceutical part, is a sedative drug mainly used by
pregnant women. However, thalidomid
limb growth) side effect in humans due to the (
racemic mixtures (Fig. 7.2).
Figure 7.2. Structures of the enantiomers of
is labelled with red star).
There are mainly two types of methods commonly used for the separation of
chiral drugs: (1) fractional crystallization (2) chromatography on a chiral column.
In Chapter 6, one possible simple way of synthesizing and purifying chiral pure
osmium arene antic
However, that method was based on useing a chiral ligand, and is not generally
applicable to osmium arene enantiomers. In that, there is an unmet need to purify
the osmium complexes which are already bee
anticancer activities as racemic mixtures. A preliminary chiral purification
Chapter
-identical atoms or groups are attached to
-superimposable mirror
.3 Thalidomide, (+)(R)-thalidomide in the racemic
e can cause a notorious dysmelia (stunted
-)(S)-thalidomide component in the
3
thalidomide (the chiral carbon centre
ancer complexes was demonstrated by crystallization.
n made and proven to show good
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screening has been carried out by CHIRAL TECHNOLOGIES EUROPE in
France on FY026. Three types of chiral column were screened. CHIRALPAC-IC
was found to be the most suitable chiral column for FY026 that giving the best
separation; it also suggested that CHIRALPAK-IC might be the most suitable
chiral separation column for osmium arene iodido azopyridine complexes (Fig.
7.3).
Figure 7.3. Separation of enantiomers of [Os(η6-p-cym)(Azpy-NMe2)I]PF6
(FY026).
7.4 Polymerization of Tubulin as Anticancer Target
In Chapter 4, a surprising inhibition of tubulin polymerization by osmium
iodido azopyridine complexes was identified which may involve the mechanism
of action. Investigations of the tubulin binding site of osmium complexes should
be continued by competitions study with known microtubule inhibitors. (eg. vinca
alkaloid). However, the anticancer activity was not improved along with the
increase of effect on inhibition of tubulin polymerization. Therefore, a possible
second mechanism of action is likely to be involved (section 4.3.9). Other than
G2/M phase cell cycle arrest which is possibly induced by inhibition of tubulin
polymerization, S phase cell cycle arrest was also observed (section 4.3.10), it
indicated a DNA damage response. Further work should be done to investigate
whether DNA damage is also involved in the mechanism of action. Since the
osmium iodide azopyridine complexes cannot
the potential interaction with DNA is possibly through the intercalation of the
aromatic arene or the chelating azopyridine ligand.
7.5 Mechanism of Catalytic Reaction with NADH
In Chapter 5, the osmium iminopyridine
NADH catalytically. The mechanism appears to be novel and involves oxygen. To
elucidate the mechanism of action, more work should be done including detecting
the intermediate product during the catalytic reaction with NADH.
proposed mechanism (Chart 7.1), H
should be done to detect H
enzyme detection kit (Hydrogen Peroxide Assay Kit, Biovision, USA) was tried
initially for H2O2 detection.
(HRP), substrate in the presence of H
and red-fluorescent (Ex/Em = 535/587 nm) product.
Chart 7.1. Proposed catalytic mechanism for the oxidati
Chapter
create a binding site by hydrolysis,
complexes were found to oxidize
2O2 can form as a product, so further tests
2O2. Consider the instability of H2O2, a very sensitive
This involves of action of horse radish peroxidase
₂O₂ can produce a coloured (λmax = 570 nm) 
on of NADH to NAD
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From the
+.
Fig. 7.4. NADH Instability under the hydrogen peroxide assay
The negative controls were examined firstly: different concentrations of
NADH alone at 0.1, 0.2, 0.4, 0.8 and 1.6 mM were incubated for 1h at 310K, then
the H₂O₂ detection assay was performed following the protocol for the kit. The
increasing red colour with a concentration dependent manner indicated that the
NADH was not to be stable under the conditions of this enzyme assay (Fig 7.4). It
might due to the organic solvent (DMSO) used in the assay. In order to avoid the
similar affect introduced by detecting agents, electrode detection of H
employed based on using a conventional platinum microelectrode, though the
sensitivity of this method is rel
hydride can also be extended to catalyze imine reduction as well; it makes a
possibility to explore the capability of becoming hydrogen transfer catalysts for
osmium iminopyridine complexes. Further work sh
hydrogen transfer efficiency to different imine subtracts.
7.6 Tetranuclear Osmium Azopyridine Complexes
This work was encouraged by work on macrocyclic polynuclear platinum
complexes from Fujita`s group
square [Pt(en)(4,4′-dipyridyl)]
and anticancer activity.
Chapter
atively low: 0.05 mM.4 The ability of transfer
ould be done to explore the
5, 6 such as self-assembled platinum molecular
4 which showed G-quadruplex binding selectivity
8
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2O2 can be
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Self-assembly of both polynuclear platinum complexes and arene ruthenium
polynuclear complexes with anticancer activity had received a lot of attention in
recent years.9-11 Early work from Therrien`s group established an interesting size
dependence for the anticancer activity of ruthenium metalla-rectangles though the
mechanism of action is not completely clear yet.12 Later on, the osmium
analogues were also found to show anticancer activity.13 It should also be noted
that the scarcity of such reports is striking in contrast to the relative abundance of
papers on Pt-based14 and Ru-Based15 macromolecules.
Preliminary data showed that when the linker was changed from pyrazine to 4-
4`-azopyridine, a 10-fold increase in anticancer activity was achieved (Fig. 7.5).
Further investigations to uncover the mechanism of action should be carried out.
Figure 7.5. Synthetic routes for tetranuclear osmium complexes.
7.7 Osmium Complexes for Photodynamic Therapy
Ruthenium and osmium polypyridyl complexes have demonstrated interesting
photophysical properties16, 17 which can be employed for anticancer treatment.
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Two types of photochemistry can be expected. (1) Photo-substitution of a ligand
by a biomolecule such as a nucleobase; this type of photochemistry can be
developed for photoactivated chemotherapy (PACT)18-21 which has recently been
highlighted.21, 22 (2) Photo-redox processes with biomolecules such as DNA;
complexes with this type of photochemistry have the potential to become
candidates for photodynamic therapy23 (PDT) which makes use of reactive
oxygen species produced by excited photosensitizer.24, 25
The photochemical properties of osmium arene iodido complexes were
investigated. Osmium compounds with biphenyl arene and iodide as ligands were
found to undergo a arene dissociation after light irradiation. Photocatalysis of
glutathione oxidation by the osmium derivative was also observed which
indicated a production of ROS. A further work should be done to study the
improvement of anticancer activity under light irradiation. The mechanism of
action was proposed below in Figure 7.6.
Figure 7.6. Proposed mechanism for the oxidation of GSH by osmium (II) arene
iodido complexes in the presence of oxygen.
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Appendix:
Summary of 4 classes of osmium complexes with different chelating ligands
(azopyridine-R, R-azopyridine, Iminopyridine and Chiral Iminopyridine) in this
thesis, this table is made according to the observation for the tested osmium
iodido complexes within this thesis. (N/A= not avaialbe)
